Évaluation de l'activité photodynamique des photosensibilisants de type chlorine avec les nanovecteurs cyclodextrines-β by Yankovsky, Igor
HAL Id: tel-01492601
https://tel.archives-ouvertes.fr/tel-01492601v2
Submitted on 23 May 2017
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Evaluation of photodynamic activity of chlorine-type
photosensitizers with β-cyclodextrins nanovectors
Igor Yankovsky
To cite this version:
Igor Yankovsky. Evaluation of photodynamic activity of chlorine-type photosensitizers with β-
cyclodextrins nanovectors. Human health and pathology. Université de Lorraine; Belarussian State
University, 2016. English. ￿NNT : 2016LORR0171￿. ￿tel-01492601v2￿
 
 
 
 
 
 
 
 
 
 
 
AVERTISSEMENT 
 
 
Ce document est le fruit d'un long travail approuvé par le jury de 
soutenance et mis à disposition de l'ensemble de la 
communauté universitaire élargie. 
 
Il est soumis à la propriété intellectuelle de l'auteur. Ceci 
implique une obligation de citation et de référencement lors de 
l’utilisation de ce document. 
 
D'autre part, toute contrefaçon, plagiat, reproduction  illicite 
encourt une poursuite pénale. 
 
Contact : ddoc-theses-contact@univ-lorraine.fr 
 
 
 
 
 
LIENS 
 
 
Code de la Propriété Intellectuelle. articles L 122. 4 
Code de la Propriété Intellectuelle. articles L 335.2- L 335.10 
http://www.cfcopies.com/V2/leg/leg_droi.php 
http://www.culture.gouv.fr/culture/infos-pratiques/droits/protection.htm 
Ecole Doctorale BioSE (Biologie-Santé-Environnement) 
Thèse 
Présentée et soutenue publiquement pour l’obtention du titre de 
DOCTEUR DE l’UNIVERSITE DE LORRAINE 
Mention : « Sciences de la Vie et de la Santé » 
par Igor YANKOVSKY
Evaluation de l'activité photodynamique des photosensibilisants de type 
chlorine avec les nanovecteurs cyclodextrines-β 
Evaluation of photodynamic activity of chlorin-type photosensitizers with 
β-cyclodextrins nanovectors 
Le 30 Novembre 2016 
Membres du jury : 
Rapporteurs : Monsieur Vladimir SUKHORUKOV Professeur, Département de Biotechnologies 
et de Biophysique, Université de Würzburg  
Monsieur Eduard ZENKEVICH Professeur, Département des technologies  
de l'information et de la Robotique  
du l'Université technique nationale du  
Biélorussie, Minsk 
Examinateurs :  Madame Lina BOLOTINE Docteur, CRAN-UMR 7039 CNRS  
Université de Lorraine, Institut de  
Cancérologie de Lorraine  
Co-Directeur de thèse 
Monsieur Vladimir ZORIN Professeur, Université d'Etat Biélorusse,  
Minsk, Co-Directeur de thèse
--------------------------------------------------------------------------------------------------------------------------------- 
Centre de Recherche en Automatique de Nancy (CRAN), Université de Lorraine, CNRS UMR 7039, 
Institut de Cancérologie de Lorraine, 6, Avenue de Bourgogne 54511 Vandœuvre-lès-Nancy, France; 
Research Laboratory of Biophysics and Biotechnology, Physics Faculty, Belarusian State University, 
4, pr. Nezavisimosti, 220030 Minsk, Belarus 

2 
TABLE OF CONTENTS 
ABBREVIATIONS .................................................................................................................... 4 
LIST OF FIGURES .................................................................................................................... 5 
LIST OF TABLES ..................................................................................................................... 6 
GENERAL INTRODUCTION .................................................................................................. 7 
CHAPTER I. INTRODUCTION ............................................................................................... 8 
1. Photodynamic therapy ....................................................................................................... 8
1.1. An introduction to the photodynamic therapy ........................................................... 8 
1.2. Basic principles of photodynamic therapy ............................................................... 10 
1.2.1. Photophysical and photochemical processes ................................................... 10 
1.2.2. Mechanisms of photodynamic action in vivo ................................................... 13 
1.2.3. Photosensitizers ................................................................................................ 17 
2. Meta-tetra(hydroxyphenyl)chlorin (mTHPC) ................................................................. 25
2.1. General properties and usage ................................................................................... 25 
2.2. Biological behavior of mTHPC ............................................................................... 27 
2.3. Strategies for improving delivery and efficacy of photodynamic therapy with 
mTHPC ........................................................................................................................... 30 
3. Nanotechnology-based drug delivery systems ................................................................ 31
3.1. A rational design and advantages of drug delivery systems .................................... 32 
3.2. Types of nanosized antitumor drug delivery systems .............................................. 34 
4. Cyclodextrins for drug delivery ....................................................................................... 38
4.1. Cyclodextrins: classification, structure and basic properties ................................... 38 
4.2. Inclusion complex formation and mechanism of drug release ................................ 42 
4.3. Effects of cyclodextrins on drug properties in cyclodextrin-based formulations .... 44 
4.3.1. Effect on drug solubility, dissolution and stability .......................................... 44 
4.3.2. Effect on drug permeation through biological membranes .............................. 46 
4.3.3. Effect on drug bioavailability and safety ......................................................... 47 
3 
4.4. Pharmacokinetics, biological activity and toxicology of cyclodextrins .................. 49 
4.5. Mechanism of drug release from cyclodextrin complexes ...................................... 55 
5. Use of cyclodextrins in photodynamic therapy ............................................................... 58
5.1 Inclusion complexes of cyclodextrins with photosensitizers .................................... 58 
5.2 Photosensitizer/cyclodextrin conjugates ................................................................... 61 
5.3. Photosensitizers encapsulated in cyclodextrin nanoassemblies ............................... 62 
5.4. Influence of cyclodextrins on photosensitizers in biological systems ..................... 63 
5.5. Inclusion complexes of mTHPC with cyclodextrins ............................................... 65 
OBJECTIVES .......................................................................................................................... 67 
CHAPTER II. RESULTS ......................................................................................................... 68 
1. Influence of cyclodextrins on mTHPC distribution and photodynamic activity in
biological systems ............................................................................................................... 68 
2. Development of fluorescence methods suitable for monitoring of mTHPC release from
inclusion complexes ............................................................................................................ 80 
GENERAL DISCUSSION ....................................................................................................... 89 
CONCLUSIONS AND OUTLOOK ........................................................................................ 95 
REFERENCES ......................................................................................................................... 97 
SYNTHESE DES TRAVAUX DE THESE ........................................................................... 132 
SCIENTIFIC OUTPUT .......................................................................................................... 143 
4 
ABBREVIATIONS 
CD – cyclodextrin 
DDS – drug delivery system 
DLI – drug-light interval 
DMSO – dimethyl sulfoxide 
HDL – high-density lipoproteins 
Hp-β-CD – hydroxypropyl-β-cyclodextrin 
HpD – hematoporphyrin derivative 
IV – intravenous 
LDL – low-density lipoprotein 
M-β-CD – methyl-β-cyclodextrin 
mTHPBC – meta-tetra(hydroxyphenyl)-bacteriochlorin  
mTHPC – meta-tetra(hydroxyphenyl)chlorin  
mTHPP – meta-tetra(hydroxyphenyl)porphyrin 
NMR – nuclear magnetic resonance 
PBS – phosphate-buffered saline 
PDT – photodynamic therapy  
PEG – polyethylene glycol 
PS – photosensitizer  
QY – quantum yield 
ROS – reactive oxygen species  
SBE-β-CD – sulfobutylether-β-cyclodextrin sodium salt 
TM-β-CD – trimethyl-β-cyclodextrin 
TPPS4 – tetrakis(4-sulfonatophenyl)porphyrin 
VD – volume of distribution 
5 
LIST OF FIGURES 
Figure 1.1 Schematic illustration of the treatment process of PDT …………...…………..9 
Figure 1.2 Modified Jablonski energy diagram for PS. VR – vibrational relaxation, IC – 
internal conversion, ISC – intersystem crossing ……………………………………………..12 
Figure 1.3 Mechanisms of PDT tumor photoeradication (from Agostinis et al. 2011)…...14 
Figure 2.1 Molecular structures of mTHPP, mTHPC and mTHPBC and m, p and o 
isomers of the hydroxyphenyl substituent ………………..………………………....……….26 
Figure 3.1 Different types of nanocarriers have used for drug delivery (from Bamrungsap 
et al., 2012; Khodabandehloo et al., 2016; Wang et al., 2013) …………………………..…..36 
Figure 4.1 Schematic illustration of the association of CD and drug. Topology of inclusion 
complexes: (a) complete, (b) partial through the narrow side, (c) partial through the wide side, 
(d) axial …………………………..…………………………..………………………………42 
Figure 4.2 Mechanism proposed for morphological changes in red blood cells induced by 
CDs (from Arima et al., 2011) ……………………………………………………………….54 
Figure 5.1 The type of CDs binding with tetrapyrrole photosensitizers: host-guest (Lang et 
al., 2004), conjugate (Kirejev et al. 2014), nanoassemblies (Mazzaglia et al. 2013) ….….…59 
6 
LIST OF TABLES 
Table 1.1 Photosensitizers approved for clinics or undergoing clinical trials (from 
Agostinis et al., 2011; Josefsen & Boyle, 2012; Lucky et al., 2015) ………………………...23 
Table 2.1 Photophysical properties of mTHPP, mTHPC and mTHPBC in methanol 
(Bonnett et al., 1999; Senge & Brandt, 2011) …………………………..….…..…………….26 
Table 3.1 Nanotherapeutics approved for clinical use or being evaluated in clinical trials 
(adapted from Egusquiaguirre et al, 2012; Gidwani & Vyas, 2015; Marchal et al., 2015) ….35 
Table 4.1 Structure and physicochemical properties of native CDs (adapted from Loftsson 
& Brewster 2013; Del Valle 2004) …………………………..…………………………....…40 
Table 4.2 Structural and physiochemical properties of some CDs of pharmaceutical 
interest (adapted from Loftsson & Brewster, 2013; Vyas et al., 2008) …………………...…41 
Table 4.3 Pharmacokinetic parameters of some CDs IV administered (from Stella & He, 
2008) …………………………..…………………………..…………………………………51 
 
7 
GENERAL INTRODUCTION 
Photodynamic therapy (PDT) is a minimally invasive photochemical-based treatment 
with a promising clinical track record for oncological and other diseases. PDT involves three 
main components (light, photosensitizer, oxygen) to damage the target tissue by generating 
reactive molecular species. Tetrapyrrole compounds such as meta-tetra(hydroxyphenyl)-
chlorin (mTHPC) are dominate photosensitizers (PSs) employed in PDT, but several 
difficulties associated with high hydrophobicity of these PSs leading to poor water solubility 
and aggregation within the vasculature after intravenous injection hampers its successful 
clinical application. Aggregation of PSs results in a decreased photodynamic efficacy, 
unfavorable biodistribution, moderate selectivity and prolonged skin photosensitivity.  
To abolish these problems, special pharmacological forms such as liposomes, 
polymeric nanoparticles, bioconjugates are proposed for PS administration. Among the 
biodegradable and nontoxic compounds that can be used for drug delivery, cyclodextrins 
(CDs) are very promising. CDs are a family of cyclic oligosaccharides with a hydrophobic 
internal cavity and a hydrophilic outer surface. They are water-soluble, biocompatible in 
nature and can form stable inclusion (host-guest) complexes with a very wide range of solid, 
liquid and gaseous compounds. Inclusion of a hydrophobic drug into CD cavity usually 
increased the PSs solubility, physical and chemical stability, circulation time thus enhancing 
their bioavailability. Besides, CDs are used in the design of immediate as well as delayed 
release and targeted drug delivery systems. 
mTHPC, the potent second-generation PS, which is currently under clinical trial for 
the palliative treatment of head and neck cancer, appears as a promising PS exhibiting a high 
therapeutic ratio. Previously, it was shown that mTHPC forms effectively inclusion 
complexes with derivatives of β-CD resulting in an increase of the PS solubility and 
improvement of its photophysical properties in aqueous solution. However, there is no 
available data on the use of mTHPC-CDs complexes in vitro and in vivo models so far. 
The main objective of present work was to evaluate the effect of different CDs on 
mTHPC behavior at various stages of its distribution in vitro and in vivo and estimate the PS 
release from the carriers. We have also developed new approaches for analyzing mTHPC 
release from CDs. These approaches were based on the changing of fluorescence polarization 
degree and variability of mTHPC Soret band in function of PS microinvirement. 
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CHAPTER I. INTRODUCTION 
1. Photodynamic therapy 
1.1. An introduction to the photodynamic therapy  
The combination of dyes and sunlight for treatment of several skin disorders dates 
back to ancient Egyptians, Greeks and Indians (Spikes et al., 1985). However, the emergence 
of the concept of photodynamic therapy (PDT) can be attributed to early observations made 
by O. Raab and H. von Tappeiner. O. Raab under the direction of Professor Dr. Hermann von 
Tappeiner observed that low concentration of acridine and some other dyes such as eosin, that 
had no effect in the dark, provoked the rapid killing of paramecia in the presence of light 
(Raab, 1900). The first mention of the necessity of the presence of oxygen for photodynamic 
action was reported in 1902 by C. Ledoux-Lebards. He observed that eosin killed paramecia 
more efficiently in open flask than in a closed bottle (Ledoux-Lebards, 1902). In 1903, von 
Tappeiner along with a dermatologist named Jesionek reported the tumoricidal effect of eosin 
associated with exposure to the white light on skin tumors (Von Tappeiner & Jesionek, 1903). 
Despite this early success, PDT did not achieve enough impact and was lost for 
nearly 50 years when the photodynamic reaction was rediscovered by Lipson and Schwartz. 
Samuel Schwartz demonstrated that a mixture of hematoporphyrin derivative (HpD) was far 
more effective anti-tumor agent than hematoporphyrin (Schwartz et al., 1955). Lipson and his 
colleagues observed that injection of crude preparations of hematoporphyrin led to 
fluorescence of tumor lesions that could be visualized during surgery (Lipson et al., 1961; 
Lipson & Baldes, 1960). However, dissemination and application of PDT in clinical practice 
was associated with the work of Thomas Dougherty and his colleagues at Roswell Park 
Cancer Institute (University of Buffalo, USA). In contrast to previous studies, Dougherty 
created a commercially suitable photosensitizing drug, reliable light sources (Dougherty, 
1974) and showed long-term HpD-PDT efficacy in animal models and humans (Dougherty et 
al., 1975, 1978). Chromatographic isolation of HpD led to the design of the photosensitizer 
(PS) Photofrin®, which was first approved for the treatment of bladder cancer in Canada in 
1993. To date, Photofrin® is approved in the US, Europe and Japan for the treatment of 
advanced and early stage lung cancer, oesophageal adenocarcinoma, cervical cancer, 
superficial gastric cancer and bladder cancer (Dougherty, 2002; O’Connor et al., 2009). 
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Treatment by PDT is as follows (Fig. 1.1). PDT uses the combination of a 
photosensitizing drug (photosensitizers, PSs) and light to cause selective damage to the target 
tissue. In PDT, PSs are applied topically, locally or systemically (e.g., intravenously, IV). 
Firstly, PS is administered into the patient and it begins to redistribute into the body. After 
certain period, when PS accumulation in the tumor becomes greater than in normal tissue, the 
localized illumination of tumor region is carried out with a light source with an appropriate 
emission wavelength. Absorption of this light by tumor-localized sensitizer leads to 
generation of toxic free radicals and finally to the destruction of tumor tissue (Agostinis et al., 
2011). Tumor destruction can be realized from three interconnected mechanisms: direct 
killing of tumor cells, damage to the tumor vasculature, and induction of an inflammatory 
reaction that can lead to the immune response. The selectivity of PDT is achieved by both the 
preferential uptake of the PS by the tumor (Jori, 1996) and directed illumination of treated 
tissue while sparing potentially healthy tissue. 
 
Figure 1.1 Schematic illustration of the treatment process of PDT 
So far, about 250 randomized clinical trials have been officially reported for PDT of 
tumors, and essentially all types of solid tumors with the exception of melanotic melanoma 
have been found to be positively responsive to the photodynamic treatment 
(Rapozzi & Jori, 2015). The earliest known tumor approved for treatment was refractory 
superficial bladder cancer (Nseyo et al., 1998). To date, PDT is also approved for the 
treatment of obstructive and early-stage bronchial cancers (Usuda et al., 2006), esophageal 
dysplasia and carcinoma in situ (Fayter et al., 2010), and unresectable cholangiocarcinoma. 
The progress in PDT-protocols and synthesis of second-generation PSs led to efficient clinical 
treatment of head and neck tumors: widespread and unresectable or recurrent tumors (Biel, 
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2006), early stage oral cancers (Hopper et al., 2004) and nasopharyngeal tumors (Nyst et al., 
2007). PDT has been shown to have high efficacy for basal cell carcinoma, including 
extensive or recurrent lesions. Prostate cancer treatment is under clinical trials and is 
performed as a primary therapy for focal tumors (Eggener et al., 2007), as well as the 
treatment of the whole prostate in patients who have recurred locally following radiation 
therapy (Trachtenberg et al., 2007). Excellent cosmetic outcomes make PDT suitable for 
patients with skin cancers (Fayter et al., 2010; Gao et al., 2010). However, the effectiveness 
of the treatment of many cancer types with PDT remains yet to be proven due to the lack of 
well-designed clinical trials (Agostinis et al., 2011). 
An increasing number of PDT-related studies led to a better understanding of the 
factors controlling PDT and also extends the field of application of this method. Today PDT 
finds new applications not only for nononcologic dermatoses but also in the field of 
otorhinolaryngology, ophthalmology, neurology, gastroenterology and urology (Darlenski & 
Fluhr, 2013). PDT has indications for non-oncological diseases including psoriasis (Smits et 
al. 2006), ocular macular degeneration (Ziemssen & Heimann, 2012), chronic wounds 
(Morley et al., 2013), rheumatoid arthritis (Hansch et al., 2008), acne vulgaris (Pollock et al. 
2004), periodontitis (Alwaeli et al., 2015) and PDT of certain bacterial, fungal and viral 
infections (Rajesh et al. 2011; Reinhard et al., 2015a; Yin & Hamblin, 2015). 
1.2. Basic principles of photodynamic therapy 
The action of PDT consists in the interaction of three principal components: (i) a 
nontoxic drug or dye known as a PS, (ii) the light of a specific wavelength and (iii) 
tissue/molecular oxygen. The lack of any of these components results in the absence of PDT 
effect. Therefore, to better understand the mechanisms of PDT action, it is important to 
understand the particular role of each of these components and how they interact. This section 
provides an overview of PDT with brief descriptions of the photophysical, photochemical and 
biological aspects of the treatment. 
1.2.1. Photophysical and photochemical processes 
Most PSs in their ground (usually singlet) state have 2 electrons with opposite spins 
located in an energetically most favorable molecular orbital (Castano et al., 2004). The 
biological effects of PDT are a consequence of a basic photochemical reaction involving PS 
and oxygen, which can be illustrated using modified Jablonski diagram (Figure 1.2). 
Absorption of light (initial step in all photoreactions) by PS leads to a transfer of one electron 
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from their ground state (S0) to a higher energy orbital (Sn). A molecule with a high vibrational 
level of the excited state Sn (n depending on the PS and excitation wavelength used) will 
quickly fall to the lowest vibrational level of this state in a process called vibrational 
relaxation. Also, a molecule in a higher excited state Sn will finally fall to the first excited 
singlet state S1 by internal conversion. Then, the singlet state S1 can rapidly return to the 
ground state level S0 by two mechanisms, a radiative process (fluorescence), or a non-
radiative process (internal conversion). During this internal conversion, the excess of energy 
of the singlet state is released as heat, which dissipates usually into the tissue or the solvent. 
As for the radiative process, a photon is emitted with the energy equal to the energy gap 
between the S0 and the S1 levels, implying that the fluorescence does not depend on the 
excitation wavelength. Fluorescence is used very widely for PS detection in photodiagnostic 
applications (Mallidi et al., 2015). 
Alternatively, an excited PS molecule may undergo an intersystem crossing forming 
a more stable triplet state (T1) with inverted spin of electrons. The lifetime of the triplet state 
is much longer (τ > 10-7 s) than the lifetime of the singlet state (τ ~10-9 s), which greatly 
increases the probability of a reaction with a neighboring molecules, and the biologically 
relevant photochemistry is often mediated by this state (Lakowicz, 2006). There are several 
pathways for the triplet state T1 to return to S0 including the emission of a photon 
(phosphorescence) and intersystem crossing followed by vibrational relaxation.  
Generally, only the S1 and T1 can be considered as likely candidates for the initiation 
of photochemical and photophysical reactions. This is due to the fact that higher orders of 
electronic states (n ≥ 2) undergo very rapid internal conversion from Sn to S1 and from Tn to 
T1. However, under the special conditions of multiphoton absorption (short pulse, high 
intensities of irradiation), the upper excited states may be filled and complex photophysical 
and photochemical processes can occur (Shea et al., 1990; Smith et al., 1994). 
The PS in triplet state can also initiate photochemical reactions directly upon 
interaction with a substrate, giving rise to reactive free radicals (type I reaction), or transfer its 
energy to molecular oxygen (3O2), which is unique in being a triplet in its ground state (type II 
reaction) (Foote, 1968; Sharman et al., 2000). The relatively longer lifetimes for the triplet 
excited states make the collisional transfer of energy to surrounding oxygen molecules 
possible. A Type I process can occur whereby the PS reacts directly with an organic molecule 
in a cellular microenvironment, acquiring a hydrogen atom or electron to form a radical 
(Henderson & Dougherty, 1992). Both the excited PS and the ground state substrate can act as 
hydrogen donors. The resulting radical species from type I primary processes can 
12 
subsequently participate in different kinds of reactions. In the presence of oxygen, for 
example, oxidized forms of the PS or of the substrate readily react with oxygen to give 
peroxyl radicals, thus initiating a radical chain auto-oxidation. Semi-reduced forms of the PS 
or of the substrate also interact efficiently with oxygen, and the electron transfer generates 
superoxide anion radical (O2•‒). Dismutation or one-electron reduction of O2•‒ gives  hydrogen 
peroxide (H2O2), which in turn can undergo one-electron reduction to a powerful and virtually 
indiscriminate oxidant hydroxyl-radical (HO•) (Henderson & Dougherty, 1992). 
 
 
Figure 1.2 Modified Jablonski energy diagram for PS. VR – vibrational relaxation,  
IC – internal conversion, ISC – intersystem crossing 
Both type I and II reactions occur simultaneously during PDT, but the ratio of the 
frequency of the reactions depends on the type of PS, surrounding substrates, and 
concentration of molecular oxygen in the environment (Aveline et al., 1998; Plaetzer et al., 
2009). However, reactive oxygen species (ROS) generation via Type II chemistry is much 
simpler than via Type I, and most PSs are believed to operate via a Type II rather than Type I 
mechanism. In type II process, the reaction proceeds via energy transfer from the excited 
triplet-state PS to the molecular oxygen in its triplet state. Only PSs that possess an energy 
gap between the ground state and the excited triplet state higher than the energy needed to 
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excite oxygen into its excited singlet state (94 kJ/mol according to van Lier & Spikes, 1989) 
can generate singlet oxygen. Theoretically all molecules absorbing light at a wavelength < 
1260 nm can mediate generation of 1O2. However, photons with wavelengths longer than 800 
nm have insufficient energy to initiate a photodynamic reaction (Juzeniene et al., 2006). 
It is worth noting that singlet oxygen is a very reactive species, much more 
electrophilic than its ground state, and can oxidize biomolecules very rapidly. Lifetime of 
singlet oxygen varies from about 4 µs in water to 25-100 µs in non-polar organic solutions 
and greatly decreases (about 10-330 ns) in biological systems due to the presence of various 
quenchers (Baker & Kanofsky, 1992). This short lifetime allows the diffusion of singlet 
oxygen to a distance from 10 to 55 nm at the sub-cellular level (Dysart & Patterson, 2005; 
Moan & Berg, 1991), thus limiting the PDT effect to the immediate intracellular localization 
of the PS (Moan et al., 1989). 
1.2.2. Mechanisms of photodynamic action in vivo 
PDT destroys tumors by three inter-related mechanisms: direct cytotoxic effects on 
tumor cells, damage to the tumor vasculature, and processes involving the immune system. 
These are illustrated in Fig. 1.3. In the first case, the ROS that are generated by PDT can 
directly destroy tumor cells by apoptosis, necrosis and/or autophagy-associated cell death. 
PDT also damages the tumor-associated vasculature with impairment of the blood supply to 
the area via platelet aggregation and, thus, vascular occlusion. Finally, PDT can induce a 
robust inflammatory reaction that can activate an immune response against tumor. This 
section will describe the mechanisms of PDT action conditionally separated as cellular 
effects, vascular effects and systemic immune effects of the treatment. 
1.2.2.1. Direct tumor cell death effects 
Direct cell kill is an important contributor to PDT mediated tumor destruction in 
vivo. Henderson et al. (1985) showed that exposure of tumors to PDT in vivo leads to decrease 
of the number of clonogenic tumor cells through direct cells photodamage. Direct cell kill can 
occur through necrosis, apoptosis and/or autophagy-associated cell death. Mechanism of cell 
death depends on cell and PS type, treatment protocol, and photodynamic dose (Agostinis et 
al., 2011; Castano et al., 2004, 2005a, 2005b). 
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Figure 1.3 Mechanisms of PDT tumor photoeradication (from Agostinis et al. 2011) 
Apoptosis is the most studied and generally major cell death mechanism responding 
to PDT. Apoptosis or programmed cell death is identified in single cells, and morphologically 
characterized by cell shrinkage, chromatin condensation, cleavage of chromosomal DNA into 
internucleosomal fragments, blebbing of the plasma membrane, and the formation of 
apoptotic bodies without plasma membrane breakdown (Agostinis et al., 2004; Almeida et al,. 
2004). In vivo, apoptotic cells release the “find me” and “eat me” signals required for the 
clearance of the remaining apoptotic bodies by phagocytes that usually prevents inflammation 
response. The most important role in the initiation of apoptosis among all subcellular 
structures is played by mitochondria (Castano et al., 2005a; Kessel & Luo, 1999). The 
damage to mitochondria after PDT results in a cascade of reactions including the rapid release 
of mitochondrial cytochrome C into the cytosol followed by activation of the apoptosome and 
procaspase 3 that eventually cause the apoptosis (Oleinick et al., 2002). However, localization 
of the PS in the lysosomes may also activate apoptotic cascade (Bonneau & Vever-Bizeta, 
2008). Woodburn et al. (1997) demonstrated that lutetium texaphyrin, which is mostly 
localized in the lysosomes of EMT6 cells in vitro, induces apoptosis in EMT6 tumors in vivo. 
Necrosis is a rapid form of death affecting extensive cell populations, characterized 
by cytoplasm swelling, destruction of organelles and disruption of the plasma membrane, 
15 
resulting in an inflammatory reaction due to the release of cellular contents and pro-
inflammatory molecules. Necrosis has been associated with incidental cell death, caused by 
physical or chemical damage and has generally been considered an unprogrammed process. 
During necrosis, decomposition of cell is principally mediated by proteolytic activity and 
inhibition or genetic deficiency of caspases in the cell signaling (Castano et al., 2005a; 
Kessel, 2002).  
Another mechanism of cell death have been also described: mitotic cell death 
(Castedo et al., 2004), cathepsin-mediated lysosomal death pathway (Leist & Jäättelä, 2001), 
programmed necrosis (Bizik et al., 2004; Vanlangenakker et al., 2008) and autophagic cell 
death (Yu et al., 2004). The last (autophagy) is characterized by a massive vacuolization of 
the cytoplasm and can be stimulated by various stress signals including oxidative stress 
(Dewaele et al., 2010). In autophagic cell death processes, normal function used to degrade 
components of the cytoplasm is involved and characterized by appearance autophagosomes, 
autolysosomes, electron-dense membranous autophagic vacuoles, myelin whorls, 
multivesicular bodies, as well as engulfment of entire organelles (Castano et al., 2005a). 
Recent studies describe autophagy as a mechanism to preserve cell viability after PDT 
treatment (Reiners et al., 2010). On the other hand, photodamage of lysosomal compartment 
by the PS may compromise completion of the autophagic process. 
In rare cases, complete tumor destruction is achieved only through direct damage of 
tumor cells. Indeed, non-homogenous distribution of PS within the tumor, insufficient depth 
of light penetration into the tumor or distance of tumor cells from the vessels (Korbelik & 
Krosl, 1994) as well as availability of oxygen (Tromberg et al., 1990) may hamper the 
tumoricidal effect. Therefore, other mechanisms involved in the destruction of the tumor 
during PDT will be discussed in next chapters. 
1.2.2.2. Antivascular effects of PDT 
The importance of vascular damage for tumor destruction is well recognized. PDT 
damage of tumor microvasculature leads to severe and persistent tumor hypoxia and restricts 
nutrient supply to the proliferating tumor cells. Numerous studies revealed that blood vessel 
of tumors are fundamentally different from normal vasculature (Ausprunk & Folkman, 1977; 
Eberhard et al., 2000; Siemann, 2011). Tumor vasculature is typified by aberrant structural 
dynamics and vessels that are immature in nature with poorly developed, chaotic growing 
architecture and discontinuous endothelial linings (Eberhard et al., 2000). Besides, the 
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endothelial cells lining tumor vessels have an irregular, disorganized morphology that result 
in enhanced permeability (Siemann, 2011). 
Targeting the tumor vasculature is a promising approach to cancer treatment. 
Destruction of endothelial cells during PDT treatment seems to be the origin of modifications 
observed in vasculature (Fingar et al., 2000); therewith endothelial cells were shown to be 
more sensitive to PDT compared to muscle cells, together with increased PS uptake (West et 
al., 1990). PDT incites modifications of organization of the proteins of cytoskeleton of 
endothelial human cells with consecutive induction of a signal to the platelets and neutrophils 
activation which adhere on the vessel wall (Senge & Radomski, 2013). In the region of injury 
the following changes are observed: initial blanching and vasoconstriction of the tumor 
vessels, followed by heterogeneous responses including eventual complete blood flow stasis, 
hemorrhage, and, in some larger vessels, the formation of platelet aggregates (Krammer, 
2001). The combination of vessel constriction, thrombus formation, and increased interstitial 
pressure leads to tissue ischemia followed by necrosis (Fingar et al., 2000; Henderson et al., 
1985). Moreover, vascular destruction after PDT may be accompanied by inflammatory 
response like after tissue injury (Korbelik, 1996). 
It is worth noting that different PSs do not produce the same type of vascular 
response. PDT with monoaspartyl chlorin e6 (MACE®) produce blood stasis mainly due to 
platelets aggregated on the artery walls (McMahon et al., 1994) while certain phthalocyanine 
derivatives cause primarily vascular leakage (Fingar et al., 1993b). At the same time, using of 
Photofrin® leads to vessel constriction, macromolecular vessel leakage, leukocyte adhesion 
and thrombus formation corresponding to platelet activation and release of thromboxane 
(Fingar et al., 1993a). 
1.2.2.3. PDT and the immune response 
Nowadays it is shown that PDT can affect both innate immunity and adaptive 
immunity. The influence of PDT on the immune response is quite complicated and defines by 
many factors, such as the type of PS and its formulation, pharmacokinetic and location within 
tumor and surrounding cells (especially immune cells), the area treated and treatment regimen 
(e.g., drug-light interval (DLI) and settings of irradiation) (Kousis et al., 2007; Reinhard et al., 
2015a).  
PDT-induced oxidative stress frequently incites a strong acute inflammatory reaction 
observed as localized edema at the targeted site (Dougherty, 2002). The main task of 
inflammatory response consists in the disruption of homeostasis and the removal of damaged 
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cells, thus promoting local healing with the restoration of normal tissue function. The 
inflammatory signaling after PDT initiates a massive regulated infiltration of matures 
dendritic cells and other cellular components of both the innate and adaptive immune systems 
(Castano et al., 2006). Korbelik & Krosl (1994) showed that macrophages demonstrated 
preferential cytotoxicity to tumor cells after PDT treatment. Furthermore, upon 
photostimulation macrophages may regulate the release of pro- or anti-inflammatory 
cytokines (Korbelik & Krosl, 1994; Lynch et al., 1989). Besides, PDT-generated lysates are 
able to activate dendritic cells and increase ability to stimulate T-cells, which is critical to the 
development of a cellular immune response (Gollnick et al., 2002). Removal of inflammatory 
cells or inhibition of their activity after PDT demonstrated significant reducing of therapeutic 
effect (Agostinis et al., 2011). 
It has been showed that PDT can influence the adaptive immune response in different 
ways, resulted both in potentiation of adaptive immunity and immunosuppression (Castano et 
al., 2006; Hunt & Levy, 1998). Long-term effect of PDT depends on the induction of 
antitumor immunity. Canti et al. (1994) showed that resistance to MS-2 fibrosarcomas 
rechallenge was evident only in normal surviving animals treated by PDT, whereas 
immunosuppressed surviving animals and animals cured by surgery died after tumor 
recurrence. PDT treatment of murine EMT6 mammary sarcoma using Photofrin® indicate 
that whereas the direct effects of PDT can destroy the bulk of the tumor, the immune response 
is required to eliminate the surviving cells (Korbelik et al., 1996).  
 
It should be noted that all these mechanisms occur as interrelated with each other and 
the predominance of one or another mechanism of tumor destruction depends on many 
factors, such as the type of PS, light and PS dose, DLI. Therefore, determination of optimal 
PDT conditions requires a coordinated interdisciplinary effort. 
1.2.3. Photosensitizers  
Photosensitizers are one of the main components of PDT. To date, a large number of 
photosensitizing agents have been studied in PDT. The majority of PSs used both clinically 
and experimentally has a tetrapyrrole structure, such as porphyrins, chlorins, bacteriochlorins 
and phthalocyanines (Josefsen & Boyle, 2012; O’Connor et al., 2009). However, other classes 
of compounds including the synthetic dyes (e.g., phenothiazinium, squaraine) transition metal 
complexes, and natural products (e.g., hypericin, riboflavin, curcumin) have been investigated 
(Abrahamse & Hamblin, 2016).  
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1.2.3.1. General properties of photosensitizers 
Photosensitizers used both clinically and experimentally, differ widely in their 
solubility, photophysical properties, cellular and tissue distribution that requires a detailed 
understanding of the most important properties of these drugs. At the same time, regardless of 
the origin of the PS, it must possess certain properties to be considered as a PDT efficient 
drug.  
From a chemistry and manufacturing point of view, synthesis of the PS should be 
relatively easy and low coast; the PS should be a pure and stable compound. Other important 
features of an efficient PS are photophysical and photochemical properties, such as optimal 
excitation wavelength and high singlet oxygen generation yield. PSs should absorb light in the 
red or far-red wavelengths (600-800 nm) for maximum light penetration into the tissue. Due 
to light scattering and absorption of tissue chromophores, shorter wavelengths (<600 nm) 
have less tissue penetration and are mostly absorbed, resulting in high skin photosensitivity  
(Castano et al., 2004). As mentioned earlier (see chapter 1.2.1), absorption at longer 
wavelengths (>800 nm) is not sufficient for PS triplet state to transfer energy for singlet 
oxygen generation. PSs should possess high ROS generation quantum yield (QY) for high 
photodynamic efficiency (implying high triplet state yield). For diagnostic use, the 
fluorescence QY needs to be sufficient. 
Although certain PS features can be simply modified (e.g., wavelength absorption), 
other aspects such as manipulation of PS biodistribition and pharmacokinetic profile are not 
as easily regulated (O’Connor et al., 2009). In this regard, it is important that the medication 
had optimal absorption, distribution, metabolism and excretion properties for relevant 
application. PDT drugs should have selective uptake in target tissues and sufficient 
penetration depth to induce cytotoxic effects, as well as microlocalization to sensitive 
cellular/subcellular targets (e.g., mitochondria). The substance should have little or no dark 
toxicity, low incidence of administrative toxicity (e.g., allergic reaction), absence of metabolic 
creation of toxic byproduct and do not trigger mutagenic effects (regardless of the presence of 
illumination) (Allison & Sibata, 2010). Besides, PDT drugs should have relatively rapid 
clearance from normal tissues (ideally, measured in hours or few days), thereby minimizing 
phototoxic side effects. From clinical point of view PS should be commercially available, 
reliable and pain-free upon activation, acceptable for outpatient treatment with versatile and 
easy administration, depending on the clinical situation. 
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1.2.3.2. Photosensitizers pharmacokinetics and distribution in the body 
As discussed in Chapter 1.2.2, treatment protocol and the mechanism of PDT 
damage to the target tissue is largely determined by the pharmacokinetics and distribution of 
PS in the body. It is well recognized that the distribution of parenterally administrated PS 
molecules during PDT of solid tumors may be defined by three main stages: i) PS interactions 
with the various blood components after injection and transport in bloodstream, ii) PS transfer 
from the bloodstream to the extravascular tissue and iii) PS interaction with intracellular 
targets within the tumor environment. 
Firstly, after injection into the bloodstream the PS must come to equilibrium with the 
blood components. Introduced PSs are mostly associated with plasma proteins (Lang et al., 
2004); although in cases of relatively hydrophobic PSs a significant part of the administrated 
drugs can bind to the blood cells (Maugain et al., 2004). The distribution of the PS in blood 
allows defining three classes of PSs: 
 relatively hydrophilic compounds such as chloroaluminum phthalocyanine and 
sulfonated tetraphenylporphyrin derivatives are bound to albumin and possibly 
globulins fractions; 
 asymmetric and amphiphilic PSs such as monoaspartyl chlorin e6, the adjacent 
disulfonates and benzoporphyrin derivative monoacid are primarily partitioned 
between albumin and high-density lipoproteins (HDL); 
 hydrophobic PSs such as unsubstituted phthalocyanines, tin-etiopurpurin and 
meso-tetra(hydroxyphenyl)porphyrins can be incorporated into the inner lipid core 
of lipoproteins particularly low-density lipoprotein (LDL) (but also HDL and very 
low-density lipoprotein) 
Plasma protein binding pattern is an important factor governing the in vivo 
pharmacokinetics and biodistribution of PSs, thereby affecting its photosensitizing efficiency 
during PDT (Castano et al., 2005b). Based on numerous studies it was established that the 
type of protein-carrier governs the delivery of sensitizer to the tumor and may lead to different 
mechanisms of tumor destruction. Indeed, the PS associated with albumin and globulins are 
delivered mainly to the vascular stroma of tumors (Jori, 1989; Peters, 1995), HDL delivers PS 
to cells via a non-specific exchange with the plasma membrane, LDL probably delivers a 
large fraction of the PS via an active receptor-mediated pathway (Jori & Reddi, 1993). It has 
been showed that most effective PS preferentially binds to LDL (better tumor localizers) due 
to upregulated LDL receptors on tumor cells (Kessel, 1992), but this is not always the case 
(Korbelik, 1992). 
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After penetration through the wall of the blood vessels the PSs accumulate in healthy 
and tumor tissues. It is difficult to compare the distribution of different PSs for a number of 
reasons (delivery system, route of administration, different animals and tumor types). 
However, there are common features of the PS organ distribution in experimental animals, 
which is inherent for most of the studied PSs. In most cases the highest concentration of PS 
was detected in the liver of investigated animals that is due to its detoxifying role in the body 
(particularly excretion of organic molecules such as PS from the blood) (Ocakoglu et al., 
2015; Qian et al., 1987; Woodburn et al., 1992). Large concentrations of PSs are also found in 
kidney and spleen, which (like the liver) strongly support the major role of tissue vascularity 
and are part of the reticuloendothelial system (Jori, 1989). Sulphonated derivatives such as 
tetrakis(4-sulfonatophenyl)porphyrin (TPPS4) have the greatest accumulation in the kidneys 
and were found to be neurotoxic on systemic administration (Winkelman & Collins, 1987). 
Chan et al. (1990) showed on the model of sulfonated phthalocyanines that increase in the 
degree of sulfonation (increasing of PS hydrophilicity) correlated with the increase of PSs 
accumulation in the kidney and simultaneous decrease of its uptake by the liver. At the same 
time, the accumulation of PSs in the spleen varies greatly depending on the PS structure 
(hydrophobicity and charge) and form of administration (dosage, solution or delivery system) 
(Egorin et al., 1999; Qian et al., 1987; Woodburn et al., 1992). It is shown that shortly after 
administration of PSs at a high dosage (generally relates to hydrophobic compounds), the PS's 
aggregates could accumulate in large quantities in the fine capillary network of the lungs 
resulting in pulmonary hemorrhage and acute interstitial pneumonia (Egorin et al., 1999). 
Organs such as the heart, brain, eyes, skeletal muscles and bones, which are relatively 
impermeable to the blood supply, accumulate the lowest concentrations of PS (Castano et al., 
2005b). The organs of the digestive system (stomach, large and small intestines), as a rule, 
accumulate intermediate amount of PS. It was not revealed that skin accumulates a large 
amount of PSs (usually not considerably different from PS uptake by a tumor); however, even 
a small residual concentration of drugs may cause significant cutaneous photosensitivity 
(Moriwaki et al., 2001). 
With the aim of improving the effectiveness of PDT, the ratio between the tumor and 
normal tissue (peritumoral/distant muscle or skin) should be maximal at the time of tumor 
irradiation. It is useful to make a difference between selective accumulation and selective 
retention of PS. As a rule, the tumor localizing ability of the PS with the faster 
pharmacokinetics is probably due to selective accumulation in the tumor, while the 
localization of PS with slower pharmacokinetics is likely due to selective retention (Castano 
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et al., 2005b). The properties of tissues also play an important role in the selective drug 
accumulation. The selective accumulation may be facilitated by a large number of LDL-
receptors (e.g., accumulation of PS bound to LDL) (Bonneau et al., 2004) and/or low 
interstitial pH of targeted tissues (e.g., accumulation of anionic PS) (Tannock & Rotin, 1989; 
Pottier & Kennedy, 1990). The correlation between the PS accumulation in tumors and their 
structure (e.g., lipophilicity, the symmetry of the chemical structure including the distribution 
of PS polar and hydrophobic chains around the macrocycle and the electric charges of these 
chains) has been established (Boyle & Dolphin, 1996). Furthermore, each step of distribution 
and clearance of the photosensitizer from the body is determined by characteristic times, 
which considerably influence treatment protocol. An important parameter LDI in clinical PDT 
is determined by preferentially localization of PS in tumors. For example, tumor localization 
of verteporfin changed from the tumor vasculature at 15 min after injection, to tumor 
parenchyma at 3 h after injection (Chen et al., 2005). This feature of the PS distribution 
allows combining both damage of tumor vasculature and parenchyma by two intervals of 
treatment and leads to enhancement of PDT efficacy. The selective retention of PS in tumors 
may be favored by retention of protein-bound PS in the tumor extravascular space due to 
poorly developed lymphatic drainage (Roberts & Hasan 1992) and by macrophages 
(accumulate up to 13 times the amount of PS compared to cancer cells) infiltration into solid 
tumors (Korbelik & Krosl, 1994). 
The last step of PSs transport is elimination from the tissue and the body. In the case 
of non-metabolic organ, elimination will be probably by lymphatic drainage and back into the 
circulation via the thoracic duct. For the majority of PS in clinical and preclinical use, the 
clearance route being almost exclusively via liver and bile even if a PS mainly accumulates in 
the kidney (Richter et al., 1990). There has been a wide variation in pharmacokinetics 
reported for different PSs with significant differences in PS retention into the tumor and its 
elimination pathways. The study showed that the pharmacokinetics of Photofrin® in patients 
with carcinoma of the lung or skin is described by a triexponential three-compartment 
pharmacokinetic model with half-lives of approximately 16 h, 7.5 days, and 155.5 days 
(Bellnier & Dougherty, 1996). On the other hand, padeliporfin (PS based on the 
bacteriochlorin macrocycle) has an elimination half-live in the range of minutes (Brandis et 
al., 2005) that is common to photosensitizers derived from natural bacteriochlorophylls or 
bacteriochlorins (Dąbrowski & Arnaut, 2015).  
It is worth noting that incorporation of PSs into a delivery vehicle may considerably 
change the plasma behavior and the cellular localization of the PS, as well as its the 
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pharmacokinetics and biodistribution (Konan et al., 2002; Lucky et al., 2015). For example, 
Richter et al. (1993) showed that liposomal formulation of the benzoporphyrin derivative 
monoacid ring A demonstrates faster PS accumulation in the tumor (maximal level reaches at 
15 min vs 3 h for dimethyl sulfoxide (DMSO) or phosphate-buffered saline (PBS) injection 
form of PS) and the highest tumor/normal tissue ratios at 24 h (19.2 vs 12.6 for DMSO or 
PBS form of PS injection). 
1.2.3.3. Classification of PDT photosensitizers 
To date, there are a huge number of compounds that are either experimentally 
studied or have already been approved for clinical use in PDT. Accordingly to their chemical 
structure, these PDT drugs are generally classified as porphyrinoids (tetrapyrrolic 
compounds) and non-porphyrinoids (O’Connor et al., 2009). The class of nonporhyrinoid PSs 
includes several types of molecules of different chemical structure (common is only the 
presence of multiple conjugated π bounds) and origin (natural compounds, such as hypericin 
and curcumin, and synthetic dyes, such as phenothiazinium and cyanines). Although the 
sensitizers of this type are of interest for anticancer therapy, at the moment none of such PSs 
are approved clinically (Abrahamse & Hamblin, 2016). Some of the nonporhyrinoid PSs such 
as phenothiazinium salt and hypericin are in the early stages of clinical trials (mostly in the 
area of antimicrobial PDT or for samples sterilization) (Abrahamse & Hamblin, 2016; 
O’Connor et al., 2009). 
Porphyrinoids PSs are most widely used in cancer PDT. Porphyrinoid PSs have in 
common a carbon heterocyclic macrocycle (four pyrrolic sub-units) comprising 18 to 22 
electrons in conjugated π bounds (Josefsen & Boyle, 2012). In addition, this class also 
includes prodrugs (a metabolic precursor of PS). For example, aminolevulinic acid (ALA) is 
metabolized to photoactive protoporphyrin IX, which is the endogenous photactivating agent. 
Porphyrinoids PSs that have received clinical approval or are currently in trials are 
summarized in the Table 1.1. PDT drugs are commonly classified as first, second or third 
generation PSs. First generation PSs include HpD and their commercial form (Photofrin, 
Photogem) that have been for a very long time the only PSs used in clinical PDT. However, 
non-optimal photophysical properties (absorption maximum at 630 nm with molar extinction 
coefficient 1170 M-1cm-1), lack of tumor selectivity, poor bioavailability, and unfavorable 
biodistribution, as well as prolonged photosensitivity of HpD were major reasons for a search 
and development of new photosensitizing drugs named second generation PSs. They are pure 
chemical substances of synthetic (e.g., phthalocyanines, naphthalocyanines and purpurins) or 
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Table 1.1 Photosensitizers approved for clinics or undergoing clinical trials (from 
Agostinis et al., 2011; Josefsen & Boyle, 2012; Lucky et al., 2015) 
Sensitizer Trade name Structure Current status Potential indications 
HpD (partially 
purified),porfimer 
sodium 
Photofrin, 
Photogem porphyrins Worldwide approved 
Endobronchial lung cancer, 
esophageal cancers, bladder cancer, 
gastric cancer and cervical cancer 
5-Aminolevulinic Acid 
(5- ALA) Levulan 
Porphyrin 
precursors 
Worldwide approved 
Treatment of actinic keratosis, basal-
cell carcinoma, head and neck and 
gynecological tumors; diagnosis of 
bladder, brain, head & neck cancers 
5-ALA-hexylester/ H-
ALA Hexvix, Cysview Approved / USA Diagnosis of bladder tumors 
5-ALA-methylester/ 
MALA 
Metvix, Metvixia, 
Visonac  
Approved / USA, EU, 
New Zealand & 
Australia   
Actinic keratosis, Bowen's disease 
and basal cell carcinoma 
Benzoporphyrin 
derivative monoacid, 
ring/ Verteporfin 
Visudyne 
Chlorines 
Approved / USA, EU, 
Canada  
Treatment for wet age-related 
macular degeneration, pathologic 
myopia, histoplasmosis 
meta-tetra-
(hydroxyphenyl) 
chlorin /Temoporfin 
Foscan Approved / EU  Head and neck, prostate and pancreatic tumors 
Mono-L-aspartyl 
chlorin e6 
(Talaporfin,NPe6, 
LS11 or MACE) 
Aptocine 
Approved / Japan  Lung cancer and solid tumors from diverse origins 
Laserphyrin 
chlorin e6 
polyvinypyrrolidone 
/chlorin e6 derivatives  
Fotolon Approved / Belarus, 
Russia, Ukraine  
Nasopharyngeal, sarcoma, brain, 
skin cancer;  Radachlorin, Photodithazine 
Sulfonated aluminium 
phthalocyanines 
(A1PCS4) 
Photosens 
ph
th
al
oc
ya
ni
ne
s Approved / Russia  
Age-related macular degeneration, 
Various cancers 
Silicon 
phthalocyanines Pc4 Clinical trials / USA 
Actinic keratosis, Bowen's disease, 
T-cell non-Hodgkin lymphoma and 
skin cancers 
Zinc phthalocyanine 
(ZnPc) CGP55847 Clinical trials / USA 
Actinic keratosis, Bowen's Disease, 
skin cancer; squamous carcinoma of 
upper aerodigestive tract 
Lutetium texaphyrin Lutex 
texafirins 
Approved / USA Breast cancer and malignant melanomas 
Motexafin 
1utetium hydrate Antrin Clinical trials /USA Prostate cancer and photoangioplasty 
2-[l-hexyloxyethyl]- 
2-devinyl 
pyropheophorbide a 
Photochlor 
pheophorbide 
Clinical trials / USA Early esophageal cancers, non- small cell lung cancer 
Palladium- 
bacteriopheophorbide Tookad (WST09) Clinical trials / EU Recurrent prostate cancer 
Tin etiopurpurin 
(SnET2)/ Purlytin/ 
Rostaporfin 
Photrex purpurins Clinical trials / USA 
Cutaneous metastatic breast cancer, 
basal-cell carcinoma, Kaposi's 
sarcoma, and prostate cancer 
9-Acetoxy-2,7,12,17-
tetrakis-(β-
methoxyethyl)-
porphycene 
ATMPn porphycene Approved / Germany  Psoriasis and non-melanoma skin cancer 
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natural (e.g., pheophorbides and bacteriochlorins) origin with improved photophysical 
characteristics. However, the second generations PSs are still poorly selective for tumors and 
very hydrophobic thus requiring the application of special delivery systems. The first and 
second generation PSs covalently attached to various biological modifiers like 
oligosaccharides, lipoproteins, antibodies and amino acids, or formulated into drug delivery 
systems like liposomes, polymeric nanoparticles, cyclodextrins, and emulsions with the aim to 
improve the photosensitizing and pharmacokinetic properties of the drugs are classified as 
third generation PSs. It is noteworthy that new generation of drugs are not always superior to 
older ones (Allison & Sibata, 2010; Lucky et al., 2015) and in each case it is necessary to 
compare the properties of different PSs and their forms to each other, both in pre-clinical and 
clinical trials. 
Of special interest for this study is mTHPC, which is an extremely potent PS 
(approximately 100 times more photoactive than Photofrin®) (Mitra & Foster, 2005; Senge & 
Brandt, 2011). The properties of mTHPC and some of its formulation will be described in 
detail in the next chapter. 
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2. Meta-tetra(hydroxyphenyl)chlorin (mTHPC) 
2.1. General properties and usage 
5,10,15,20-Tetra(m-hydroxyphenyl)chlorin (mTHPC, temoporfin) is one of the most 
potent second generation PS. The discovery and the chemical synthesis of PSs of 
tetra(hydroxyphenyl)porphyrinoid series (Fig. 2.1) was performed by the group of professor 
Raymond Bonnett (Berenbaum et al., 1986; Bonnett et al., 1989). The ortho, meta and para 
isomers (Fig. 2.1) of these compounds have been tested and after thorough comparison the 
meta isomers of the PSs demonstrated the greatest efficiency in vitro and in vivo. They are 
namely meta-tetra(hydroxyphenyl)porphyrin (mTHPP), mTHPC and meta-
tetra(hydroxyphenyl)-bacteriochlorin (mTHPBC). These PSs have attractive photophysical 
characteristics compared with the first generation PSs (Table 2.1). All three compounds have 
a high triplet state QY formation ranging between 0.69-0.89 and a good QY of singlet oxygen 
formation (0.43-0.45) in aerated methanol (Bonnett et al., 1999). Besides, they are 
characterized by a strong absorption in the far red region: 3400 M-1cm-1 at 644 nm for 
mTHPP, 29600 M-1cm-1 at 650 nm for mTHPC and 91000 M-1 cm-1 at 735 nm for mTHPBC. 
Although the photophysical characteristics of mTHPBC from PDT point of view look more 
attractive compared to mTHPC, the rapid degradation of mTHPBC precludes a practical use 
in PDT (Grahn et al., 1997; Lassalle et al., 2005). 
mTHPC use in PDT is characterized by a very low drug dose (order of 0.1 mg·kg-1), 
light intensity (order of 10 J·cm-2) and total PDT doses (light dose x PS dose) more than 100 
times higher compared to HpD (Savary et al., 1997, 1998), which explains its popularity in 
PDT. Along with Photofrin, mTHPC is the only other PS approved for use in systemic cancer 
therapy. In 2001 mTHPC was approved in the EU and used as a solvent-based formulation 
(Foscan®; Biolitec Research GmbH, Jena, Germany) for the palliative treatment of head and 
neck cancers (Senge & Brandt, 2011). In addition, mTHPC has been successfully used for the 
treatment of early squamous cell carcinoma (de Visscher et al., 2013; Jerjes et al., 2011), 
basal cell carcinoma (Betz et al., 2012), biliary tract carcinoma (Wagner et al., 2015), prostate 
(Swartling et al., 2010, 2016), pancreatic cancer (Huggett et al., 2014) and nonmelanoma skin 
cancers (Horlings et al., 2015). Moreover, mTHPC finds application in areas other than 
cancer treatment. For examples, there are studies demonstrating the prospects of mTHPC 
application for antibacterial therapy (Ossmann et al., 2015), rheumatoid arthritis (Hansch et 
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al., 2008), and for relieving colitis and preventing colitis-associated carcinogenesis (Reinhard 
et al., 2015b). 
 
 
Figure 2.1 Molecular structures of mTHPP, mTHPC and mTHPBC and m, p and o isomers of 
the hydroxyphenyl substituent 
Table 2.1 Photophysical properties of mTHPP, mTHPC and mTHPBC in methanol (Bonnett 
et al., 1999; Senge & Brandt, 2011) 
Property Value 
Compound 
 
mTHPP 
 
mTHPC 
 
mTHPBC 
Absorption maximum, nm        644               650               735        
Extinction coefficient, M-1 cm-1 3400 29600 91000 
Fluorescence maximum, nm 649 652 746 
Fluorescence quantum yield (Q.Y.) 0.12 0.09 0.11 
Triplet Q.Y. 0.69 0.89 0.83 
Singlet oxygen generation Q.Y. (air-saturated) 0.46 0.43 0.43 
Singlet oxygen generation Q.Y. (oxygen-saturated) 0.59 0.59 0.62 
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2.2. Biological behavior of mTHPC  
The high PDT-efficiency of mTHPC is usually associated with the features of its 
biological behavior. In many papers it is shown that temoporfin forms large aggregates in 
aqueous medium (Kruijt et al., 2009; Tikhomirov et al., 2009). As a rule, mTHPC is IV-
introduced to patients and the PS’s hydrophobic nature defines its pharmacokinetics and 
biodistribution behavior. Plasma protein binding pattern is an important factor governing 
mTHPC biological behavior. Previous studies have revealed two main features of mTHPC 
interaction with plasma proteins. First, about 95% of the sensitizer in plasma is associated 
with HDL and LDL, and the binding with HDL is twice higher than that with LDL (Reshetov 
et al., 2012; Triesscheijn et al., 2007). Secondly, as compared with other non-polar drugs, 
mTHPC releases from lipoprotein carriers very slowly and proceeds on a timescale of hours 
(Sasnouski et al., 2005, 2006). High affinity to cell membranes and plasma proteins and the 
presence of PS aggregates modifies the interaction of mTHPC with biological objects, as will 
be more fully described hereinafter. 
Interaction with cells in vitro 
Time-dependent mTHPC accumulation demonstrates a continuous increase in PS 
cellular uptake within the first 20 h, reaching a plateau at 24 h (Berlanda et al., 2010). 
Temoporfin is rigidly fixed in model membranes (Kachatkou et al., 2009) and is strongly 
retained in cells in vitro (Ball et al., 1999; Berlanda et al., 2010). Cellular uptake of mTHPC 
is affected by many factors. Temoporfin seems to be taken up by cells in its aggregated form, 
followed by slow monomerization (Rezzoug et al., 1998) attested by fluorescence lifetime 
imaging microscopy data (Lassalle et al., 2008). The uptake of PS into cells appears to be pH 
independent in the rage 6.8-7.8; however, photosensitivity of cells increased with decreasing 
pH value (Ma et al., 1999). As discussed above, due to the high affinity of mTHPC to 
lipoproteins, the PS uptake may be mediated by LDL. However, HDL-mediated endocytosis 
was proposed as the main mode of temoporfin transport into the cells (Sasnouski et al., 2006). 
Primary research reported that mTHPC is localized generally within cellular 
organelles, but not in the nucleus (Melnikova et al., 1999). It has been demonstrated that the 
Golgi apparatus and endoplasmic reticulum are preferential sites of mTHPC accumulation in 
MCF-7 human adenocarcinoma cells (Teiten et al., 2003a) and the latter two were the sites of 
primary PDT damage (Teiten et al., 2003b). On the other side, confocal fluorescence 
microscopy study showed only weak localization in lysosomes and mitochondria. A study by 
Kessel (1999) showed mitochondrial damage, release of cytochrome c and activation of 
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caspase-3 resulting in an apoptotic response after mTHPC-PDT in vitro. Mitochondrial 
damage and cytochrome c release has been described for various cancer cells (Marchal et al., 
2004; Yow et al., 2000). However, investigation of the relationship between mTHPC 
subcellular localization and post-PDT intrinsic apoptotic pathway demonstrated that 
temoporfin localization in endoplasmic reticulum improves the photoactivation of the 
caspase-7 apoptotic pathway, which is poorly related to photoinduced mitochondrial damage 
(Marchal et al., 2007). Thus, although mitochondria are not affected directly they will 
significantly contribute to late and indirect apoptotic effects originating in Endoplasmic 
reticulum and/or Golgi apparatus.  
Biodistribution and pharmacokinetic properties 
The pharmacokinetics of mTHPC depends on using of animal models (Senge & 
Brandt, 2011). Early studies showed that mTHPC displays an unusual plasma 
pharmacokinetic behavior in humans and rabbits, with a secondary peak at about 10 h and 6 h 
after injection, respectively (Glanzmann et al., 1998; Ronn et al., 1996). These phenomena 
were interpreted by the initial retention of the PS in the liver or PS aggregates in the 
vasculature, with subsequent disaggregation, binding to lipoproteins and mTHPC release from 
the depot. Depending on the study and animal models a half-life of the drug of 26–45 h was 
established (Campbell et al., 2002; Glanzmann et al., 1998; Ronn et al., 1996; Triesscheijn et 
al., 2007). It was shown that mean values for plasma drug concentrations were in good 
agreement with the injected dose of mTHPC. Pharmacokinetic study of radiolabeled mTHPC 
in tumor-bearing rats demonstrated a tri-exponential model with half-lives of 0.46, 6.91 and 
82.5 h, respectively (Jones et al., 2003). However, a detailed study comparing the 
pharmacokinetics in mice and humans showed the different pharmacokinetics between 
rodents and human (Triesscheijn et al., 2007). The initial (5 min) plasma drug levels in 
humans were on average 86% of the maximal plasma concentration, which occurred at about 
5 h after injection. On the contrary plasma pharmacokinetics in mice was characterized by a 
standard bi-exponential decline of the drug concentration. Besides, the drug distribution over 
the lipoproteins and the metabolism of the lipoproteins had no impact on the plasma 
pharmacokinetics. 
Temoporfin biodistribution studies have shown that the time course of the uptake 
differs from organ to organ. Highly perfused organs (liver, spleen, kidney and lung) contained 
a large amount of the drug and the less perfused organs contain less of the PS (Campbell et 
al., 2002; Whelpton et al., 1996). However, the maximum level of mTHPC can be different 
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for different animal models and doses of administration (Ronn et al., 1996, 1997). The 
intratumoral distribution of mTHPC depends on the time of circulation and the distance to 
blood vessels. Peng et al. (1995) showed that mTHPC was distributed in the vascular 
interstitial and neoplastic cells of the breast cancer implanted in mice. Mitra et al. (2005) used 
high-resolution confocal fluorescence imaging to simultaneously map microscopic 
intratumoral mTHPC localization with respect to perfused vasculature as a function of time 
after injection. Three hours after injection, maximal mTHPC fluorescence was detected in the 
periluminal structures, but after 24 h, mTHPC was mainly localized in parenchyma of tumor. 
All these aspects have clear clinical applications, which will be discussed below. 
A study of mTHPC excretion in a murine model showed that nearly 40% of the drug 
was excreted in the faeces during the first day, and less than 0.2% of the dose was recovered 
from the urine (Whelpton et al., 1996). Furthermore, in vitro and in vivo experiments, using 
HPLC and electrospray mass spectrometry, have confirmed that mTHPC is not metabolized 
and is excreted unchanged via biliary excretion in the faeces (Cai et al., 1999a, 1999b). 
Mechanism of action 
Early pre-clinical studies have demonstrated that in PC6 tumor bearing mice the 
depth of necrosis was 3.79 ± 0.28 mm after mTHPC administration (Bonnett et al., 1989). 
Melnikova et al. (1999) showed that mTHPC mediates cell photodamage, principally through 
singlet oxygen formation and its efficacy is sensitive to oxygenation conditions (Coutier et al., 
2002). Moreover, in the case of mTHPC-PDT, singlet oxygen dose to the tumor volume does 
not track even qualitatively tumor response, so in this case any PDT dose metric that is 
proportional to singlet oxygen creation and/or deposition would fail to predict the tumor 
response (Wang et al., 2008) 
mTHPC has a small initial volume of distribution with important retention in the 
vasculature together with two peaks of PDT efficacy (2 and 24 h) in rats (Jones et al., 2003). 
Thus, PDT at early time of irradiation resulted mainly in the destruction of the 
microvasculature of the tumor while the latter one affected both the vascular walls and the 
tumor cells. Features of such intratumoral distribution were used in mTHPC-PDT of mice 
bearing EMT6 tumors (Garrier et al., 2010). Indeed, a fractionated double injection (3 and 24 
h prior to PDT) was superior to any single dose of administration of the drug at 3 h, 6 h and 
24 h of DLI. The absence of correlation between the mTHPC concentration in tumor and PDT 
efficiency was observed (Garrier et al., 2010; Ris et al., 1998; Veenhuizen et al., 1997), while 
accumulation of PS in leukocytes exhibited a good correlation with PDT efficacy (Maugain et 
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al., 2004). Thus, photodynamic effect will depend on the treatment protocol (i.e. 
photodynamic dose and DLI). In fine, although direct cells damage is a predominated in 
tumor destruction by mTHPC-PDT, other mechanisms play an important role for the 
complete tumor destruction and prolonged PDT-effect.  
Side effects 
mTHPC is a highly active PS with a significant clinical efficacy, however the skin 
photosensitivity still remains a major issue in clinical management. For example, there is the 
evidence indicating a mild to moderate pain in the treated area (Allison & Sibata, 2004). The 
main side effect of mTHPC is its photosensitivity. Although several studies have indicated 
that mTHPC is less photosensitivity than Photofrin® (van Geel et al., 1995; Wagnieres et al., 
1998), skin photosensitivity persists for up to 6 weeks (usually 2-3 weeks) post-mTHPC 
administration (Allison & Sibata, 2004). Usually, Foscan-based PDT resulted in mild to 
moderate skin photosensitivity and caused neither functional nor cosmetic impairments after 
treatment of early oral squamous cell carcinoma (O’Connor et al., 2009). There are also other 
side effects, but they are very rare and specific (http://sideeffects.embl.de/drugs/60751/pt). 
Moreover, as noted earlier, mTHPC molecule is hydrophobic, leading to its poor water 
solubility and aggregation within the vasculature requiring the use of special systems suitable 
for clinical applications.  
2.3. Strategies for improving delivery and efficacy of photodynamic 
therapy with mTHPC  
The side effects of mTHPC clearly accentuate the need to improve the treatment 
protocols by optimizing the DLI, increasing bioavailability and selectivity of PS accumulation 
thus reducing the damage to healthy tissues. Various solutions were proposed over the past 
decades, including mTHPC conjugation with different molecules and using special 
formulations, such as liposomes, polymer solutions and nanoparticles (Senge, 2012; Senge & 
Brandt, 2011). The first attempt to improve the pharmacokinetic properties of mTHPC is 
related to the conjugation with polyethylene glycol (PEG) (Westermann et al., 1995; Morlet et 
al., 1997). Although mTHPC-PEG conjugate showed increased water solubility and selective 
retention of the drug in tumor tissue, PDT-effect of unconjugated form of mTHPC 
demonstrated the same or superior efficiency (Kübler et al., 2001; Westermann et al., 1999).  
Besides, various glucoconjugated analogues of mTHPC were investigated (Bautista-Sanchez 
et al., 2005; Laville et al., 2003), along with folic acid conjugate (Gravier et al., 2008). 
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More significant advances were made through the use of nanocarriers for mTHPC 
development. In order to improve its bioavailability and PDT-efficacy and to reduce side 
effects of mTHPC, various nanosized vehicles such as nanoemulsion (Primo et al., 2008), 
lipid vesicle systems (liposomes, invasosome, ethosomes) (Bovis et al., 2012; Chen et al., 
2011; Reshetov et al., 2013; Xie et al., 2015), nanoparticles (mainly biodegradable) (Navarro 
et al., 2014; Rojnik et al., 2012; Silva et al., 2015) were proposed. A study of mTHPC 
encapsulated in polyethylene glycol (PEG) poly-(D,L-lactide-co-glycolide) nanoparticles 
showed significant decrease of mTHPC dark cytotoxicity, but also significantly reduced 
mTHPC cellular uptake, whereas phototoxicity was similar to that of Foscan® (Rojnik et al., 
2012). Silva et al. (2015) demonstrated that using mTHPC-loaded magnetic iron oxide 
microvesicles, the uptake of mTHPC by cancer cells could be kinetically modulated and 
spatially controlled under magnetic field and that photoinduced cell death was enhanced by 
magnetic targeting. Another study compared vesicular systems (liposomes, invasosome and 
ethosomes) with non-vesicular systems on the skin penetration of mTHPC. Both vesicular and 
non-vesicular formulations provided drug localization predominantly in the superficial skin 
layer (Chen et al., 2011).  
Two mTHPC liposomal formulations (Foslip® and Fospeg®; Biolitec Research 
GmbH) are the most studied and widely used in experimental research. Foslip® is a 
formulation of mTHPC embedded in conventional (non-pegylated) liposomes. Fospeg® is a 
sterically stabilized form of Foslip®, containing a small amount of PEG-
phosphatidylethanolamine layer on the surface. Compared to the standard solution of mTHPC 
(Foscan®), liposomal formulations Foslip® and Fospeg® provide better bioavailability of the 
PS, higher tumor/tissue ratios and result in better PDT-efficacy (Bovis et al., 2012; Buchholz 
et al., 2005; Svensson et al., 2007). PDT efficiency with Foslip® in EMT6-grafted mice, 
studied by Lassalle et al. (2009), was maximal at the DLI 6 h, indicating the presence of both 
direct and vascular PDT effects. Reshetov et al. (2013) showed that Fospeg®-PDT of HT29 
human colon adenocarcinoma bearing mice was more effective than Foslip® treatment at 
almost all DLIs, except 24 h. Its higher efficiency can be achieved by combination of 
enhanced permeability and retention-based tumor accumulation, stability in the circulation, 
and release properties of Fospeg® compared to Foslip® (Reshetov et al., 2013; Xie et al., 
2015). 
These different nanocarriers of mTHPC, in particular Foslip has now closely 
approached the clinical stage. Further development of PDT in general and mTHPC-PDT in 
particular is associated with nanotechnology-based drug delivery systems.  
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3. Nanotechnology-based drug delivery systems 
The application of many drugs is hampered by their non-optimal pharmacological 
properties, such as low aqueous solubility, irritating nature, lack of stability, rapid 
metabolism, and non-selective drug distribution. Nanocarriers were developed to palliate 
these problems by improving drug delivery, opening the era of nanomedicine in oncology 
including PDT (Calixto et al., 2016; Marchal et al., 2015). Significant efforts have been made 
toward this goal by developing nanoparticle drug delivery systems (DDSs), having particle 
diameters up to 200 nm (Khodabandehloo et al., 2016). Nanocarriers can deliver drugs in a 
spatiotemporally controlled manner that potentially increase therapeutic efficacy of the drugs, 
reduce their systemic side effects, and improve patient's adherence to regimen by reducing the 
dose and administration frequency (Lee & Yeo, 2015).  
3.1. A rational design and advantages of drug delivery systems 
It is well known that drugs should ideally be released at the target sites in a 
controlled manner to enhance their therapeutic efficiency and reduce the side effects. The 
design of an efficient DDS requires the knowledge of the drug physicochemical properties, 
specific intended therapeutic application of the drug and the characteristics of interaction of 
the DDS with the biological structures (Khodabandehloo et al., 2016).  
Smart DDSs are defined as the process when the drugs are not released before 
reaching target tissues/organs (or with extremely slow rate), and are released only at the sites 
of action (Liu et al., 2016). Although the drug molecules themselves sometimes can be smart 
components, here we primarily discuss smart DDSs by means of nanotechnology. Stimuli-
responsive DDS can respond to endogenous and/or exogenous stimulus. The endogenous 
triggers such as pH variations, hormone level, enzyme concentration, small bio-molecules, 
glucose or redox gradient (Mura et al., 2013; Kelley et al., 2013) are related to the disease 
pathological characteristics. While the exogenous triggers, including temperature, magnetic 
field, ultrasound, light, electric pulse/ high energy radiation, can also be used to trigger or 
enhance the drug release at diseased areas. 
For the drug that is already in clinical application, the advantages of a particular DDS 
shall be compared to a free drug. Besides, toxicity profile (not degree) of the free drug is 
generally similar to its DDS-entrapped form (Allen & Cullis, 2004), thus facilitating the 
estimation of the side effects. Hence, in many cases the formulation of the already-approved 
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drug into the DDS is more efficient than the development of entirely new drugs and their 
DDS formulation. The mechanism of action of a drug also dictates its suitability for delivery 
in a particular DDS. If release from the DDS is required, a question arises as to whether the 
DDS leads to appropriate rates and levels of drug bioavailability. Bioavailability will depend 
on the release rate. Thus, the methods to measure drug release rates should also be integrated 
into the development of DDSs, not only the measurements of the total drug level (e.g., in 
plasma). 
Although final properties will depend on the particular design of the DDS, there are 
several general advantages of using DDS for cancer therapy:  
 DDSs can carry a large payload of drug molecules, protect them from degradation 
and increase drug water solubility. 
 Changes in the biodistribution of the DDS generally occur through passive or 
active targeting. Passive targeting exploits the characteristics of tumor biology 
that allow nanocarriers to accumulate in the tumor by the enhanced permeability 
and retention effect (Peer et al., 2007). Chauhan et al. (2012) findings emphasize 
the importance of size in nanomedicine design by demonstrating that 12 nm 
particles penetrate tumors better than larger particles. Active approaches achieve 
this by conjugating nanocarriers containing chemotherapeutics with molecules 
that bind to overexpressed antigens or receptors on the target cells. 
 The alteration of pharmacokinetics and biodistribution compared to a free drug 
must match the current use of medications. Surface modifications of the DDS 
such as PEGylation may dramatically change the circulation time, as discussed in 
the next section. Surface characteristics contribute to the DDS solubility, 
aggregation tendency, ability to traverse biological barriers (such as the cell wall), 
biocompatibility, and targeting ability (Mrsny et al., 2006).  
 Nanocarriers composed of biocompatible materials are safe alternatives to 
existing vehicles such as Cremophor® that may cause severe adverse effects 
(Fang & Al-Suwayeh, 2012). Biodegradability implies that the unloaded carrier is 
degraded or metabolized into nontoxic components and cleared from the 
circulation (Petros & DeSimone, 2010). Thus, toxicities associated with the 
carrier molecules per se tend to be mild. 
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3.2. Types of nanosized antitumor drug delivery systems 
To increase the effectiveness of treatment and reduce side effects, the incorporation 
of nanotechnology-based DDS such as polymeric nanoparticles, solid lipid nanoparticles, 
nanostructured lipid carriers, gold nanoparticles, protein-based nanoparticles, cyclodextrin 
complexes and host–guest supramolecular nanosystems represents an interesting option for 
drug delivery, as demonstrated in Fig. 3.1. These structures are different in the way of drug 
incorporation (i.e., conjugation, non-covalent inclusion, enzyme binding), have distinct 
structural features (the composition, surface labeling) and size (1-400 nm), as well as different 
mechanisms of cellular and tissue targeting (active, passive). Examples of nanotherapeutics 
approved for clinical use or subjected to advanced clinical trials are listed in Table 3.1. 
Polymeric carriers 
Important range of application of polymers is its conjugation with the drug 
molecules. Several polymer-drug conjugates have entered clinical trials and some of them, 
like Zinostatin stimalamer® and Oncaspar®, are approved at the market (Table 3.1). They are 
especially useful to increase water solubility and to target blood vessels in tumors. Apart from 
polymers, there are several ways to functionalize drugs, including conjugation to peptides, 
saccharides and proteins, which leads to improved bioavailability and delivery specificity (Liu 
et al., 2016). However, polymer–drug conjugates require chemical modification of the 
existing drugs; as a consequence, their production could cost more, and further purification is 
needed. Moreover, the drug-polymer conjugates are usually considered as new chemical 
entities owing to a pharmacokinetic profile distinct from that of the parent drugs (Bamrungsap 
et al., 2012). 
Micelles 
Micelles are spherical colloidal amphiphilic systems, having a particle diameter 
within the range of 10-100 nm. They consist of self-assembled amphiphilic block copolymers 
with a hydrophobic core and hydrophilic shell. Among drug carrier systems, micelles provide 
considerable advantages, since they can solubilize and increase the bioavailability of poorly 
soluble drugs, and offer long blood circulation (Biswas et al., 2013). Drug release from 
micelles is dependent on the interactions between drugs and micellar cores (e.g., hydrogen 
bonding) and, therefore, is determined by molecular weight and hydrophobicity of 
amphiphilic block copolymers (Lee & Yeo, 2015). To date, several polymeric micelle 
anticancer drug-targeting systems are at different stages of clinical studies.  
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Table 3.1 Nanotherapeutics approved for clinical use or being evaluated in clinical trials 
(adapted from Egusquiaguirre et al, 2012; Gidwani & Vyas, 2015; Marchal et al., 2015) 
Nanocarrier Name Formulation Drug Indications Status 
Liposomes 
Doxil® PEGylated liposome 
Doxorubicin 
Karposi's sarcoma Ovarian cancer 
Multiple myeloma Market 
Myocet® conventional liposome Breast cancer (cyclophosphamide) Market 
Caelyx® PEGylated liposome 
Karposi's sarcoma, multiple myeloma, 
breast and ovarian cancer Market 
ThermoDox® 
Heat-activated 
PEGylated 
liposome 
Hepatocellular carcinoma Phase III 
DaunoXome® conventional liposome Daunorubicin Karposi's sarcoma Market 
DepoCyt® conventional liposome Cytarabine Lymphomatous meningitis, leukaemia, Market 
Marqibo® sulfate liposome Vincristine acute lymphoblastic leukemia FDA 2012 
Polymeric and 
Polymer-drug 
conjugate 
nanoparticles 
Zinostatin 
stimalamer® 
conjugate 
protein or 
copolymer  
styrene-maleic 
acid Hepatocellular carcinoma Market 
Oncaspar® PEG-drug L-Asparaginase acute lymphoblastic leukemia Market 
Docetaxel-
PNP 
Polymeric 
nanoparticle Docetaxel 
Various solid malignancies Phase I 
BIND-014 PEG-PLGA nanoparticle Various solid malignancies Phase II 
Abraxane® 
(ABI-007)  
Albumin-bound 
nanoparticle Paclitaxel 
Breast cancer, non-small cell lung 
cancer, Pancreatic cancer Market 
Opaxio® 
(Xyotax) 
Polyglutamic 
acid-drug Lung cancer, ovarian cancer FDA 2012 
XMT-1001 Fleximer®-drug Camptothecin Gastric cancer, lung cancer Phase I 
NKTR-102 PEG-drug Irinotecan Breast cancer Phase III 
Host–Guest 
Supramolecular 
Nanosystems 
CRLX101 CD-PEG nanoparticle Camptothecin Various malignancies Phase II 
CALAA-01 
CD-PEG-
transferrin-
nanoparticle 
Anti-RRM2 
siRNA Various solid malignancies Phase I 
Vfend 
SBE-β-CD/drug 
solution for IV 
injection 
voriconazole Invasive Fungal Infection Hematological Malignancy Phase III 
Inorganic 
nanoparticles NanoTherm
® nanoparticle Iron oxide Glioblastoma Market 
Polymeric 
micelles 
Paclical® Polymeric micelle Paclitaxel 
Ovarian cancer Phase III 
Genexol-PM® PEG-PLA micelle Breast cancer Market 
Livatag® Polymeric micelle Doxorubicin Hepatocellular carcinoma FDA 2014 
Other drug-
conjugated 
based 
nanoparticles 
Rexin-G 
Retroviral-
vector-dnG1 
plasmid DNA 
G1 gene Various solid malignancies Market/ Phase III  
Kadcyla® Antibody-drug Emtansine/trastuzumab Breast cancer Market 
Adcetris® Antibody-drug Brentuximab vedotin CD30+ lymphomas Market 
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Figure 3.1 Different types of nanocarriers have used for drug delivery (from Bamrungsap et 
al., 2012; Khodabandehloo et al., 2016; Wang et al., 2013) 
Liposomes and solid lipid carriers 
Constituted by an aqueous core surrounded by one or several phospholipid bilayers, 
liposomes are biocompatible and biodegradable entities able to entrap hydrophilic drugs into 
their cavity, while allowing water insoluble drugs to be inserted into the lipid bilayers 
(Marchal et al., 2015). PEGylation of liposomes can increase circulation time and protect the 
cargo during the circulation in the body. Liposomes, together with drug-polymer conjugates, 
are the most widely used for DDS. Some liposome formulations have been approved for 
commercial use as shown in Table 3.1. Except for liposomes on the market, a number of 
lipidic nanoparticles are in the pipeline from concept to clinical application (Liu et al., 2016). 
Solid lipid carriers, also referred as lipospheres or solid lipid nanospheres are solid at 
human physiological temperature and had a diameter of 50-100 nm. The solid lipid carriers 
could be made from diverse range of lipids including mono-, di- and triacylglycerols, fatty 
acids, waxes and combination of these materials. The solid lipid carriers could be formed by 
replacing oil with solid lipid in oil and water emulsion. Also, the solid lipid carriers were 
biodegradable and biocompatible and could be used in humans because of their reduced 
cytotoxicity (Wong et al., 2007). These carriers have formed a lipophilic matrix which 
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enabled the drug to load onto it. The important factors affecting drugs loading into the solid 
lipid carriers matrix were solubility of drug in lipid (drug must be lipophilic), physical and 
chemical properties of lipid or mixture of lipids, crystalline properties of lipids in biological 
temperature, and polymorphic form of the lipids. Solid lipid carriers have been investigated 
for delivery of various anticancer drugs with promising results in mouse preclinical models 
(Khodabandehloo et al., 2016). 
Dendrimers  
Dendrimers are natural and synthetic polymers with a central structure labeled as 
“the core”, from which the branches of other groups called “dendrons” grow through various 
reactions (Lee & Yeo, 2015). The unique surface characteristics of dendrimers enable them to 
be simultaneously conjugated with several molecules, such as imaging contrast agents, 
ligands or therapeutic drugs, and hence have created a multifunctional drug delivery system 
(Khodabandehloo et al., 2016). Drug molecules may be covalently conjugated to the 
peripheral groups of a dendrimer or included inside the core via hydrogen bonding, 
hydrophobic or electro-static interactions. In regards of biomedical applications, the 
biological properties of dendrimers are important. For example, cationic dendrimers were 
usually hemolytic and cytotoxic. On the other hand, anionic dendrimers had longer circulation 
time and higher bioavailability. Dendrimers clearance rate was generation-dependent, and 
lower generation would have longer circulation time (Jain & Tekade, 2013). Our laboratory 
together with the laboratory of photobiophysics (Berlin, German) demonstrated that 
dendrimer formulations of chlorin e6 may offer effective biocompatible nanoparticles for 
improved PDT in a preclinical tumor model (Bastien et al., 2015; Pfitzner et al., 2016) 
Host–guest supramolecular nanosystems 
The typical supramolecular hosts (i.e., cyclodextrins, calixarenes, and cucurbiturils) 
and their nanosystems have a promising application in cancer diagnostics and therapeutics 
(Gidwani & Vyas, 2015; Wang et al., 2013). A few examples have been reported where the 
supramolecular nanosystems could serve as cancer imaging probes and/or drug delivery 
vehicles in clinical trials (Davis, 2009; Davis et al., 2010). The use of DDSs, based on 
cyclodextrins or its colloidal silica nanoparticles, represents a promising and innovative 
strategy that enables effective therapy with minimum side effects. The focus of the following 
sections will be on cyclodextrins as one of the most promising delivery systems. 
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4. Cyclodextrins for drug delivery 
The inclusion complexes of cyclodextrins (CDs) with wide variety of organic and 
non-organic compounds refer to a class of the simplest supramolecular systems extensively 
studied for the last decades. The inclusion complexes based on CDs are of interest from both 
a theoretical and a practical point of view. On the one hand, their study facilitates 
understanding of the mechanisms of interaction of molecules and molecular recognition, on 
the other hand the unique properties of CDs enables using them as additives to improve the 
properties of various substances (Challa et al., 2005). As a result CDs have been explored as 
additives in the food, cosmetic and pharmaceutical industries to improve product stability and 
solubility (Loftsson & Brewster, 2010). Applications of CDs in the pharmaceutical industry 
are constantly expanding. To date there are above 40 products or formulations containing 
various CDs, especially β-CD and its derivative (Gidwani & Vyas, 2015). Moreover, CDs are 
promising delivery systems for PDT purpose (Kryjewski et al., 2015; Mazzaglia, 2012). 
4.1. Cyclodextrins: classification, structure and basic properties 
The cyclodextrins (CDs) of biomedical and pharmaceutical interest are a family of 
cyclic oligosaccharides with a hydrophobic internal cavity and a hydrophilic outer surface 
consisting of six α-cyclodextrin (α-CD), seven β-cyclodextrin (β-CD), eight γ-cyclodextrin (γ-
CD) D-glucopyranose units linked by α -(1,4) bonds. The general properties of the native CDs 
are summarized in the Table 4.1. These so-called “parent CDs” have been used in food (e.g., 
β-CD approved as a food additive E459) and pharmaceutical products (including anticancer 
drugs) for many years (Gidwani & Vyas, 2015). CDs are also known by other names 
(cycloamyloses, cellulosine, cyclomaltoses, etc.) (Loftsson & Duchêne, 2007). Usually CDs 
are formed as a result of intermolecular transglycosylation reaction (Szejtli, 1998). Due to the 
steric hindrances CDs with fewer than 6 units cannot be formed. On the other hand, the higher 
than eight glucopyranose units do exist but are of limited interest as drug solubilizers and 
stabilizers because they are rapidly reduced to smaller products (Loftsson & Brewster, 1996).  
Due to the chair structure of the glucopyranose molecules, CDs have the shape of a 
truncated cone (Table 4.1). According to X-ray study, the secondary hydroxyl groups (C2 and 
C3) are located on the wider rim and the primary hydroxyl groups (C6) on the narrow side 
(Kusmin et al., 2008). It should be noted that the primary hydroxy groups can rotate, while the 
secondary ones are relatively fixed. The apolar C3 and C5 hydrogens are located in the cavity 
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of CDs (Del Valle 2004). As a result CD molecules have a hydrophilic outside (LgKoctanol/water 
between (−13) and (−17)), and an apolar cavity, which provides a hydrophobic matrix 
comparable to about a 60–70% aqueous ethanolic solution (Connors, 1997; Loftsson & 
Brewster, 2013). The presence of a hydrophobic interior cavity allows forming inclusion host-
guest complexes with a large variety of organic and non-organic compounds. While the height 
of the CDs torus remains constant, the diameter of the cavity increases considerably with 
increase in the number glucopyranose units (Table 4.1). It is worth noting that despite the fact 
that β-CD has been more widely used in the pharmaceutical applications than other native 
CDs (Rajewski &Stella, 1996), for each specific drug, it is necessary to select the type of CD, 
depending on the size of the guest molecules or its side substituents. Thus, molecules with 
aliphatic chains fit better into the small α-CD cavity, whereas molecules containing phenyl 
groups fit better into the larger cavity of either β- or γ-CD (Duchêne, 2011; Gabelica et al., 
2002) 
An important characteristic in the pharmaceutical industry is CDs solubility in water. 
In the case of native CDs solubility changes in the range 18-250 mg/ml (Table 4.1) that is 
much lower than that of similar acyclic saccharides (Duchêne, 2011). Relatively low water 
solubility of CDs, especially of β-CD, significantly reduces their applicability. Chemically 
modified CD derivatives can overcome these problems and extend the physicochemical 
properties and inclusion capacity of parent CDs. These derivatives usually are produced by 
aminations, esterifications or etherifications of primary and secondary hydroxyl groups of the 
CDs (Szente & Szejtli, 1999). Almost all derivatives have a changed hydrophobic cavity 
volume and can improve solubility, physical and microbiological stability, reduce parenteral 
toxicity and help to control the chemical activity of guest molecules (Challa at al., 2005; 
Davis & Brewster, 2004).  
Structural and physicochemical properties of some commercially available CD 
derivatives of pharmaceutical interest are summarized in the Table 4.2. The physicochemical 
properties of CDs, including their complexation ability, depend on the structure of the 
attached substituents but also on their number and location within the CD molecule. The 
molar degree of substitution (MS) is defined as the average number of substituents per one 
glucopyranose repeat unit (Table 4.2). However, the “degree of substitution” does not 
uniquely characterize a CD derivative due to the variation of possible locations of substituted 
groups (e.g., hydroxypropyl) at different positions on the parent CD molecule (Blanchard & 
Proniuk, 1999). 
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Table 4.1 Structure and physicochemical properties of native CDs (adapted from Loftsson & Brewster 2013; Del Valle 2004) 
 
   
Property α-Cyclodextrin β-Cyclodextrin γ-Cyclodextrin 
Number of glucopyranose units: 6 7 8 
Molecular weight of anhydrous compound (Da): 973 1135 1297 
Melting temperature range (°C): 255–260 255–265 240–245 
Crystal water content (% w/w): 10.2 13.0–15.0 8–18 
Height of torus (nm): 0.78 0.78 0.78 
Inner diameter (nm): 0.50 0.62 0.80 
Outer diameter (nm): 1.46 1.54 1.75 
Cavity volume (nm3) 0.174 0.262 0.427 
Solubility in water at 25 °C (mg/ml): 129.5 ± 0.7 18.4 ± 0.2 249.2 ± 0.2 
Calculated LgK(octanol/water) at 25 °C: −13 −14 −17 
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Table 4.2 Structural and physiochemical properties of some CDs of pharmaceutical interest 
(adapted from Loftsson & Brewster, 2013; Vyas et al., 2008) 
 
Cyclodextrin n R MSa 
MWb 
(Da) 
Solubilityc 
(mg/ml) 
LgKo/wd 
2-Hydroxypropyl-α-
cyclodextrin (HP-α-CD) 
6 
-CH2CHOHCH3 
or -H  
0.65 1199 >500 < -10 
2-Hydroxypropyl-β- 
cyclodextrin (HP-β-CD) 
7 
-H2CHOHCH3  
or -H 
0.65 1400 >600 -11 
Sulfobutylether-β- 
cyclodextrin sodium salt 
(SBE-β-CD) 
7 
-(CH2)4SO2–Na+  
or -H 
0.9 2163 >500 < -10 
Randomly methylated-β-
cyclodextrin (M-β-CD) 
7 
-CH3  
or -H 
1.8 1312 >600 -6 
Maltosyl β-cyclodextrin 
(Mal-β-CD) 
7 
Maltaosyl-  
or -H 
0.14 1459 >500 < -10 
2-Hydroxypropyl- γ -
cyclodextrin(HP-γ-CD) 
8 
-H2CHOHCH3  
or -H 
0.6 1576 >600 -13 
aMolar degree of Substitution :  average number of substitution (R) per glucose repeat unit; 
derivatives may have differing degrees of substitution on the 2, 3, and 6 positions (inserted figure); 
bMW, molecular weight;  
cSolubility in pure water at approx. 25 °C;  
dPartition coefficient octanol/water; 
n, number of glucopyranoside units 
 
In aqueous solutions CDs are chemically stable under neutral and basic conditions 
and they are more resistant to both enzymatic and non-enzymatic hydrolysis than the linear 
sugars (Frömming & Szejtli, 1994). The stability of CDs toward acid hydrolysis depends on 
the temperature and acidity. Under normal experimental conditions (pH higher than 3.5 and 
temperature below 60 °C), CDs are fairly stable (Hirayama et al., 1992). Besides, CDs are 
quite resistant to light within the ultraviolet-visible spectrum and infrared ranges (Loftsson & 
Brewster, 1996).  
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4.2. Inclusion complex formation and mechanism of drug release 
Inclusion complexes 
Despite the fact that CDs are able to form non-inclusion complexes and complex 
aggregates (de Jesus et al., 2012; Loftsson et al., 2004), it is assumed that the most common, 
as well as representing the greatest pharmaceutical interest are non-covalent inclusion 
complexes (Duchêne, 2011; Loftsson et al., 2005). The most notable feature of CDs is their 
ability to form stable inclusion complexes (host – guest complexes) with a very wide range of 
solid, liquid and gaseous compounds by a molecular complexation (Laza-Knoerr et al., 2010; 
Del Valle, 2004; Vyas et al., 2008). Inclusion complexation is accomplished by the 
intermolecular interaction between CDs (host molecule) and guest, which leads to the 
penetration of the guest molecule partly or completely into the central cavity of the CDs, as 
illustrated in Figure 4.1 (Song et al., 2009). Besides, depending on their respective size, one 
CD molecule can bind more than one drug molecule, as a drug molecule may form complexes 
with several CD molecules (stoichiometry of inclusion complex).  
 
 
Figure 4.1 Schematic illustration of the association of CD and drug. Topology of 
inclusion complexes: (a) complete, (b) partial through the narrow side, (c) partial through the 
wide side, (d) axial 
Two most important properties of the complexes are their stoichiometry and the 
values of their association constants. The stoichiometry of the complex varies depending on 
the CD-drug combination. The most common stoichiometry is 1:1 (Figure 4.1a) (Tablet et al., 
2012), but others  like 1:2, 2:1, 2:2, 1:3,…can be encountered as well (Baglole et al., 2005; 
Sancho et al., 2011). Moreover, often there are systems in which there is a mixture of 
complexes with different stoichiometry. For example, Tablet et al. (2012) showed that 7-
Diethylamino-3-carboxycoumarin with γ-CD formed the mixture of 1:1+1:2 complexes. The 
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efficiency of complexation is determined by the values of association constants also known as 
affinity constant, stability constant or binding constant. The value of association constant 
correlates with the stability of the inclusion complexation (lower probability of dissociation). 
In the case of Drug/CD 1:1 complexes the values of the binding constants are usually between 
10 and 103 M−1 and values > 105 M–1 are very rare (Stella & He, 2008). One of the few 
examples of high value of the binding constant (about 107 M–1) is the complexes of 
rocuronium with sugammadex (modified γ-CD) (Adam et al., 2002). 
Inclusion complexation with CDs is a reversible process (dynamic equilibrium), i.e. 
each molecule can dissociate from the complex. There are two key factors influencing the 
ability of CDs to form inclusion complex with a guest molecule: steric and thermodynamic. 
Complex formation is a dimensional fit between host cavity and guest molecule (Muñoz-
Botella et al., 1995). It is important that no covalent bonds are broken or formed during 
formation of the inclusion complex (Schneiderman & Stalcup, 2000). The driving forces for 
the complex formation include release of enthalpy-rich water molecules from the cavity, 
electrostatic interactions, van der Waals interactions, hydrophobic interactions, hydrogen 
bonding, release of conformational strain and charge-transfer interactions 
(Loftsson et al., 2005; Liu & Guo, 2002).  
It is important to note that the physicochemical properties of free drug molecules are 
different from those bound to the CD molecules. Any changes in the physico-chemical 
properties of the guest molecules through complexation with CDs allow determining the 
stoichiometry of the complexes and the value of binding constants (Del Valle, 2004). These 
modifications include changes in solubility (Higuchi & Connors, 1965), changes in chemical 
reactivity (Másson at al., 1998), changes in photophysical properties (Lang et al., 2004), 
nuclear magnetic resonance (NMR) chemical shifts (Pessine et al., 2012), changes in drug 
retention (e.g., in liquid chromatography), changes in the physicochemical properties of 
aqueous complexation media (e.g., measurements of conductivity, viscosity), etc. Although 
there are many techniques, information on the structure of the complexes can be 
experimentally obtained only from 2D-NMR and induced circular dichroism spectra. 
Especially interesting is the last one. Circular dichroism is essentially an absorption 
phenomenon occurring when an optically active molecule absorbs to different degrees the 
right and left components of a circularly polarized light beam (Berova et al., 2000). Optically 
active molecules of CDs themselves do not show any significant ultraviolet absorbance and 
do not fluoresce. Being symmetrical molecules, CDs have no dichroic activity, but they can 
modify that of guest molecules by perturbation of the microenvironment polarity resulting 
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from the inclusion (Duchêne, 2011; Ventura et al., 2006). The formation of an inclusion 
complex between an optically inactive molecule and CDs may result in the appearance of an 
induced circular dichroism (Desroches et al., 2001; Nablet et al., 2012).  
It is worth noting that the efficiency of the formation of inclusion complexes is 
determined by many factors, including temperature, solvents composition, amount of water 
(the degree of complexes dilution), complexation techniques. Ionization of the guest, salt 
formation, formation of metal complexes, application of supercritical fluids and addition of 
organic co-solvents to the drug/CDs aqueous solution will, if the conditions are correct, lead 
to enhanced complexation efficiency (e.g., enhanced solubility) (Arun et al., 2008; Loftsson 
& Duchêne, 2007; Van Hees et al., 1999). 
4.3. Effects of cyclodextrins on drug properties in cyclodextrin-based 
formulations 
Inclusion in CDs exerts a profound effect on physicochemical properties of guest 
molecules as they are temporarily locked or partially caged within the host cavity giving rise 
to beneficial modification of guest molecule properties. Indeed, CDs increase drug solubility, 
dissolution, circulation time thus enhancing their bioavailability (Acartürk & Çelebi, 2011).  
4.3.1. Effect on drug solubility, dissolution and stability  
Drug solubility and dissolution  
The most common application of CDs in pharmacy and other fields is related to their 
ability to increase solubility of poorly water-soluble substances. The increased apparent 
solubility allows solution-based dosage forms, such as parenteral (IV) and peroral 
formulation. Besides, improving the apparent solubility of a drug through CDs complexation 
can increase its dissolution rate and, for compounds whose oral bioavailability is limited by 
solubility or dissolution rate, can increase oral bioavailability (Acartürk & Çelebi, 2011; 
Ahuja et al., 2011). For example, the solubility of cortisone acetate increased from 0.039 g/L 
to 7.382 g/L (almost 200 times) in the presence of HP-β-CD that is far superior to 
dimethylformamide and ethanol (Kalogeropoulos et al., 2009). 
The use of CDs is usually preferred over organic solvents from both a toxicological 
perspective and solubility mechanism. In the case of organic solvents or co-solvent cocktails, 
significant drug solubility in aqueous solution is occurred at sufficiently high content of 
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organic solvent (> 30-40%) and solubility depends in a very nonlinear fashion on water 
quantity (Stella & He, 2008).  
CDs may acting as tablet dissolution enhancers for drugs at high dose (with which 
use of a drug/CD complex is difficult) e.g., paracetamol (Tasić et al., 1992). Out of some 
commercially available CDs, methylated CDs with a relatively low molar substitution appear 
to be the most powerful solubilizers (Challa et al., 2005). The water solubility enhancement 
factor of melarsoprol was about 7.2·103 times greater when the drug was complexed with M-
β-CD (Gibaud et al., 2005). 
Reduction of drug crystallinity upon complexation with CDs also contributes to the 
CD increased apparent drug solubility and dissolution rate (Becket et al., 1999; Vyas et al., 
2008). For example, during storage carbamazepine strongly crystallizes that significantly 
reduces predictable dissolution and bioavailability. Introduction of Hp-β-CD, as a carrier, 
reduced crystalline nature of carbamazepine in solid dispersions and resulted in better and 
predictable dissolution profiles (Londhe & Nagarsenker, 1999). Furthermore, CDs can 
significantly accelerate the drug release, for example β-CD and their derivatives enhanced the 
release rate of poorly soluble naproxen and ketoprofen from inert acrylic resins and 
hydrophilic swellable (high-viscosity hydroxypropyl methyl cellulose) tableted matrices (Ann 
et al., 1997; Bettinetti et al., 1992; Sangalli et al., 2001).  
Drug stability 
CDs can improve both chemical and physical stability of drugs. CDs reduce the rate 
of drug hydrolysis, oxidation, steric rearrangement, racemization, isomerization and 
polymerization as well as enzymatic and photo-decomposition of labile drugs thus increasing 
the shelf life of drugs (Ahuja et al., 2011; Babu & Pandit, 1999; Li et al., 2002; Loftsson & 
Brewester, 1996; Lutka, 2002). Ansari et al. (2009) demonstrated that dihydroartemisinin/HP-
β-CD complexes prepared using commercial (untreated) or recrystallized dihydroartemisinin 
showed a 40% increase in thermal stability and a 29-fold decrease in hydrolysis rates 
compared to dihydroartemisinin. It was reported that CD-induced enhancement of drug 
stability may be a result of inhibition of drug interaction with vehicles and/or inhibition of 
drug bioconversion at the absorption site (Matsuda & Arima, 1999). By providing a molecular 
shield, CD complexation encapsulates labile drug molecules at the molecular level and thus 
insulates them against various degradation processes (Arima et al., 2011). Since the 
hydrolysis of drugs encapsulated in CDs is slower than that of free drugs (Brewster et al., 
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1992), the magnitude of the complex stability constant plays a significant role in determining 
the extent of protection (Kang et al., 2002; Nagase et al., 2001). 
The stabilizing effect of CDs depends on the nature and effect of the included 
functional group on the drug stability and the nature of the vehicle. The large charged groups 
on SBE-β-CD showed greater stability enhancement of many chemically unstable drugs than 
other CDs including the Hp-β-CD and M-β-CD (Ma et al., 2000; Ueda et al., 1998). From the 
solubility of phenytoin and the kinetic information, the fosphenytoin shelf life was as high as 
nine years at 25 °C and pH 7.4 in the presence of 60 mM of SBE7m-β-CD, although increasing 
the pH to 8 could increase the shelf life fosphenytoin even more (Narisawa & Stella, 1998).  
However, there are enough examples that CDs catalyze the degradation of some drug 
molecules (Jarho et al., 2000; Narisawa & Stella, 1998; Tonnesen et al., 2002). The effects of 
CDs on the rate of drug degradation are pH-sensitive and depend on ionization stage of the 
drug (Loftsson & Brewster, 2013).  
4.3.2. Effect on drug permeation through biological membranes 
CDs can enhance the permeation of poorly water-soluble drugs through different 
biological membranes (Másson et al., 1999). For example, permeation studies of omeprazole 
indicated a 1.7-fold increase in drug permeation when complexed with M-β-CD (Figueiras et 
al., 2009). Only relatively lipophilic molecules can penetrate through the biological 
membranes. Through CD complexation it is possible to increase aqueous solubility of drugs 
without affecting their intrinsic abilities to penetrate through lipophilic membranes. However, 
the effect of CDs cannot be explained by only increasing of the drug solubility in the aqueous 
solution or by assuming that CDs act as classical permeation enhancers (reducing the barrier 
function of the lipophilic membrane). The CDs allow delivering the drug to the biological 
membrane via the water phase. In general, the resulting unstirred water layer formed by water 
molecules in the skin is relatively thin and permeable (Wertz, 2004). On the other hand, 
mucosal epithelium is covered by the layer of mucus, a gel-like fluid containing mainly water 
(∼95%) and mucin (Bansil & Turner, 2006). Researchers have shown that passive drug 
diffusion through mucus is up to 100-times slower than through pure water (Khanvilkar et al., 
2001).  
Complexation of hydrophobic drugs with CDs makes them available at the surface of 
the biological barrier (e.g., eye cornea, skin). Besides, inclusion complexes permeate into the 
membrane without disrupting the lipid layers of the barrier. After analyzing the existing 
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studies (Ahuja et al., 2011; Khanvilkar et al., 2001; Loftsson et al., 2007; Loftsson & 
Brewster, 2013), the following patterns can be identified: 
 introduction of excess amount of CDs, more than is needed to solubilize the drug, 
leads to decreasing drug permeation. Study by Másson et al. (1999) demonstrated 
that the flux of hydrocortisone at different M-β-CD and Mal-β-CD concentrations 
increased sharply with increase of CD concentration and decreased when CDs 
were in excess;  
 only with considerable resistance of unstirred water layer (equal or greater than 
resistance of the membrane), the use of CDs can improve the delivery of drugs 
across biological membranes; 
 CDs allow better penetration through the skin surface only water-based dermal 
vehicles, i.e. requires the presence of unstirred water layer at the membrane 
surface. For example, CDs enhance dermal delivery of hydrocortisone from o/w 
(oil in water) creams but not w/o creams (Preiss et al., 1995); 
 CDs themselves and their inclusion complexes do not penetrate biological 
membranes. Therefore drug molecules have to be released from the complexes 
before they can permeate the membranes; 
 permeation of labile drugs may be increased through CD-stabilization, i.e. CDs 
are able to prevent enzymatic degradation of drugs at the exterior aqueous 
membrane (Majumdar & Srirangam, 2009); 
 usually, CDs do not enhance membrane permeation of water-soluble drugs; 
 CDs can significantly increase the solubility and enhanced permeation of ionized 
drugs. For example, the flux of the ionized ketoprofen at 10% w/v HP-β-CD 
concentration was enhanced approximately 8 times compared to the intrinsic 
permeability of the nonionized drug (Sridevi & Diwan, 2002). 
4.3.3. Effect on drug bioavailability and safety 
CDs enhance the bioavailability of wide range of drugs (especially hydrophobic) by 
increasing the drug solubility, dissolution, and/or drug permeability. Literature data have 
shown that CDs are used to increase oral (Corti et al., 2008), nasal (Tas et al., 2009), ocular 
(Cappello et al., 2001), rectal (Değim et al., 2005) and dermal–transdermal (Kear et al., 2008), 
bioavailability. The mechanisms enhancing bioavailability of the drugs complexed with CDs 
are summarized as follows (Acartürk & Çelebi, 2011; Ahuja et al., 2011; Davis & Brewster, 
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2004; Miyake et al., 2000; Rajewski & Stella, 1996; Stella et al., 1999; Vyas et al., 2008; 
Uekama et. al., 2006; Uekama, 2004): 
 increasing the solubility, dissolution rate, and wettability of hydrophobic drugs in 
inclusion complexes; 
 CDs prevent the degradation  of chemically unstable drugs, as well as during 
storage; 
 competitive inclusion complexation with endogenous components of blood (e.g., 
cholesterol) to release the included drug; 
 CDs disturb the membranes fluidity lowering their barrier function, which 
consequently enhances the absorption of medication through the mucosa; 
 CDs can also allow reducing drug-related irritation and masking bitter tastes; 
 CDs (e.g., DM-β-CD) can affect multidrug efflux pump, P-glycoprotein (P-gp) 
and multidrug resistant-associated protein 2 enabling oral bioavailability of 
hydrophobic drugs (e.g., tacrolimus and vinblastine) (Carrier et al., 2007; 
Yunomae et al., 2003). 
Various factors associated with CD complexation affect the bioavailability of drugs: 
(1) the binding constant, (2) the type of CDs, (3) the properties of the drug, (4) the 
complexation methods and (5) the composition of ingredients used in formulation (Acartürk 
& Çelebi, 2011). For example, the high association constant (106 M-1) between ozonide 
antimalarial and SBE7-β-CD resulted in slow dissociation of the complex after IV 
administration (Charman et al., 2006). It causes significant alteration of pharmacokinetics of 
the ozonide expressed as an 8.5-fold decrease in the steady-state blood volume of distribution, 
a 6.6-fold decrease in the mean residence time and a greater than 200-fold increase in renal 
clearance of the drug. Moreover, CDs with such a high association constant can alter the 
pharmacokinetics and bioavailability of the already administered drug through an additional 
injection of CDs. (Mannila et al., 2012). In addition, CDs also prevent crystallization of active 
ingredients by complexing individual drug molecules so that they can no longer self-assemble 
into a crystal lattice (Arima et al., 2001). Thus, CDs can enhance the oral bioavailability of 
drugs in different ways (Challa et al., 2005). 
The increased drug efficacy and potency (i.e., reduction of the dose required for 
optimum therapeutic activity), caused by CD-increased drug solubility, may reduce drug 
toxicity by making the drug effective at lower doses. For example, β-CD enhanced the 
antiviral activity of ganciclovir on human cytomegalovirus clinical strains and the resultant 
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increase in the drug potency reduced the drug toxicity (Nicolazzi et al., 2002). The toxicities 
associated with crystallization of poorly water-soluble drugs in parenteral formulations can 
often be reduced by formation of soluble drug/CD complexes (Blanchard et al., 2000). 
Finally, inclusion of drugs into CDs cavity at the molecular level prevents their direct contact 
with biological membranes and thus reduces their side effects and local irritation with no 
drastic loss of therapeutic benefits (Challa et al., 2005; Uekama et al., 1998). 
4.4. Pharmacokinetics, biological activity and toxicology of 
cyclodextrins 
As shown earlier, CDs have a great potential in the pharmaceutical field due to their 
ability to improve the drug properties. However, application of CDs as drug delivery systems 
requires knowledge of its pharmacokinetic and pharmacodynamic properties including in 
vitro cellular interactions and in vivo safety profiles. Moreover, CDs have ability to interact 
with various endogenous and exogenous molecules (e.g., cholesterol), and affect cellular 
processes. We shall further consider the most important properties of the cyclodextrin 
behavior in biological systems. 
Pharmacokinetics and biodistribution  
Pharmacokinetics of CDs and their excretion from the body will be defined inter alia 
by route of administration. However, there are general patterns, which will be described, for 
example, for oral and parenteral routes of CDs administration. Due to the relatively high 
molecular weight (from 973 to over 2000 Da) and hydrophilic nature only insignificant 
amounts of intact CDs are absorbed from the gastrointestinal tract, thus, their oral 
bioavailability is generally below 3% (Loftsson & Brewster, 2011). The absorbed CDs are 
rapidly excreted with the urine without any significant metabolism. The native α-CD and β-
CD are practically resistant to stomach acid and pancreatic enzyme digestion, whereas γ-CD 
is metabolized partly by amylases in the gastrointestinal tract. The oral bioavailability of Hp-
β-CD in humans is between 0.5 to 3.3% depending on the dosage and formulation (Gould & 
Scott, 2005; Szathmary et al., 1990; Zhou et al., 1998). Besides, more than half of the initial 
oral dose is excreted intact in the feces (Loftsson & Brewster, 2013). At the same time more 
lipophilic methylated CDs have a strong absorption in the body. According to Mosher & 
Thompson (2007) the absorption of DM-β-CD in rats is 6.3% to 9.6% and in the case of M-β-
CD can reach 15% (Antlsperger & Schmid, 1996).  
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Parenteral administration of CDs, on the other hand, can be somewhat more limited. 
IV-injected CDs eliminate rapidly from systemic circulation and more than 90% of introduced 
CDs are renally excreted in intact form (Stella & He, 2008). For example, IV-administrated to 
humans, Hp-β-CD has a relatively small volume of distribution VD ≈ 200-250 mL/kg and 
short half-life t1/2≈1.8 h, and is mainly excreted unchanged with the urine (Szathmary et al., 
1990; Zhou et al., 1998).  Rapid elimination and a small volume of distribution are inherent 
for the majority of CDs administered to animals or humans (see Table 4.3). The small VD 
indicates that systemically absorbed CDs distribute mainly in the extracellular compartments 
without involving deep compartments or storage pools (Stella & He, 2008). However, due to 
the ability to interact with components of blood and cellular membranes, the methylated β-CD 
has a larger volume of distribution (VD ≈ 2.5 L/kg) and longer half-life (t1/2 ≈7 h) compared 
to other CDs derivatives (Thompson, 1997). For parenterally administered Hp-β-CD in 
humans, a non-saturable excretion mechanism is observed even at high doses. The 
pharmacokinetics of SBE-β-CD is very similar to that of Hp-β-CD. Indeed, the total plasma 
clearance for HP-β-CD and SBE-β-CD in all tested species is similar to the glomerular 
filtration rate (Davies & Morris, 1993; Rajewski & Stella, 1996) and almost all introduced 
CDs are excreted in the urine within 12 h (Zhou et al., 1998), except methylated β-CD. For 
example, M-β-CD persists for at least 6 days after a single IV administration (10 mg /kg) and 
is almost at the same level in the renal cortex (50-70% of all absorbed CD according to 
radioactivity study) as at 24 h after injection (Antlsperger & Schmid, 1996). In this regard, it 
is necessary to use CDs with extreme caution in patients with renal failure, because CDs, in 
this case, will accumulate in the body (Slain et al., 2001; von Mach et al., 2006). 
The main distribution areas of CDs after their absorption include the following 
tissues: kidney, bladder, adrenal glands and liver (Antlsperger & Schmid, 1996; De Bie et al., 
1998; Gerloczy et al., 1990; Kubota et al., 1996; Van Ommen et al., 2004). The highest 
concentration of absorbed CDs is in the kidneys. In regards to biodistribution in tumor-
bearing rodents, the results of several studies have showed that a significant amount of 
methylated CDs is distributed in the tumor tissue, e.g. primary effusion non-Hodgkin 
lymphoma (Gotoh et al., 2014), and various carcinoma in xenograft tumor bearing mice 
(Grosse et al., 1998; Onodera et al., 2013a). Grosse et al. (1998) have showed that M-β-CD 
after 3 hours of parenteral administration in MCF7 xenografts was accumulated mostly in 
tumor and kidneys and a small quantity in intestine and liver. Concentrations in lungs and 
muscle were almost undetectable. 
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Table 4.3 Pharmacokinetic parameters of some CDs IV administered  
(from Stella & He, 2008) 
Cyclodextrin Species 
Dose 
(mg/kg) 
t1/2 
(min) 
VD 
(mL/kg) 
Plasma 
clearance 
(mL/min/kg) 
β-CD Rat 50 21.6 201.8 7.53 
HP-β-CD Rat 200 23.9 194 7.2 
HP-β-CD Human 43 102 222 1.57 
HP-β-CD Human 114 114 253 1.54 
SBE-β-CD Rat 600 18 300 9.8 
SBE-β-CD Rabbit 600 30 200 5.2 
SBE-β-CD Dog 240 66 430 4.7 
SBE-β-CD Human 100 84 200 1.9 
M-β-CD Rabbit 200 420 2500 3.8 
 
Toxicology of CDs 
To date, there are a huge number of publications, including a detailed review of the 
toxicological status of CDs and their biological activity (Antlsperger & Schmid, 1996; Arima 
et al., 2011; Irie & Uekama, 1997; Gould & Scott, 2005; Loftsson & Brewster, 2011; Mosher 
& Thompson, 2007; Thompson, 1997; Zidovetzki & Levitan, 2007). We shall further briefly 
review the toxicology issues.  
Toxicological studies of various CDs have been conducted following different 
administration routes in numerous formulations. In the case of oral administration of CDs the 
following abnormalities were observed: soft feces or diarrhea, cecal enlargement on oral 
administration, and renal effects subsequent to systemic absorption (Mosher & Thompson, 
2007; Thompson, 1997). The major findings following parenteral administration of CDs at 
high doses or during a long period of application include vacuolation of hepatocytes and 
urinary bladder and foamy macrophages in the liver, lung, and lymph nodes (Stella & He, 
2008). With the exception of α-CD, β-CD, and methylated-β-CD, no evidence of 
inflammatory responses, cell death, and cell degeneration or regeneration is observed in 
studies reported to date (Mosher & Thompson, 2007). Furthermore, in the case of γ-CD, Hp-
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β-CD, and SBE-β-CD vacuolation is reversible after discontinuation of the CDs (Frijlink et 
al., 1991a; Rajewski & Stella, 1996). 
Since kidneys are the main absorption site of CDs in the body, the renal toxicity 
should be carefully considered. The main effect of CDs in the kidney is vacuolation of 
proximal tubular epithelium. Many studies have demonstrated that CDs, especially β-CD and 
its methylated derivatives cause renal toxicity (Frank et al., 1976; Irie & Uekama, 1997; 
Thompson, 1997). These changes begin with an increase of apical vacuoles and the 
appearance of giant lysosomes. Prominent acicular microcrystals are observed in lysosomes. 
These changes are followed by disruption of mitochondria and other organelles, and 
eventually, irreversible cell injury and kidney dysfunction occurs. The effective dose of M-β-
CD to induce kidney damage is even lower than that of β-CD (Antlsperger & Schmid, 1996; 
Irie & Uekama, 1997). The renal toxicity may be caused by CDs according to the following 
scheme: (1) IV-injected cyclodextrin binds endogenous cholesterol and some phospholipids 
(also CDs may extracted its from the cells); (2) glomerular filtration of the cholesterol-
cyclodextrin complex is followed by dissociation of the complex in the ultrafiltrate, resulting 
in cholesterol accumulation in the proximal tubule cells; (3) due to limited aqueous solubility 
of the complexes in renal tissue, the complexes crystalize and formed needle-like crystals 
cause kidney damage (Frijlink et al., 1991a). However, CDs like γ-CD, Hp-β-CD, and SBE-β-
CD may be used in high doses without causing any significant effects on the human kidney. 
For example, IV-introduction of Hp-β-CD in healthy volunteers has been studied at a single 
dose up to 3 g and was well tolerated (Gould & Scott, 2005). CDs such as Hp-β-CD and SBE-
β-CD are widely used in marketed parenteral drug formulations (Kurkov et al., 2012). 
It should be noted that at the joint introduction of CDs with drugs, a decrease of 
toxicological effects of both substances was reported (Arima et al., 2011; Mosher & 
Thompson, 2007). For example, IV injection of M-β-CD (5 mg/kg) to tumor-bearing mice 
significantly increased blood urea nitrogen, aspartate aminotransferase and lactate 
dehydrogenase levels, compared to control, suggesting induction of systemic side effects 
(Onodera et al., 2013a). On the other hand, co-administration of doxorubicin (5 mg/kg) with 
M-β-CD (12 mg/kg) significantly reduces systemic side effects of both compounds (in the 
case of M-β-CD compared to 5 mg/kg dosage) (Motoyama et al., 2013).  
Biological activity 
Numerous studies have shown that a variety of cellular functions are affected when 
cells are treated by β-CD and its derivatives. For example, M-β-CD has the high affinity for 
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cholesterol and is used widely as a lipid raft–disrupting agent (Kilsdonk et al., 1995; 
Mohammad et al., 2014; Zidovetzki & Levitan, 2007). Due to the highest affinity for 
inclusion, cholesterol is a primary target of CDs in the cell membrane (Irie et al., 1992; 
Ohtani et al., 1989; Ohvo & Slotte, 1996). Depletion of membrane cholesterol results in 
increased membrane fluidity and induces membrane invagination through a loss of bending 
resistance and as such causes cell lysis (Challa et al., 2005). It has been shown that under 
certain conditions β-CD and its methylated derivatives induce apoptosis via the activator 
caspase-8, which subsequently activates the effector caspases-3/-7 (Onodera et al., 2013b; 
Schönfelder et al., 2006). Removal of cholesterol disrupts integrity of lipid rafts and 
concurrently enhances the permeability of ions and small non-electrolytes (Chen et al., 1978; 
Mohammad et al., 2014). On the other hand, membrane cholesterol depletion at high CD 
concentration (higher than 1-5 mM) inhibits endocytotic processes (O' Neill et al., 2011; 
Zuhorn et al., 2002) and increases exocytosis (Chen et al., 2010). 
Decreasing the concentration of the CDs and/or using shorter incubation time result 
in moderate depletion effects. On the other hand, depletion of membrane phospholipids (e.g., 
phosphatidylcholine and sphingomyelin) by CDs results in bilayer imbalance. The removal of 
lipids may also promote in part the formation of stomatocytes through an inward bending of 
biological membranes (Figure 4.2). A similar mechanism leads to the lysis of artificial 
membranes treated by CDs (Hatzi et al., 2007). However, unlike detergents, CDs solubilize 
membrane components without entering inside cells and, thus, the perturbing effects of CDs 
can be mild and reversible (Challa et al., 2005; Irie & Uekama, 1997). Besides, CDs may 
function as a cholesterol shuttle, enhancing cholesterol bidirectional flux without changing the 
equilibrium cholesterol distribution between cells and medium (Atger et al., 1997). Leventis 
& Silvius (2001) demonstrate that β-CDs and γ-CDs can dramatically accelerate the rate of 
cholesterol transfer between lipid vesicles.  
At the initial stage after administration, CDs interact with blood cells, thus, 
erythrocytes are good and simple model for assessing the instinct toxicity of CDs. The in vitro 
hemolytic activity of CDs is reported in the order β-CD >α-CD > Hp-β-CD >γ-CD >> Hp-γ-
CD ≥ Hp-α-CD in red blood cells freshly collected from human and P388 murine leukemic 
cells (Leroy-Lechat et al., 1994; Rajewski & Stella, 1996). Irie & Uekama (1997) reported 
that hemolytic effects of various CD derivatives decreased in the order dimethyl-β-CD >> 
trimethyl-β-CD >β-CD > Hp-β-CD ≥ α-CD >>> γ-CD. The concentration of Hp-β-CD less 
than 5 mg/ml did not cause hemolysis. It is clear that these differences are attributed to the 
differential solubilization effects of membrane components by each CDs rather than their 
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intrinsic solubility or surface activity (Arima et al., 2011). This is supported by the fact that a 
positive correlation arises between the hemolytic activity of several CDs and their capacity to 
solubilize cholesterol and some phospholipids (Irie & Uekama, 1997; Thompson, 1997). The 
suggested mechanisms of morphological changes in erythrocytes induced by different CDs 
are represented in the Figure 4.2.  
 
 
 
Figure 4.2 Mechanism proposed for morphological changes in red blood cells induced by 
CDs (from Arima et al., 2011) 
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4.5. Mechanism of drug release from cyclodextrin complexes 
Studies on drug release mechanism provide important information about the behavior 
and functioning of drug/carrier complex in biological systems. Although it is possible to 
predict the pharmacokinetics of the drug after administration from the value of drug/CD 
association constants, physiological environment has to be considered (e.g., plasma proteins 
competition with CDs for drug binding) (Loftsson et al., 2016). Different mechanisms play an 
important role in drug release from the drug/CD inclusion complex. Drug/CD complexes are 
dynamic system continually forming and dissociating with life-times in the range of 
milliseconds or less (García-Ruiz et al., 2005; Stella et al., 1999). Therefore, it will not be the 
governing factor in the study of the kinetics of drug release. Even at high affinity the drug is 
quickly released from the complexes. Despite the fact that the major driving force for 
dissociation of drug from the complex is related to simple dilution (Stella & He, 2008), other 
mechanisms have a significant impact, such as competitive displacements of the drug from 
the complex, binding to protein, uptake by tissues (Stella et al., 1999). 
Dilution  
Dissociation due to dilution appears to be a major release mechanism for the drug 
from CD complexes. Indeed, a simple dilution of 1000 times of drug/CD complex with the 
association constant 610 M-1 leads to the release of more than 95% of the drug from the 
complex (Stella et al., 1999). Only for strongly bound drugs, with association constants of 
104 M-1 or higher, other ways to of release may be considered (Loftsson et al., 2016; Stella & 
He, 2008). Dilution is minimal when a drug/CD complex is administered by ophthalmic, 
transdermal and transmucosal routes (Rajewski & Stella, 1996). Peroral administrated 
complexes also dissociate rapidly upon dilution in the stomach and intestine and it is 
considered that only the drug is absorbed (not the complex) (Loftsson & Masson, 2001; Tong 
& Wen, 2008). 
Protein binding  
Drug binding to plasma proteins is an important mechanism of drug release from a 
drug/CD complex. Obviously the proteins may effectively compete with CDs for drug 
binding and thus facilitate the in vivo drug release. Frijlink et al. (1991b) studied the effect of 
Hp-β-CD on the displacement of both naproxen and flurbiprofen from plasma proteins in 
vitro. The complexes of Hp-β-CD with naproxen (K = 2207 M-1) or flurbiprofen 
(K = 12515 M-1) characterized by 2207 M-1 and 12515 M-1 binding constants, respectively. 
Only in the case of flurbiprofen a significant fraction of the drug associated with the CD in 
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serum was observed in vitro, which is reflected with altered biodistribution and 
pharmacokinetic of flurbiprofen by Hp-β-CD immediately after IV-injection (10 min) in vivo. 
In the case of complexes with moderate binding constant (less than 104 M-1) and relatively 
high affinity to plasma proteins, binding of drug to plasma proteins will play a major role in 
the drug release from the compexes and its further distribution (Kurkov et al., 2012). 
Oppositely, for drugs showing large CD complex binding constant and low protein binding 
like rocuronium in presence of sugammadex (K = 2.5·107 M−1 and 30 % protein binding) 
(Adam et al., 2002), significant decrease in distribution volume and enhanced excretion of 
unmetabolized drug are observed (Loftsson et al., 2016). 
Competitive displacement  
Another important mechanism influencing the drug release from the complexes is 
competitive displacement by endogenous molecules in vivo. Frijlink et al. (1991b) study 
showed that the cholesterol could displace both naproxen and flurbiprofen from CD by 
competitive binding. On the other hand, the addition of a competing agent allows a controlled 
release of the drug from the CD complexes (Hirayama & Uekama, 1999). Oral administration 
of the complex of cinnarizine with β-CD showed decrease in the drug bioavailability due to 
strong complexation (Tokomura et al., 1986). Co-administration of phenylalanine (competing 
agent) improved the bioavailability of cinnarizine in comparison to the conventional tablets 
formulation. 
Drug uptake by tissue  
In the case of highly bound drugs or when the complex is administered at a site 
where dilution is minimal (e.g., ocular, nasal, rectal administration) drug uptake by tissues is a 
potential contributing mechanism for drug release from CD complex. If the lipophilic drug 
has an access to tissue, which in ite turn is not available to the CD or the complex, the tissue 
then acts as an absorber causing dissociation of the complex based on simple mass action 
principles (Stella et al., 1999). The scheme of drug absorption from the CD complex by 
tissues can be demonstrated on ocular drug administration. Upon ocular administration, the 
free drug is transported across the cornea competing with elimination of the free CDs and the 
complex via the nasolacrimal drainage (Loftsson & Stefansson, 1997). The absorption rate 
will depend on CD concentration (laws of mass action).  
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Change in ionic strength and temperature 
Binding of drug to CD is an exothermic process, i.e. any increase in temperature 
results in weakening of the complex, and thus increasing the release of drug (Inoue et al., 
1993). Most of the drug/CD complexes are usually prepared and stored at/or below room 
temperature. Normal body tissue temperatures (37°C) may contribute to drug dissociation in 
physiological environment (Stella et al., 1999). In the case of a weak electrolyte, the strength 
of binding to CD is determined by the charged state of the drug and, hence, depends on the 
pH of environment. For most molecules, the ionized or charged form of the molecule has 
weak affinity to CDs compared to the non-ionized or neutral form of the drug especially when 
bound to a neutral CD (Patel et al., 2007). 
 
In summary, the relative contribution of all mentioned mechanisms will however 
depend on the route of administration, volume of distribution of drug and CD, binding 
strength and concentrations of drug and CD, as well as relative affinity and concentration of 
competing agent (e.g., proteins, cholesterol). 
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5. Use of cyclodextrins in photodynamic therapy 
In previous chapters it was shown that CDs effectively interact with a large number 
of compounds improving their properties, hence, it is not surprising that the CDs were tested 
as delivery systems in PDT. Although the first mention of the use of CDs in the field of PDT 
dates back to the early 1990s (Kessel et al., 1991; Garbo, 1990), intensive research began only 
in the last decade (Kryjewski et al., 2015; Lang et al., 2004; Mazzaglia, 2011). Nowadays, 
over than 150 papers and conference reports have been published on CDs application in PDT. 
Most of these studies are related to the tetrapyrrolic (porphyrinoid) PSs. At the same time 
literature data indicate the successful use of CDs with other PSs, such as hypericin (Sattler et 
al., 1997; Zhang et al., 2013), aminolevulinic acid (Aggelidou et al., 2014), fullerene (Ikeda et 
al., 2013; Iohara et al., 2012; Zhao et al., 2009), squaraine dyes (Arun et al., 2011), curcumin 
(Haukvik et al., 2009; Wikene et al., 2014) and phenosafranin (Kundu et al., 2016). However, 
in this section we will focus exclusively on the porphyrinoid (e.g., porphyrins, chlorins and 
phthalocyanines) PSs. 
The following problems were tried to be solved by means of the use of CDs in PDT: 
i) enhancement of PSs water solubility, ii) changes of the photophysical characteristics of 
PSs, including the generation of ROS and iii) improving of PS delivery to targets cells/tissues. 
The solution to these problems was carried out by various ways, such as non-covalent 
inclusion complexation, covalent conjugation or formation of nanoassamblies between PSs 
and CDs (Figure 5.1).  
5.1 Inclusion complexes of cyclodextrins with photosensitizers 
Host–guest complexes between tetrapyrrole PSs and CDs are usually formed by 
incorporating a part of the sensitizer (e.g. aryl substitutes) into CD cavity due to relatively 
large size. The small size of the α-CD cavity does not allow forming inclusion complexes 
with porphyrinoid PS. The binding modes of aryl substituted tetrapyrroles can be classified 
into three types (Lang et al., 2004):  
 Inclusion through the secondary face (typical for β-CDs). Inclusion complexes of 
tetrakis(3,5-dibromo-2-hydroxylphenyl)porphyrin with β-CD is an example of this 
inclusion mode (Zhang et al., 2005). 
 Inclusion through the primary face (typical for γ-CD). For example, complexes  
of   tetrakis(4-sulfonatophenyl)porphyrin  (TTPS4)  with  β-CD  and  γ-CD  show  
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Figure 5.1 The type of CDs binding with tetrapyrrole photosensitizers: host-guest (Lang et 
al., 2004), conjugate (Kirejev et al. 2014), nanoassemblies (Mazzaglia et al. 2013) 
different geometry: insertion of the phenyl substituent through the CD secondary 
face for β-CD and through the primary face for γ-CD (Ribó et al., 1995). 
 Non-specific external binding. This type of binding is of interest in the formation 
of CD-PS nanoassembly and will be discussed later (chapter 5.3) 
Binding of PS to CDs increases water solubility of PS, usually leading to spectro-
fluorescence changes and minimally affecting the formation of singlet oxygen compared to 
monomer form of PS. For example, inclusion complexation between mTHPP and Hp-β-CD 
results in nearly 300 times enhancement of fluorescence intensity of PS in PBS solution (Guo 
et al., 2005). It is worth noting that PS:CD 1:2 stoichiometry along with the 1:1 is the most 
common. Although, computer modeling of interaction between Zn-phthalocyanines and 
native CDs showed 1:4 stoichiometry in all cases (Lu et al., 2016). The inclusion of PS in the 
CD does not alter the equilibrium between Type I and Type II pathways in the ROS 
production (Cellamare et al., 2013; Lang et al., 2004). 
The study of Mosinger et al. (2002) showed the influence of different CDs on the 
photophysical properties of porphyrin PSs (TPPS4, Zn-TPPS4, Pd-TPPS4 and tetrakis(4-
carboxyphenyl)porphyrin). Almost all obtained complexes were characterized by 1:1 
stoichiometry of binding. The binding constants (102–105 M−1) depend on the cavity size and 
the functionalization of the primary and secondary faces of CDs. The highest binding 
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constants and relevant changes in photophysical characteristics were obtained for Hp-β-CD 
(~105 M-1). While the magnitude of the QY of fluorescence and triplet state are practically not 
changed, the lifetime of the triplet states of the bound porphyrins in the absence of oxygen is 
considerably extended (in some cases more than an order of magnitude). This fact is due to 
the exclusion of water molecules from the solvation shell of porphyrins and reduction of 
collisional quenching (Lang et al., 2004). Furthermore, in the case of Hp-β-CD complexes the 
QY of singlet oxygen generation increased by 15-20% compared to free PS, which is 
associated with an increase in the lifetime of the triplet state. Similar results were obtained for 
the other porphyrinoid/CD inclusion complexes (Cosma et al., 2006; Guo et al., 2005; Kano et 
al., 2002, 2005; Wang et al., 2012; Wu et al., 2005; Yang et al., 2001). On the other hand, 
cationic sensitizer tetrakis(N-methylpyridinium-4-yl)porphyrin binds with the external surface 
of native CDs and complex formation do not affect the behavior of the PS triplet states 
(Mosinger et al., 2009). Typically, methylated CDs have the highest affinity for aryl 
substituted tetrapyrrole PS. Indeed, in the case of TTPS4 the association constants for 
different CDs keep the following order: M-β-CD> Hp-β-CD> β-CD (Wu et al., 2005).  
In addition, the complexes of CDs with PSs such as chlorophyll a and chlorin e6 
were studied (Cellamare et al., 2013; Cosma et al., 2008; Dentuto et al., 2005, 2007; Paul et 
al., 2016). Paul et al. (2016) showed that chlorin e6 effectively interacts with Hp-β-CD 
(K = 5.6·103 M-1 at pH 7) with 1:1 stoichiometry. The solubility of chlorin e6 increased by 
about 14-fold at pH 7. Contrary, due to low affinity of CDs to chlorophyll a (K ~ 10 M-1) 
(Dentuto et al., 2005),  a complexation with CDs leads to only to a partial dissolution of PS in 
PBS showing the appearance of a different aggregates (Dentuto et al., 2007; Cosma et al., 
2008).  Besides, the quantum yield of 1O2 generation of TM-β-CD/chlorophyll a complexes is 
low too (0.076 relative to chlorophyll a in CH3-CN) (Dentuto et al., 2005). 
One way to improve the delivery of a PS to target tissues is conjugation of specific 
molecules (e.g., antibodies, aptamers, and peptides) to the DDS surface or to the sensitizer 
molecules. Kitagishi et al. (2013, 2015) studied the interaction of octaarginine-conjugated 
TPPS4 with permethylated-β-CD and TPPS4 with an octaarginine-conjugated permethylated-
β-CD aiming to improve tumor cells targeting (octaarginine chain is used as a cell-penetrating 
peptide). In both cases CDs demonstrated high affinity to sensitizers and formed 1:2 inclusion 
complexes preventing self-aggregation of PSs. Furthermore, in vitro studies demonstrated that 
conjugation (§ 5.2) of octaarginine to CD was a more effective compared to conjugation of 
octaarginine to PS. 
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5.2 Photosensitizer/cyclodextrin conjugates 
One of the possible ways to improve the physicochemical properties of the PS is its 
conjugation with various biomolecules and therefore a covalent conjugation of porphyrinoid 
molecules to CDs has been explored (Gonzalez et al., 1984; Kano et al., 2003; Kryjewski et 
al., 2015). In most cases, conjugation of tetrapyrroles with CDs enhances the water solubility 
of PSs, improves their photophysical characteristics and increases the generation of singlet 
oxygen (Kryjewski et al., 2015). According to absorption and fluorescence spectra, the 
conjugation of protoporphyrin IX with β-CD leads to increase of aqueous solubility of PS at 
biologically relevant concentrations (µM) range, while protoporphyrin IX alone was soluble 
only in DMSO (Aggelidou et al., 2013). Kirejev et al. (2014) showed that CD/mTHPP 
conjugate had a significantly improved solubility of CD/mTHPP in aqueous solution 
compared to unconjugated mTHPP resulting in more than tenfold increase of fluorescence 
intensity compared to free mTHPP in 4% DMSO-PBS solution (v/v). Conjugation of meso-
tetrakis(pentafluorophenyl)-chlorin to four β-CD leads to about 250 times enhancement of PS 
fluorescence QY in PBS, as well as causes increase of the QY of singlet oxygen generation 
from less than 0.05 (free PS) to 0.4 (conjugated PS) in PBS (Silva et al., 2008). On the other 
hand, Lang et al. (2002) demonstrated that the attachment of β-CD to meso-
tetrakis(pentafluorophenyl)porphyrin does not affect the spectral properties including 
quantum yields of the triplet states of the PS. Contrary, 5,10,15-tris(pentafluorophenyl)corrole 
conjugates with one or two molecules of β-CD demonstrated a 25 % decrease in the 
fluorescence QY in the case of one β-CD conjugation and 40-50 % decrease in the QY of 
singlet oxygen generation for both conjugates compared to unconjugated PS in 
dimethylformamide solution (Barata et al., 2015). 
Increasing the amount of CDs conjugated to a porphyrinoid molecules (e.g., 
silicon(IV) phthalocyanines and tetrakis(pentafluorophenyl)porphyrin) leads to a greater 
solubility of PS (Králová et al., 2006; Lau et al., 2011a). On the other hand, the water-
solubility of such systems primarily depends on the solubility of the cyclodextrin. Indeed, 
Lourenço et al. (2014) showed that phthalocyanines conjugated with α-CDs and γ-CDs were 
more water soluble compared to conjugates with β-CDs. In addition, the CD cavity can 
include (non-covalently) another PS, anticancer or antibiotic compound making possible a 
multimodal therapy against cancer or pathogens (Ermilov et al., 2011; Králová et al., 2010; 
Theodossiou et al., 2015). For example, Leng et al. (2007) demonstrated that formation of a 
stable 1:1 host-guest complex between a silicon(IV) phthalocyanine conjugated axially with 
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two permethylated beta-cyclodextrin units and a tetrasulfonated porphyrin exhibits a light-
harvesting property and works as an efficient photosensitizing system against HT29 human 
colon adenocarcinoma cells. 
5.3. Photosensitizers encapsulated in cyclodextrin nanoassemblies 
Chemical modifications of native CDs by grafting substituent groups to different 
positions (narrow rim, wide rim, or both rims) provides non-ionic or cationic CD derivatives 
able to form supramolecular nanoassemblies. Nanoassemblies are supramolecular colloidal 
systems formed by drugs and usually amphiphilic CDs (Zerkoune et al., 2014). In addition, 
the grafting of small portions of polyethylene glycol at the secondary rim of CD can increase 
drug bioavailability and potentially decrease the immunogenicity (Mazzaglia, 2011). The size 
of obtained nanoassemblies is in a range 20 nm- 1000 nm depending on CD nature, 
preparation method, included drug and so on (Ferro et al., 2009; Mazzaglia et al., 2005, 
2006). For example, self-aggregation of natural β-CD leads to the formation of polydispersed 
stable nanoaggregates with the size of 200–300 nm (Bonini et al., 2006). Mazzaglia et al. 
(2011) demonstrated that the presence of the dansyl group gives rise to 2-o-amino oligo-
ethylene amphiphilic CD aggregates with sizes smaller (50 nm) than those of the CD 
precursor alone (190 nm). The formation of nanoassemblies between PSs and CDs leads to 
the enhancement of water solubility of PS, causes spectro-fluorescence changes of PS 
properties, provides a high yield of singlet oxygen photogeneration and as a result high PDT-
efficiency toward tumor cells (Conte et al., 2014; Sortino et al., 2006). Inclusion of 5-[4-(1-
dodecanoylpyridinium)]-10,15,20-triphenyl-porphyrinyl chloride in CD nanoagregates at a 
molar ratio 1:10 causes drastic alterations in their spectroscopic properties such as 4-times 
increasing of its fluorescence QY and provides a high QY of PS triplet formation (≥ 0.9) and 
1O2 generation (≈ 0.9) (Ferro et al., 2009). The physical–chemical properties of PS-CD 
nanoassemblies such as size, fluorescence lifetimes and QY of singlet oxygen generation are 
strongly dependent on the PS:CD molar ratio. For example, Sortino et al. (2006) demonstrated 
that high loading of the nanoassemblies (i.e., 1:1, 1:2) causes aggregation of the PS with the 
subsequent loss of its photodynamic activity. Increasing the amount of CDs in the 
nanoassemblies (1:10-1:50) leads to PS monomerization, which is reflected in the increase of 
the quantum yield of singlet oxygen generation. Moreover, cross-linking CD with polymer 
molecules allows forming nanoparticles combining two-photon fluorescence imaging and 
bimodal phototherapeutic activity in a single nanostructure that was achieved through the 
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appropriate choice of a PS (singlet oxygen) and a nitric oxide (NO) photodonor (Fraix et al., 
2013, 2014; Kandoth et al., 2014). 
5.4. Influence of cyclodextrins on photosensitizers in biological systems  
The effective photophysical characteristics and the high QY of generation of singlet 
oxygen not always allow achieving high parameters of PDT effectiveness in biological 
systems. In the case of complexes of CDs and PSs it is important to determine which 
parameters will have the greatest impact. While the main part of the researches was focused 
on the study of the photophysical characteristics of such systems and their ability to sensitize 
singlet oxygen (Cellamare et al., 2013; Lu et al., 2016; Mazzaglia et al., 2006; Silva et al., 
2008), there are a number of studies which demonstrated that CDs can be successfully used as 
carriers in photodynamic anti-cancer therapy (Garbo, 1990; Králová et al., 2006) and 
photodynamic antimicrobial therapy (Ferro et al., 2009; Hanakova et al., 2014). 
Inclusion complexation 
Influence of inclusion complexation with CDs on the accumulation of arylporphyrins 
and some other porphyrin-like sensitizers in cellular systems have been studied by several 
research groups (Dentuto et al., 2007; Kitagishi et al., 2015; Kolárová et al., 2003, 2004). 
TPPS4 and Zn-TPPS4 in the inclusion complex with Hp-β-CD represent efficient PSs with a 
high phototoxicity towards G361 human melanoma cells (Kolárová et al., 2003, 2005). 
Nevřelová et al. (2005) determined that the generation of ROS and H2O2 in photosensitised 
cells was higher for free Zn-TPPS4 than for the sensitiser bound to Hp-β-CD. In the study of 
Kolárová et al. (2004) the one hundred excess of Hp-β-CD in relation to the PSs TTPS4 and 
Pd-TTPS4 leads to a 2 fold increase of TTPS4 and Pd-TTPS4 uptake in melanoma G361 cells 
with a simultaneous (~1.5 times) increase in phototoxicity. At the same time, Kitagishi et al. 
(2015) observed that the addition of TTPS4 complexed with 2.4 time excess of trimethyl-β-
cyclodextrin led to approximately 30% reduction of PS cellular uptake and consequently cell-
photokilling ability in HeLa cells. Similarly, Dentuto et al. (2007) showed that the interaction 
of chlorophyll a with trimethyl-β-cyclodextrin at a ratio 1:10, Hp-β-CD (1:100) or Hp-γ-CD 
(1:100) resulted in a 2-4 fold decrease in phototoxicity observed in Jurkat cell line. Despite 
the lower cells accumulation, inclusion complexes of chlorin e6 with Hp-β-CD demonstrated 
significantly higher phototreatment efficacy of human oral squamous carcinoma compared to 
unbounded PS (the value IC50 decreses 3 times) (Paul et al., 2016). 
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Surprisingly, to date, there is only one publication on the influence of inclusion 
complexation on PDT efficacy in vivo (Garbo, 1990) and no one study on the effect of CDs 
on the PS distribution in vivo. Garbo (1990) showed that PDT of the bladder tumor 
transplanted into rats with inclusion complexes of tin etiopurpurin and γ-CD was 3.5 and 5 
times more efficient compared to emulsion and liposome delivery systems respectively. 
Conjugates 
Conjugates of PS-CD demonstrated significant PDT-efficiency in vitro and in vivo. 
The results of Kirejev et al. (2014) indicated that CD-porphyrin conjugates exhibit improved 
skin distribution compared to PS alone using aqueous vehicles. Lau et al. (2011a, 2011b) 
investigated PDT efficacy of different phthalocyanines/CD conjugates in vitro and in vivo. In 
the case of most active permethylated-β-CD bis-substituted phthalocyanines, the values of 
IC50 for phototreated HT29 and HepG2 cells in vitro were 0.04 and 0.05 μM respectively. The 
study of subcellular localization of this conjugate showed that PS targets lysosomes and not 
mitochondria, and that the major cell death pathway was apoptosis. In vivo tests of this PS-
CD conjugate in HT29 tumor bearing mice demonstrated that the tumor size in the treated 
group was less than half of that found in the control group on 15 day post PDT treatment (Lau 
et al., 2011a).  In another study, the phthalocyanine axial conjugated with permethylated-β-
CD from one side and galactose unit from other side demonstrated a 2-times improvement of 
in vitro PDT efficacy toward the same cells line compared to describe above PS-bis-CD 
conjugate, but reduction in tumor growth was similar at the same condition (Lau et al., 
2011b). It is worth noting that the amount of conjugated CD molecules has an ambiguous 
effect on the PDT-efficiency in various models. Králová et al. (2006) demonstrated that 
mono-CD porphyrin conjugates exhibited stronger in vitro phototoxic effect than bis-CD 
conjugates. Hovewer, bis-analogue was found to be a better PS in vivo, exhibiting fast and 
selective tumor uptake, high PDT-antitumor activity, and fast elimination from body.  
The synergistic therapeutic efficiency of PDT with PS-CD conjugates and 
chemotherapy drugs incorporated into CD cavity was an object of several works (Aggelidou 
et al., 2013; Kejík et al., 2011; Králová et al., 2010; Theodossiou et al., 2015). For example, 
the combination of porphyrin-bis-CD (β-CD or γ-CD) conjugates with the corresponding drug 
(paclitaxel and doxorubicin, respectively) in mice bearing subcutaneously growing mammary 
carcinoma 4T1 leads to increased therapeutic efficiency of both PDT (20-30 %) and 
chemotherapy (40-50 %) (Králová et al., 2010). Moreover, using metalloporphyrin rends 
possible forming a supramolecular coordination complexes with immunoglobulins that in the 
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case of PS-CD conjugate allows combined PDT, chemotherapy and immunotherapy (Kejík et 
al., 2011).  
Nanoassemblies 
It was shown that encapsulation of PSs into CD nanoassemblies improves PS 
delivery and PDT-efficacy in vitro (Mazzaglia, 2011). For example, Sortino et al. (2006) 
demonstrated that anionic porphyrin binding to nanoassemblies leads to a decrease in singlet 
oxygen production, but enhances the delivery of PS to the HEP-2 cells resulting in a higher 
phototoxicity compared to free PS. Different studies suggest that the uptake of the 
nanoassembly is mediated by endocytosis (Conte et al., 2014; Mazzaglia et al., 2011). 
Mazzaglia et al. (2013) showed that delivery of poor-water-soluble porphyrin by 
nanoassemblies based on nonionic and hydrophilic CD increases the internalization efficiency 
and photocytotoxicity (apoptosis) and, at lower concentrations, changes the morphology of 
A375 melanoma cells and prevents its proliferation. Besides, the monocationic meso-
substituted porphyrin complexed into supramolecular aggregates of cationic amphiphilic CDs 
demonstrated high antimicrobial activity towards both gram-positive and gram-negative 
bacterial pathogens (Ferro et al., 2009).  Further development of the nanoassembly system 
was achieved by introducing NO photodonor (Kandoth et al., 2012). Studies on HeLa cells 
proved that there was a synergistic cytotoxic effect, caused by singlet oxygen and NO. In 
addition, in vitro study of Conte et al. (2016) demonstrated that CD based nanoparticles may 
be used for dual delivery of zinc-phthalocyanine and docetaxel combining photodynamic and 
antimitotic effects toward tumor cells. However, to date, there are no studies devoted to the 
PS-CD nanoassemblies in vivo. 
5.5. Inclusion complexes of mTHPC with cyclodextrins 
The complexes of mTHPC with native CDs, M-β-CD and Hp-β-CD were studied by 
P. Prognon and A. Kasselouri group from France (Demore et al., 1999; Desroches et al., 
2001; Bautista-Sanchez et al., 2005). It was shown that α-CD does not form inclusion 
complexes with mTHPC while β-CD has limited effect on the PS solubility due to relatively 
low own water solubility. On the contrary, mTHPC effectively forms inclusion complexes 
with derivatives of β-CD and γ-CD resulting in the destruction of mTHPC aggregated forms 
with the restoration of the absorption spectrum of the monomer form (like in methanol) 
(Demore et al., 1999). The formation of such inclusion complex leads to enhanced mTHPC 
fluorescence intensity in water solution up to 300-times in the case of M-β-CD. Indeed, M-β-
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CD demonstrates a higher affinity to mTHPC molecules as reflected by the high value of the 
association constant: 1.2·105 M-1 for 1:1 (Bautista-Sanchez et al., 2005) and 2.8·1010 M-2 for 
1:2 complexes (Desroches et al., 2001). Besides, in the case of M-β-CD and Hp-β-CD 
association with mTHPC, the authors observed an increase in the QY fluorescence about 1.4 
times compared to monomeric PS (Bautista-Sanchez et al., 2005). Taking into account the 
molecular size and Van der Waals interactions between mTHPC and CDs, molecular 
modeling demonstrates that one mTHPC molecule cannot bind more than two CDs molecule. 
According to Demore et al. (1999) calculations, the most convenient model appears to be the 
one-step 1:2 mTHPC:CD association. The data on circular dichroism confirm the formation 
of inclusion complexes (Desroches et al., 2001). Insertion of mTHPC phenyl group into CD 
cavity causes an appearance of induced circular dichroism spectrum with three main circular 
dichroic signals: a positive maximum at 416 nm and two negative signals at 432 and 652 nm 
that well correlate with three main mTHPC absorption bands.  
The study of Bautista-Sanchez et al. (2005) showed ambiguous effect of CDs on 
triplet state characteristics and QY of singlet oxygen generation of mTHPC. On the one hand, 
calculated quantum yields values of triplet state and singlet oxygen generation of mTHPC 
were not affected by the presence of M-β-CD, but triplet lifetimes were strongly enhanced 
(about 5 times). On the other hand, the value of QY of singlet oxygen generation determined 
from infra-red measurement of 1O2 luminescence was lowered in 1.5 times. The authors 
suggest that such changes can be related to some protective effect of the CD ring, i.e. the 
formation of the complex reduces the interaction of mTHPC with molecular quenchers, 
including oxygen. 
The effective formation of mTHPC/β-CD inclusion complex can be obtained in the 
whole plasma (Desroches et al., 2001). This study demonstrated that competition between 
lipoprotein and CDs for mTHPC binding occurs in human plasma. Besides, competing 
displacement of mTHPC from CD cavity by lipid molecules was observed. The addition of 
M-β-CD (0.01 M) to plasma containing mTHPC leads to an increase of PS fluorescence 
intensity by a factor of 1.9. Such effect allows exploiting fluorescence measurements for 
direct mTHPC pharmacokinetic studies with improvement of the sensitivity of mTHPC 
detection in human plasma (Desroches et al. 2001).  
Despite the wealth of data about mTHPC/CD inclusion complexes, there is no 
available data on the use of CDs as a delivery system of mTHPC on in vitro and in vivo 
models so far. 
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OBJECTIVES 
Supramolecular systems of mTHPC with derivatives of β-CD are the general objects 
of this study. Comprehensive characterization of drug/carrier (PS/CD) complex is essential to 
achieve an adequate understanding of drug behavior after introduction to biological systems 
and resulting therapy outcome. To this end, it is necessary to investigate the physicochemical, 
photophysical and biological properties of the system and how these parameters correlated 
with each other. An important parameter is the drug release from the DDS and its distribution 
between components of the biological system. Investigations of the drug release from DDS in 
vitro and in vivo require developing of suitable and preferably minimally invasive methods 
for monitoring and control of these processes. 
The objective of the work was to determine the effect of β-CD derivatives on 
mTHPC properties in vitro and in vivo and estimate its release from CD vehicles. For this 
purpose, the following studies were carried out: 
 Determination the kinetic and equilibrium distribution of mTHPC between β-
CDs and serum.
 Investigation of β-CDs influence on the rate of mTHPC cellular uptake.
 Estimation the effect of β-CD derivatives on mTHPC intracellular distribution
and photodynamic efficiency in vitro.
 Study of mTHPC/CD complexes distribution processes in tumor bearing mice.
These tasks are addressed in the first research section (Chapter II, section 1). 
 Determination of the absorption and fluorescence characteristics of mTHPC in
solutions and model biological systems. Identification of differences between
the spectral-fluorescent characteristics of the sensitizer bound to CDs and other
biological structures (e.g., serum proteins, lipid membranes).
 Development the method based on the variation of mTHPC Soret band to
evaluate PS redistribution from CD carriers in biological systems. Evaluation
of the possible application fields of this technique.
 Comparison the spectroscopic-based methods suitable for mTHPC release
studies from β-CD carriers in biological systems.
These points are addressed in the second research section (Chapter II, section 2).
CHAPITRE II. RÉSULTATS 
1. Influence des cyclodextrines sur la distribution et l’activité
photodynamique de la mTHPC en milieu biologique 
La première partie des résultats est décrite dans l’article « Inclusion complexation with β-
cyclodextrin derivatives alters photodynamic activity and biodistribution of meta-
tetra(hydroxyphenyl)chlorin » et décrit l’effet des dérivés β-CD sur le comportement de la 
mTHPC aux différents niveau de sa distribution in vitro et in vivo.  
Les propriétés photophysiques de la mTHPC libre ou complexée aux β-CDs ont été 
comparées. Il a été démontré que l’association de la mTHPC avec les β-CDs abolissait 
complétement son agrégation après son introduction dans le sang. La cinétique et l’équilibre 
de distribution de la mTHPC entre les β-CDs et les protéines du sérum ont été étudié par 
chromatographie d’exclusion de taille et par mesure de polarisation de fluorescence. Les β-
CDs augmentent les mouvements de diffusion de la mTHPC entre les structures biologiques. 
De plus, il a été démontrés que les β-CDs ont un effet concentrations dépendantes sur le 
procédé de distribution dans le sérum et d’accumulation dans les cellules de la mTHPC. Les 
études de photosensibilisation ont montré que les β-CDs affectent la distribution 
intracellulaire de la mTHPC et améliore sa phototoxicité sur une lignée cellulaire HT29. Les 
procédés de biodistribution de la mTHPC sur des souris porteuses de tumeur HT29 après 
l’injection du PS seul ou accompagné des β-CDs ont été comparés. L’étude in vivo confirme 
le fait que l’utilisation des β-CDs permet de modifier la biodistribution de la mTHPC sur des 
animaux porteurs de tumeur, se traduisant par une diminution du taux d’accumulation du PS 
dans la peau et dans le muscle accompagné d’une augmentation de son accumulation 
tumorale.  
Cette partie du travail a été publié dans le journal « European Journal of Pharmaceutical 
Sciences » et présenté si après sous sa version publiée. 
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CHAPTER II. RESULTS 
1. Influence of cyclodextrins on mTHPC distribution and
photodynamic activity in biological systems 
The first part of the results is described in the article “Inclusion complexation with β-
cyclodextrin derivatives alters photodynamic activity and biodistribution of meta-
tetra(hydroxyphenyl)chlorin” on the effect of β-CD derivatives on mTHPC behavior at 
various stages of its distribution in vitro and in vivo. 
Comparison of mTHPC photophysical characteristics in the serum and β-CDs 
solutions was carried out. It was showed that association of mTHPC with the β-CDs 
completely abolishes its aggregation after introduction into blood. Kinetic and equilibrium 
distribution of mTHPC between β-CDs and serum were studied by using size-exclusion 
chromatography and fluorescence polarization measurements. β-CDs increase diffusion 
movement of mTHPC molecules between biological structures. It was demonstrated that the 
β-CDs have a concentration-dependent effect on the process of mTHPC distribution in blood 
serum and accumulation in cellular culture. Photosensitization studies have shown that the β-
CDs affect intracellular distribution of mTHPC and enhance its photocytotoxicity in HT29 
cultured cells. The processes of mTHPC biodistribution in HT29 tumor bearing mice after 
intravenous injection of PS alone or with the β-CDs were compared. In vivo study confirms 
the fact that the use of β-CDs allows modifying mTHPC distribution processes in tumor 
bearing animals that is reflected in the decreased level of PS accumulation in skin and 
muscles, as well as in the increased PS accumulation in tumor. 
This part of the work was published in European Journal of Pharmaceutical 
Sciences and is presented thereafter in its published form. 
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Application ofmeta-tetra(hydroxyphenyl)chorin (mTHPC) one of themost effective photosensitizer (PS) in pho-
todynamic therapy of solid tumors encounters several complications resulting from its insolubility in aqueous
medium. To improve its solubility and pharmacokinetic properties, twomodified β-cyclodextrins (β-CDs)meth-
yl-β-cyclodextrin (M-β-CD) and 2-hydroxypropyl-β-cyclodextrin (Hp-β-CD) were proposed. The aim of this
work was to evaluate the effect of β-CDs on mTHPC behavior at various stages of its distribution in vitro and in
vivo. For this purpose, we have studied the influence of the β-CDs on mTHPC binding to the serum proteins, its
accumulation, distribution and photodynamic efficiency in HT29 cells. In addition, the processes of mTHPC
biodistribution in HT29 tumor bearing mice after intravenous injection of PS alone or with the β-CDs were com-
pared. Interaction of mTHPC with studied β-CDs leads to the formation of inclusion complexes that completely
abolishes its aggregation after introduction into serum. It was demonstrated that the β-CDs have a concentra-
tion-dependent effect on the process of mTHPC distribution in blood serum. At high concentrations, β-CDs can
form inclusion complexes with mTHPC in the blood that can have a significant impact on PS distribution out of
the vascular system in solid tissues. Besides, the β-CDs increase diffusion movement of mTHPC molecules that
can significantly accelerate the delivery of PS to the targets cells and tissues. In vivo study confirms the fact
that the use of β-CDs allows to modify mTHPC distribution processes in tumor bearing animals that is reflected
in the decreased level of PS accumulation in skin and muscles, as well as in the increased PS accumulation in
tumor. Further studies are underway to verify the optimal protocols of mTHPC/β-CD formulation for photody-
namic therapy.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
Photodynamic therapy (PDT) is a minimally invasive photochemi-
cal-based treatment with a promising clinical track record for oncologi-
cal and some other diseases (Agostinis et al., 2011; François et al., 2013).
PDT uses light-activated drugs (photosensitizers, PSs) to induce cell
deathmediated by theproduction of singlet oxygen andoxygen radicals.
These reactive oxygen species induce damage inmalignant and nonma-
lignant cells alike, depending on the PS distribution (Castano et al.,
2005a). Clinical application of PDT encounters several difficulties due
to the high hydrophobicity of most PSs, thus leading to poor water solu-
bility and aggregationwithin the vasculature after intravenous injection
(Josefsen and Boyle, 2012). In fine, a decrease in photosensitizing effi-
ciency and extended skin photosensitivity caused by unfavorable
biodistribution are considered as major drawbacks of PDT.
The use of biocompatible nanoscale systems for PSs delivery demon-
strated a significant improvement in their bioavailability, biodistribution
and in treatment efficacy (Marchal et al., 2015). Special delivery forms
such as liposomes (Reshetov et al., 2013), polymeric nanoparticle
(Ogawara et al., 2016) and dendrimers (Bastien et al., 2015)were exten-
sively studied and showed important progress in drug delivery and PDT.
Among the investigated drug delivery systems, cyclodextrins are prom-
ising PSs carriers (Kryjewski et al., 2015; Mazzaglia, 2011). Cyclodex-
trins are a family of cyclic oligosaccharides with a hydrophobic internal
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cavity and a hydrophilic outer surface consisting of six α-cyclodextrin,
sevenβ-cyclodextrin (β-CD), eightγ-cyclodextrin ormore glucopyranose
units. Due to its appropriate cavity size, β-CD derivatives are most com-
monly used for inclusion complexationwith PSs, especially aryl substitut-
ed porphyrins. Sensitizers binding to cyclodextrins usually increased the
solubility of highly hydrophobic drugs, their physical and chemical stabil-
ity (Kryjewski et al., 2015; Lang et al., 2004). Several reports documented
that cyclodextrins change PSs delivery into the cells and their
photosensitizing activity (Dentuto et al., 2007; Kitagishi et al., 2015;
Kolárová et al., 2003, 2004). It should be noted that currently available ex-
perimental data on the influence of cyclodextrins on PSs accumulation
and photosensitized processes in cells are highly contradictory.
One of the most potent clinically approved PS is meta-
tetra(hydroxyphenyl)chlorin (mTHPC). The main limitation of mTHPC
application is related to its low water solubility necessitating the use of
special delivery systems (Senge and Brandt, 2011). It was shown that
this PS forms effectively inclusion complexes with derivatives of β-CD
(Demore et al., 1999). Introduction of β-CDs into aqueous solutions of
mTHPC causes PS disaggregation with the restoration of the absorption
and fluorescence spectra of the monomer form (Bautista-Sanchez et al.,
2005; Demore et al., 1999; Desroches et al., 2001). However, there is no
available data on the use of cyclodextrins as a delivery system ofmTHPC
on in vitro and in vivo models so far. In the present study, we analyzed
the influence of methyl-β-cyclodextrin (M-β-CD) and 2-hydroxypro-
pyl-β-cyclodextrin (Hp-β-CD) at wide range concentrations on the pro-
cesses of mTHPC biodistribution and its photosensitizing activity.
The aim of this work was to evaluate the effect of two β-CDs on
mTHPC behavior at various stages of its distribution in vitro and in
vivo. For this purpose we have studied the influence of β-CDs on
mTHPC binding to the serum proteins, its accumulation, distribution
and photodynamic efficiency in HT29 cells. In addition, the processes
ofmTHPC biodistribution in HT29 tumor bearingmice after intravenous
injection of PS alone or with β-CDs were compared.
2. Material and methods
2.1. Chemical and reagent preparation
mTHPCwas kindly provided by Biolitec Research GmbH (Germany).
Phosphate buffered saline (PBS), phenol-red-free RPMI-1640 medium,
penicillin-streptromycin and L-glutamine were supplied by GibcoBRL
(Belgium). Fetal bovine serum (FBS) was purchased from PAN™ BIO-
TECH GmbH (South America). M-β-CD and Hp-β-CD were purchased
from AraChem (Netherlands).
mTHPC stock solution (1 mM) was prepared in absolute ethanol
(99.6%) and was kept at 4 °C in the dark. The concentration of mTHPC
in the solution was estimated by a spectrophotometric method using
an mTHPC molar extinction coefficient of 30,000 M−1 cm−1 at
650 nm in ethanol.
β-CDs and mTHPC complexes were formed using co-precipitation
method (Martin Del Valle, 2004). Briefly, β-CDs were dissolved in PBS
at the required concentrations with the subsequent addition of
mTHPC stock solution. The final content of ethanol in the mTHPC/β-
CD solutions did not exceed 0.5%. Solution was thoroughly mixed over
15 min under magnetic stirring.
For in vitro cell culture experimentsmTHPC stock solutionwas dilut-
ed in RPMI medium, supplemented with 2% FBS to reach unless other-
wise indicated the final mTHPC concentration of 1.47 μM.
All other chemicals and solvents used in our experimentswere com-
mercial products of the highest grade of purity and its manufacturers
will be specified below.
2.2. Spectroscopic measurements
The absorption spectra were measured on PerkinElmer Lambda 35
UV/Vis (PerkinElmer, Waltham, USA) and Solar PV1251 (Solar, Belarus)
spectrophotometers using 1 cm optical path quartz cuvettes. Fluores-
cent measurements were performed on PerkinElmer LS55B (Perkin-
Elmer, USA) and Solar SFL 1211A (Solar, Belarus) fluorescence spec-
trometers equipped with thermostat cuvette compartments (PTP-1
Peltier temperature controller in the case of LS55B) and magnetic stir-
ring. mTHPC fluorescence lifetime was measured in a pulsed fluorome-
ter PRA-3000 (Photochemical Research Associates, Canada), working in
photon counting mode.
Absorption andfluorescent characteristics ofmTHPC associatedwith
β-CDs or serum proteins were carried out for samples containing
50 μMM-β-CD, 500 μMHp-β-CDor 2% FBS (vol/vol) providing complete
PS binding with studied structures. All measurements were carried out
at room temperature 22–24 °C.
2.3. Fluorescence polarization measurements
Measurements of mTHPC fluorescence polarization degree (P) were
performed on PerkinElmer LS55B equippedwith polarizers. In this case,
samples were excited at 435 nm and fluorescence was registered at
652nmsimilar to (Reshetov et al., 2011b). Kinetic and equilibriumchar-
acteristics of mTHPC distribution between β-CDs and serum proteins
were controlled on the base of fluorescence polarizationmeasurements
as described in (Rossi and Taylor, 2011). Quantitative characteristics of
mTHPC distribution were estimated from P values taking into account
the difference in the fluorescence quantum yields of mTHPC in β-CDs
and serum solutions.
Fluorescence polarization technique was also used to estimate
the cyclodextrin effect on the molecular movement of mTHPC in
blood plasma. For this purpose, different concentrations of mTHPC
(0.1–1 μM) were added to 5% FBS solution and incubated for 10 h
at room temperature (22–24 °C). Binding of several mTHPC mole-
cules to a molecule of low density lipoproteins (LDL) or high density
lipoproteins (HDL) was accompanied with concentration-dependent
depolarization of PS fluorescence (effect occurs at mTHPC concentra-
tions above 0.5 μM). Mixing mTHPC loaded serum with an excess of
PS-free serum (ratio 1:19) was accompanied by the PS redistribu-
tion, expressed as the change in P value. Final concentration of FBS
was kept as 5%.
2.4. Size-exclusion chromatography
mTHPC (1.47 μM) was incubated during 2 h with different M-β-CD
concentrations in PBS supplemented with 2% FBS at 37 °C under light
protection.
Chromatography experiments and biochemical analysis of the pro-
tein fraction were performed as described earlier (Reshetov et al.,
2012) except that we used Sigma 1.5 × 35 cm column filled with
Sephadex G-200 gel (GE Healthcare, USA), pre-equilibrated with PBS.
Concentration of mTHPC in the chromatographic fractionswas estimat-
ed by fluorescence intensity measured after the addition of 0.2% neutral
detergent Triton®X-100 (Sigma–Aldrich, USA) to the samples. Intensi-
ties were corrected for fraction volume.
2.5. Cell culture
HT29 human adenocarcinoma cells were obtained from the ATCC®
(LGC Standards, France) and regularly controlled for mycoplasma con-
tamination. HT29 cells were maintained in RPMI medium supplement-
ed with 9% (vol/vol) heat-inactivated FBS, penicillin (10,000 IU),
streptomycin (10,000 μg/mL), and 1% (vol/vol) 0.1 M glutamine. Cells
were kept as a monolayer culture in a humidified incubator (5% CO2)
at 37 °C. Cell culture was reseeded every week to ensure exponential
growth.
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2.6. Cellular uptake of mTHPC
HT29 cells (5 · 104 cells perml)were seeded in the 6-well plate, 48 h
later the cells were washed twice with PBS and incubated in RPMI sup-
plementedwith 2% FBS, containing 1.47 μMmTHPC alone or complexed
with β-CDs at various concentrations. After incubation, the cells were
three times consecutively washed with PBS, trypsinized and centri-
fuged. Cells were counted with a Thoma hemocytometer by using
trypan blue exclusion assay in order to determine cell viability. The via-
bility of the control (untreated cells)was regarded as 100%. Then the su-
pernatant was discarded and the methanol was added to the pellet.
Afterwards, the suspension was sonicated during 15 min and centri-
fuged. The mTHPC fluorescence contained in the supernatant was
measured with Perkin-Elmer LS 55B spectrometer and mTHPC concen-
tration was evaluated by fluorescence calibration curves constructed by
plotting the peak height of PS standard solutions in methanol. The
obtainedmTHPC concentrationwas normalized to the number of viable
cells.
2.7. Fluorescence microscopy
HT29 cells (1.5 · 104 cells per ml) were plated into Lab-Tek II cham-
ber Slide (Roskilde, Denmark), incubated in the dark at 37 °C with
1.47 μM of mTHPC alone or complexed with M-β-CD (10 μM) during
1 h, then rinsed with PBS. Fluorescence of mTHPC was observed under
anupright epifluorescencemicroscope (AX-70 Provis, Olympus, France)
equipped with a 100 W mercury vapor lamp and a Peltier cooled CCD
camera (DP70, Olympus). The filter was set at 400–440 nm band pass
excitation associated with a 570 nm dichroic mirror and a 590 nm
long pass emission filter for mTHPC fluorescence measurements. Fluo-
rescence images were recorded using an oil immersion ×40 objective.
Fluorescence microscopy technique based on filipin III cholesterol
assay kit (ab133116 Abcam, UK) was used to estimate of β-CD effect
on plasma membrane cholesterol content. The filter was set at 330–
385 nm band pass excitation associated with a 400 nm dichroic mirror
and a 420–460 nm long pass emission filter for filipin III fluorescence
measurements. A cholesterol inhibitor, U-18666A, was used as a posi-
tive control. In vitro detection and quantification of cholesterol levels
in HT29 cells by filipin III staining were performed as described earlier
(Wolfe et al., 2015).
To prevent the photobleaching of dyes, the samples were analyzed
immediately after staining. Fluorescence microscopy data were ana-
lyzed using ImageJ software.
2.8. Assessment of cell viability
Cell viability was assessed by the MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-2H-tetrazolium bromide; Sigma] colorimetric assay,
which measures the capacity of mitochondrial dehydrogenase in viable
cells to reduceMTT to purple formazan crystals. HT29 cells (5 · 104 cells
per ml) were seeded in the 96-well plates, 48 h later the cells were
washed twice with PBS and incubated during 3 h or 24 h in RPMI sup-
plemented with 2% FBS containing 1.47 μM of mTHPC only or in pres-
ence of 10 μM of M-β-CD or 200 μM of Hp-β-CD. Each series of
samples contained non-irradiated plate as the control of the dark cyto-
toxicity. Irradiation was performed at room temperature with a laser
diode (Biolitec AG, Germany) at 652 ± 4 nm at different exposition
times varying from 4 s to 500 s, power output was adjusted to 2 mW/
cm2. Following irradiation, cells were washed twice with cold PBS, the
fresh medium was added and cells were maintained in the humidified
incubator. 24 h later, the medium was removed, the MTT solution was
added to each dish and cells were kept in the humidified incubator for
3 h. The formazan crystals were solubilized by adding dimethyl sulfox-
ide and absorbance was measured at 540 nm with a Multiskan Ascent
spectrometer (Labsystems, USA). From these values, cell viability per-
centages of treated and non-irradiated control samples were calculated.
All experiments were carried out in triplicate. The efficacy of mTHPC
phototoxicity was based on LD50 (Lethal Dose inducing 50% cell death).
2.9. Fluorescence analysis of in vivo distribution of mTHPC
All experiments were performed in accordance with animal care
guidelines from European Union and were carried out in an establish-
ment approved by the appropriate authority. The animal project regis-
tered under the number 1353–2015080615338957, received a
favorable opinion from the Ethics Committee and was definitely ap-
proved by the French Higher Education and Research Minister.
All procedures involving animals were performed under general an-
esthesia with inhaled isoflurane (Forene; Abbott Laboratories, Abbott
Park, IL, USA) using a Univentor 400 anesthesia unit (Genestil,
Royaucourt, France), with every effort made to minimize suffering. Fe-
male NMRInu/nu mice (Janvier, St Berthevin, France) aged 9–10 weeks
were used, with a mean bodyweight of 29 ± 2 g. Mice were inoculated
subcutaneously in the right flank with 8 ∙106 exponentially growing
HT29 cells. When the tumor volume reached ~100 mm3, the mice
were randomized into three groups (n = 3–4 mice/group) according
to the injected formulation: mTHPC alone, mTHPC/M-β-CD and
mTHPC/Hp-β-CD. All drugs were administered intravenously by a tail
vein injection at a dose of 0.5 mg/kg of mTHPC. Following injection,
mice were kept in the dark and experiments were undertaken with
minimal ambient light.
PDT fluorometer (JETI Technische Instrumente GmbH, Germany)
was used tomeasure the in vivomTHPC fluorescence after injection. Ex-
citationwavelengthwas 405 nm, emissionwavelength 600–700 nm. At
each time interval the mTHPC fluorescence was measured in three
points on the surface of tumor through the skin.
To compare tissues and organs distribution of mTHPC alone and
complexed to β-CD 24 h after i.v. injection, the excised tissues including
liver, spleen, kidney, muscle, lungs, heart and skin as well as the tumor
were analyzed byfluorescence imaging. The FluorVivo™ 300 image sys-
tem (Indec Systems, Santa Clara, CA, USA) equipped with a LED at 510–
550 nm and a long wave emission filter (630–690 nm). Imaging data
were analyzed using ImageJ software.
2.10. Statistical analysis
Each experimentwas repeated at least three times. Data are present-
ed as mean ± SD. The data were evaluated using Student's t-test. The
difference was considered significant at p b 0.05. Data analysis was car-
ried out with the STATISTICA 10 (StatSoft, Inc., USA).
3. Results
3.1. The spectral characteristics ofmTHPC in the serum and β-CDs solutions
Absorption andfluorescence characteristics ofmonomericmTHPC in
organic solutions are typical for chlorin-type compounds (absorption
spectrum with two main peaks at 418 nm and 650 nm and emission
spectrumwith a peak at 652 nm). Like other hydrophobic tetrapyrroles,
mTHPC molecules aggregate in aqueous solutions resulting in signifi-
cant changes of the spectral properties and almost complete disappear-
ance of PS fluorescence. Introduction of the serum or β-CDs to aqueous
solution prevents mTHPC aggregation and restores its spectral proper-
ties (Fig. S1–4 in Supplementary material). A comparison of mTHPC
spectral features in the serum and β-CDs solution showed only slight
differences in the absorption and fluorescence spectra (1–2 nm shifts
of the spectra maxima). Fluorescence capacity of mTHPC is increased
in 2.0 fold in M-β-CD solution and 1.7 fold in HP-β-CD solutions com-
pared to PS in 2% serum solution. The fluorescence decay time varies
slightly from 10.2 ± 0.1 ns in the serum to 10.8 ± 0.1 ns in β-CDs
(Fig. S5 and Table S1 in Supplementarymaterial). Significant differences
in the presence of polarized fluorescence in the compared solutions are
174 I. Yankovsky et al. / European Journal of Pharmaceutical Sciences 91 (2016) 172–182
71
observed (Fig. S2 and Table S1 in Supplementarymaterial). The P values
of mTHPC complexed with β-CDs molecules are about 4.5% while the
fluorescence of PS associated with the serum proteins is characterized
by high polarization degree (P = 25%). The gap in P values at equal
decay times indicates the difference in hydrodynamic volumes of
small β-CDs molecules and large LDL and HDL being the main carriers
for mTHPC in plasma.
3.2. Kinetic and equilibrium distribution of mTHPC between β-CDs and
serum
Complexation of mTHPC with β-CDs is a reversible process, i.e. each
molecule can dissociate from the inclusion complex with the subse-
quent binding to other molecules (e.g. plasma proteins). Therefore, the
introduction of mTHPC/β-CD complexes into the serum is accompanied
by the processes of PS redistribution to plasma proteins. We have esti-
mated the rates of mTHPC transfer from complexes with β-CDs to the
serum proteins and in the opposite direction from the serum to β-CDs.
A convenient tool for this purpose ismeasuringmTHPCfluorescence po-
larization changes (see 2.3). Fig. 1a shows typical kinetics of P changes
when mTHPC/M-β-CD complexes are mixed with 2% serum solution.
A competition between M-β-CD and the serum proteins leads to redis-
tribution of mTHPC molecules from inclusion complexes to proteins,
which results in the growth of fluorescence polarization degree. When
M-β-CD concentration is low (Fig. 1a, curve 1) the P value reaches
24–25% in 5–7min of incubation indicating that almost all mTHPCmol-
ecules have changed their location. In the samples containingmoderate
β-CDs concentration only limited amount of mTHPC transfer from β-
CDs to the serum proteinswith the achievement of transitional P values
at equilibrium (Fig. 1a, curve 2). Return transfer of mTHPC molecules
from serum proteins to β-CDs is controlled in a similar way (Fig. 1a,
curves 3, 4). After adding an excess amount of M-β-CD (100 μM) to
mTHPC stained 2% serum solution, containing mTHPC, the P value
drops from 25% to 4–5% in several minutes reflecting complete PS redis-
tribution to β-CDs.
Estimation of cyclodextrin effect on mTHPC movement in serum
may be obtain from the polarization measurements (Fig. 1b,c). As men-
tioned above, the binding of mTHPC with LDL and HDL limits PS mobil-
ity as manifested in corresponding to the increase in the P value. The P
value does not change at small mTHPC concentrations (b0.5 μM) in 5%
FBS solution (Fig. 1b). When mTHPC concentration overcomes 0.5 μM,
a significant decrease of P is observed and at PS concentrations above
5 μMa completely depolarizedfluorescenceofmTHPC in serum solution
is observed. The mechanism of this phenomenon is well known and is
associatedwith the concentration depolarization.When one lipoprotein
molecule bindsmore than onemolecule ofmTHPC, there ismigration of
energy between the dye molecules. A decrease in the distance between
dye molecules increases the probability of resonance energy transfer,
which leads to significant depolarization (Reshetov et al., 2011a). On
the basis of changes in the P values it is possible to estimate the degree
Fig. 1. (a) Kinetics ofmTHPC fluorescence polarization degree P changes aftermixing of FBSwithmTHPC/M-β-CD solution (curves 1, 2) and aftermixing ofM-β-CD solutionwithmTHPC/
FBS solution (curves 3, 4). Concentration of mTHPC was 0.2 μM, concentration of FBS was 2% (vol/vol). Concentrations of M-β-CD were 1 μM (curve 1), 10 μM (curves 2, 3) and 100 μM
(curve 4). (b) Influence of PS concentration on theP value ofmTHPC fluorescence in 5% FBS solution. (c) Influence ofM-β-CD on the rate of mTHPC P value changes aftermixing ofmTHPC
loaded serum (100 μL) with PS-free FBS solution (1.9mL) (curves 1-3). Curve 4 corresponds to the changes of mTHPC P value after introduction of 5 μMM-β-CD tomTHPC-loaded serum
solution (0.25 μMmTHPC, 5% FBS). Final concentration ofmTHPCwas0.25 μM, concentration of FBSwas 5% (vol/vol) (curves 1-3). Concentrations ofM-β-CDwere 0 (curve 1), 2 μM(curve
2) and 5 μM (curve 3).
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of mTHPC redistribution between the serumproteins. Mixing of mTHPC
loaded serum with an excess of PS-free serum leads to a gradual slow
redistribution of PS, accompanied by the restoration (increase) of P
value (Fig. 1c, curve 1). Introduction of a small amount of β-CDs signif-
icantly accelerates the processes of mTHPC redistribution between the
serum proteins (Fig. 1c, curves 2,3). It should be noted that the concen-
tration of β-CDs did not affect significantly the equilibrium distribution
of mTHPC (Fig. 1c, curve 4).
Fig. 2 shows the dependence ofmTHPCfluorescence polarization de-
gree in FBS as the function of cyclodextrins (Fig. 2a) or FBS (Fig. 2b) con-
centrations. According to the data obtained, the detectable amount of
cyclodextrin-bound mTHPC in the 2% serum appears above 2 μM M-β-
CD and 50 μM HP-β-CD. The minimal P values corresponding to com-
plete mTHPC transfer from the serum proteins to β-CDs are observed
at 100 μM M-β-CD and 2 mM HP-β-CD. Taking into account the differ-
ences in fluorescence capacity of mTHPC we calculated the relative
weights of mTHPC fractions bound to β-CDs and serum proteins for in-
termediate P values (Fig. 2). This approach allows also analyzing com-
plexation of mTHPC and β-CDs at different serum content. As can be
seen from Fig. 2b, at a fixed concentration of β-CDs, the increase in the
FBS content leads to the increase of the relative weight of mTHPC frac-
tion bound to serum proteins. It should be noted that M-β-CD binds
more molecules of PS even at considerably lower concentrations in
comparison with HP-β-CD at the same condition (serum concentra-
tion). Evidently, this is a consequence of the greater affinity of M-β-CD
to mTHPC molecules. In the case of 100 μM M-β-CD, a greater part of
mTHPC associated with cyclodextrin fraction, even at 10% of FBS (Fig.
2b).
To further characterize the influence of β-CDs on the processes of
mTHPC distribution in the serum, we used the size exclusive gel chro-
matography technique. Fig. 3 shows elution profiles for 2% serum sam-
ples, containing 1.47 μM mTHPC and different bulk of M-β-CD. In the
control samples (mTHPC in FBS) PS passed through the column with
the main transport proteins in the range of 20–50 mL (Fig. 3 curve 1).
The biochemical analysis of protein eluting through the column shows
that mTHPC elution peaks correspond to LDL (elution volume 23 mL)
andHDL (elution volume 31mL) fraction (data not shown). The relative
weight of mTHPC bound to the serum albumin (a band with maximum
at 40 mL) does not exceed 5%. In serum samples containing higher than
1 μMM-β-CD a decrease in themain elution protein-bound peaks is ob-
served. Simultaneous a new protein free peak of mTHPC bound toM-β-
CD appears in the range of 50–70 mL. The relative weight of this new
fraction increases with increasing M-β-CD concentrations and it con-
tains all bulk of mTHPC when M-β-CD concentration is above 200 μM
(Fig. 3, curve 5). It should be noted that β-CDs do not affect the
distribution profile of the drug between themajor serum transport pro-
teins (except free inclusion complexes mTHPC/β-CD). The data of
mTHPC distribution between the serum proteins and β-CDs obtained
by chromatography are in full agreement with those obtained by fluo-
rescence polarization.
3.3. Influence of the β-CDs on the rate of mTHPC cellular uptake
HT29 cells incubated in cyclodextrin-free medium accumulates
mTHPC very slow (Fig. 4a). Estimated initial rate of PS accumulation
was 0.21 pg cell−1 h−1 and its value did not changed significantly
throughout studied duration of incubation 0-24 h. The presence of β-
CDs in incubation medium alters mTHPC uptake by cells, and this effect
critically depends on M-β-CD and Hp-β-CD concentrations (Fig. 4b,c).
Introduction of β-CDs at low concentrations results in considerable in-
crease of mTHPC cellular uptake. A maximal level of mTHPC accumula-
tion is observed at 10 μMM-β-CD and 200 μMHp-β-CD independently
of incubation time. Further increase in β-CDs concentrations is accom-
panied by a gradual decrease of mTHPC uptake, so at concentrations
Fig. 2. (a) Influence of β-CD derivatives concentration on the equilibrium distribution of mTHPC in 2% FBS solution. (b) Influence of FBS concentration on the equilibrium distribution of
mTHPC in PBS solution containing M-β-CD or Hp-β-CD. mTHPC concentration was 0.2 μM. The left ordinate is equilibrium level for mTHPC fluorescence polarization degree P in mixed
solution of β-CD derivatives and FBS. The right ordinate is mTHPC fraction bound to serum proteins calculated from polarization measurements.
Fig. 3. Elution of mTHPC from column during gel chromatography analysis of 2% FBS
solution, containing 1.47 μM of PS and different concentration ofM-β-CD. Concentration
of M-β-CD in the samples was (1) 0, (2) 5 μM, (3) 10 μM, (4) 20 μM or (5) 200 μM.
mTHPC was preincubated with FBS at 37 °C during 2 h until complete binding of PS.
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above 60 μM for M-β-CD and 2 mM for Hp-β-CD cells accumulates less
quantities of mTHPC as compared to control sample.
It is interesting to estimate the influence of β-CDs at their optimal
concentrations (10 μM M-β-CD and 200 μM Hp-β-CD) on the rate of
mTHPC uptake by HT29 cells (Fig. 4a). The highest rate of mTHPC accu-
mulation is observed immediately after adding β-CDs: 0.77 and
1.75 pg cell−1 h−1 forM-β-CD andHp-β-CD, respectively. Further incu-
bation is accompanied with gradual decrease in the rate of mTHPC up-
take until this parameter reaches a value 0.16 pg cell−1 h−1 for both
β-CDs after 10–24 h interval.
It should be noted that all determined cyclodextrin-dependent
changes in mTHPC accumulation by cells are not associated with a de-
crease in cell viability, because its level was not b95% compared to a
control sample (according to trypan blue assay). Special studies of cy-
clodextrins cytotoxicity showed that used in our articles β-CDs concen-
trations were far from toxic levels (Fig. S6 in Supplementary material).
3.4. Photocytotoxicity of mTHPC/β-CD inclusion complexes
To evaluate photosensitized cytotoxicity of mTHPC alone or its com-
plexeswithβ-CDs at concentrations providing optimal PS accumulation
we have determined the parameter LD50 from the corresponding dose-
response curves. In this experiments cells, preincubated in dark for 3 h
and 24 h with mTHPC, were irradiated by a laser diode (λ = 652 nm)
and in 24 h interval cell viability was determined. LD50 values for cells
incubated for 3 h and 24 h in the presence of mTHPC alone are equal
to 330 mJ cm−2 and 39 mJ cm−2, respectively (Fig. 5).
Introduction of β-CDs into the samples enhances mTHPC
photosensitizing activity towards HT29 cells. For M-β-CD LD50 values
are 70 mJ cm−2 at 3 h and 14 mJ cm−2 at 24 h and for Hp-β-CD these
values are 27 mJ cm−2 at 3 h and 8 mJ cm−2 at 24 h.
Fig. 4. (a) Influence of 10 μM M-β-CD (2) and 200 μM Hp-β-CD (3) on the rate of mTHPC uptake by HT29 cells. In control samples (1) HT29 cells incubated with mTHPC in β-CDs free
medium. (b,c) Effect of (b) M-β-CD and (c) Hp-β-CD on relative level of mTHPC uptake by HT29 cells in culture at 3 h and 24 h of incubation. The concentrations of CDs are shown in
the abscissa. mTHPC concentration was 1.47 μM. mTHPC cellular uptake in CDs free medium (control) taken as 100%. mTHPC uptake with CDs was normalized to control sample. The
results of three independent experiments are expressed as the mean with the vertical bar showing S.D.
Fig. 5. Influence of 10 μMM-β-CD and 200 μMHp-β-CD on photosensitivity of HT29 cells
incubated in the presence of 1.47 μMmTHPC during 3 h and 24 h. LD50 was determined in
three independent experiments and expressed as themean with the vertical bar showing
S.D.
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3.5. Fluorescent microscopy studies of mTHPC uptake by HT29 cells
The intracellular distribution of mTHPC alone and mTHPC/β-CD
complexes was assessed using epifluorescence microscopy (Fig. 6).
Fluorescence images of cells treated with mTHPC alone revealed pre-
dominant fluorescence in the plasma membrane with a weak diffuse
distribution throughout the cytoplasm. After incubation with mTHPC/
M-β-CD complexes, the overall level of mTHPC fluorescence in cells in-
creased. In this case, we observed an appearance of bright spots in the
periphery of cells fluorescent image indicating about heterogeneous
PS localization in the plasma membrane.
Using cholesterol-specific stain filipin III we assumed the involve-
ment of cyclodextrin-mediated changes of plasma membrane choles-
terol content into regulation of mTHPC binding to cells. Treatment of
cells by 10 μMofM-β-CDor 200 μMofHp-β-CD causes 15–20% decrease
of mean fluorescence intensity of fillipin III in cells indicating reduction
of cholesterol content in plasma membrane (data not shown).
3.6. mTHPC biodistribution in tumor-bearing mice
In vivo kinetics of mTHPC fluorescence from the surface of grafted
HT29 tumor after i.v. injection of PS alone (curve 1) or its complexes
with M-β-CD (curve 2) are presented in Fig. 7. Very low fluorescence
level is observed during several hours when mTHPC is injected alone.
Then, fluorescence intensity increases gradually for 24 h. In the case of
mTHPC/M-β-CD complexes fluorescence signal reaches maximal level
very quickly after introduction and keeps it during 24 h.
Several organs and tissues of the injected mice were harvested for
fluorescence imaging to visualize mTHPC distribution (Fig. 8) and to
quantify PS accumulation in these samples (Table 1) 24h after injection.
According to the data obtained, studied β-CDs strongly influence
mTHPC distribution between different organs and tissues. Indeed, intro-
duction ofmTHPCwithβ-CDs results in 1.5–3 times decreasing of PS ac-
cumulation in skin andmuscles tissues. Another interesting observation
dealswith opposite changes inmTHPC accumulation in the kidneys and
liver. Introduction of mTHPC/M-β-CD based formulation reduces the
level of mTHPC in the liver in 1.5 times and increasesmTHPC accumula-
tion by kidneys in 1.8 times compared to introduction of mTHPC alone.
Similar changes were also observed in the case of mTHPC/Hp-β–CD
based formulation. Changes in the level of PS accumulation associated
with the use of both studied β-CDs were expressed weaker in lungs
and spleen, and no significant changes were observed in the heart.
The PS distribution between the tumor (T) and normal muscle (M) tis-
sue is of a special interest. The highest mTHPC fluorescent signal in the
tumor is observedwhenmTHPCwas introducedwithM-β-CD. Calculat-
ed from the fluorescent data obtained T/M ratio for the formulations
mTHPC/M-β-CD, mTHPC/Hp-β-CD and mTHPC alone decreased in the
following order 12 N 7 N 5.
4. Discussion
Despite the high efficacy of mTHPC as a photosensitizer for PDT, its
low water solubility distorts the biodistribution processes and leads to
non-optimal pharmacokinetics and onset of a number of side effects.
The use of cyclodextrins as carriers of PSs can be useful to avoid aggre-
gation and, hence, provide favorable characteristics of pharmacokinetics
and biodistribution of photosensitizing drugs (Kryjewski et al., 2015). It
iswell documented thatmTHPC similarly to other arylporphyrins is able
to bind 1 or 2 molecules of β-CD derivatives and the side phenyl groups
penetrate into cyclodextrin cavity (Demore et al., 1999). According to
Bautista-Sanchez et al. (2005) binding constants for mTHPCwith sever-
alβ-CDs are very high especially in the case of Hp-β-CD (4.8 · 104M−1)
and M-β-CD (1.2 · 105 M−1). So, the effective formation of mTHPC/β-
CD inclusion complex can be obtained in the whole plasma. Such an ef-
fect allows exploiting fluorescence measurements for direct mTHPC
pharmacokinetic studies (Desroches et al., 2001).
Inclusion in cyclodextrins exerts a profound effect on physicochem-
ical properties of guestmolecules as they are temporarily locked or par-
tially caged within the host cavity giving rise to beneficial modification
Fig. 6. Epifluorescence images of HT29 cells incubated with 1.47 μMmTHPC alone or with 10 μMM-β-CD. Incubation time was 1 h. Incubation temperature was 37 °C. Scale bar =10 μm.
Fig. 7. Kinetics of in vivo fluorescence (λex = 405 nm, λem = 600–700 nm) from the
surface of HT29 tumor grafted to NMRInu/nu mice after injection in tale vein of 0.5 mg/kg
mTHPC alone (curve 1) or with 2.5 mg/kg M-β-CD (curve 2). Results are expressed as
the mean of 3–4 measurements with the vertical bar showing S.D.
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of guest molecule properties. Indeed, in the case of hydrophobic drugs,
cyclodextrins increase drug solubility, dissolution, circulation time
thus enhancing their bioavailability (Loftsson and Brewster, 2013;
Stella and He, 2008). Following this approach, it is reasonable to assume
that β-CDs can be used to improve the pharmacokinetic properties of
mTHPC.
It is well recognized that the distribution of PSmolecules during PDT
of solid tumors may be defined by three main stages: i) PS interactions
with plasma proteins after injection and transport in bloodstream, ii) PS
transfer from the bloodstream to the extravascular tissue and iii) PS in-
teraction with intracellular targets within the tumor environment. Data
obtained in this work allow assessing an involvement of β-CDs in
mTHPC distribution at all these stages.
Plasma protein binding pattern is an important factor governing PSs
biodistribution and photosensitizing efficiency during PDT (Castano et
al., 2005b). Previous studies have revealed two main features of
mTHPC interaction with plasma proteins. First, about 95% of the sensi-
tizer in plasma is associated with HDL and LDL, and the binding with
HDL is twice higher than with LDL (Reshetov et al., 2012; Triesscheijn
et al., 2007). Secondly, as compared with other non-polar drugs,
mTHPC releases from lipoprotein carriers very slowly and proceeds on
a timescale of hours (Sasnouski et al., 2005, 2006). According to our
fluorescence polarizationmeasurements, the addition ofM-β-CD causes
a rapid dissociation of mTHPCmolecules from complexes with proteins,
resulting in an equilibrium distribution attained in 10–15 min (Fig. 1a
curve 4). Since mTHPC dissociation from the inclusion complexes and
subsequent binding to the serum proteins is achieved even faster, it
can be concluded that β-CDs cause a significant acceleration of PS diffu-
sion movement in plasma. This conclusion is consistent with the evalu-
ation of β-CDs effect on the rate of mTHPC redistribution between
serumproteins following from themeasurements of fluorescence depo-
larization after mixing of PS loaded serumwith an excess of the PS-free
serum (Fig. 1c). Indeed, introduction of a small concentration of β-CDs
in medium significantly reduces the time of achieving the equilibrium
distribution of mTHPC in mixture.
According to our chromatography data, the equilibrium distribution
of mTHPC in serum is dependent on β-CDs concentrations. At low con-
centrations of M-β-CD (high concentration of FBS) almost all mTHPC
molecules are bound to the serum proteins (Fig. 3). That conclusion is
consistent with the results of fluorescence polarization measurements
(Fig. 2). At M-β-CD concentrations b5 μM and HP-β-CD b50 μM
mTHPC fluorescence polarization P takes the maximum value about
25% and, hence, the relative weight of mTHPC inclusion complexes in
the samples is minor. Increasing β-CDs concentration shifts equilibrium
of PS distribution towards the formation of inclusion complexes. As a re-
sult, when β-CDs concentration is high,most of the sensitizermolecules
are not bound to plasma proteins. It is obvious that concentration level
of cyclodextrins required to change themechanism ofmTHPC transport
in the blood is determined by the constant of inclusion complex forma-
tion andmay differ significantly in the case of various β-CD derivatives.
The formation of inclusion complexes in the plasma can have a sig-
nificant impact onmTHPC distribution from the bloodstream and its lo-
calization in extravascular tissues including tumor transformed one.
Indeed, the interstitial transport of molecules and particles is character-
istically described by their effective interstitial diffusion coefficient,
which decreases as their size is increased (Pluen et al., 2001). The small-
er mTHPC/β-CDs inclusion complexes, which size is 1.5–2.0 nm, must
penetrate into extravascular tissues much faster as compare to
mTHPC/HDL (8–12 nm) ormTHPC/LDL (20–25 nm) complexes. In addi-
tion, lowered cyclodextrins concentration in solid tissue compared to
the bloodstream should stimulate dissociation of entering inclusion
complexes with subsequent mTHPC binding by tissue structures (cells,
interstitial proteins).
Influence of cyclodextrins on the accumulation of arylporphyrins
and some other porphyrin-like sensitizers in cellular systems have
been studied by several research groups (Dentuto et al., 2007;
Fig. 8. Fluorescence imaging of different organs and tissues isolated from HT29 tumor bearing mice after 24 h of introduction of 0.5 mg/kg mTHPC alone, with 2.5 mg/kg M-β-CD or with
25 mg/kg Hp-β-CD.
Table 1
Fluorescence intensity of mTHPC in various organs and tissues isolated from HT29 tumor bearing mice 24 h after injection obtained from fluorescence imaging data.
Formulations of mTHPC
Fluorescence intensity (a.u.)
Tumor Muscles Skin Liver Kidney Spleen Heart Lung
Alone 196 ± 26 38.7 ± 5.6 323 ± 45 198 ± 41 135 ± 32 60 ± 6 85 ± 12 248 ± 6
M-β-CD 247 ± 30* 20.6 ± 8.9* 203 ± 87* 130 ± 36* 241 ± 39** 54.3 ± 4.2 85 ± 11 150 ± 5**
Hp-β-CD 143 ± 28* 20.3 ± 9.6* 119 ± 23** 157 ± 26 183 ± 72 39 ± 14* 77 ± 5 204 ± 33
The experimental conditions as indicated in the legend to Fig. 8.
Results are presented as mean ± SD (n = 3–4).
Significant difference compared to mTHPC alone: *р b 0.05; **р b 0.01.
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Kitagishi et al., 2015; Kolárová et al., 2003, 2004). It is worth noting that
the results on these studies are contradictory. In the study by Kolárová
et al. (2004) the one hundred excess of Hp-β-CD in relation to the PSs
5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin (TTPS4) and Pd-
TTPS4 leads to a 2 fold increase of TTPS4 and Pd-TTPS4 uptake inmelano-
ma G361 cells. At the same time, Kitagishi et al. (2015) observed that
the addition of TTPS4 complexed with 2.4 times excess of trimethyl-β-
cyclodextrin led to approximately 30% reduction of PS cellular uptake
and consequently cell-photokilling ability in HeLa cells. Similarly,
Dentuto et al. (2007) showed that the interaction of chlorophyll a with
trimethyl-β-cyclodextrin at a ratio 1:10, Hp-β-CD (1:100) or Hp-γ-CD
(1:100) resulted in a 2–4 fold decrease in phototoxicity observed in
Jurkat cell line.
Results presented in this paper confirm that mTHPC accumulation
by HT29 cells strongly depends on Hp-β-CD and M-β-CD concentra-
tions, the β-CDs can cause both acceleration and inhibition of mTHPC
cellular uptake (Fig. 4). Most of water soluble cyclodextrins are not
able to penetrate into cells. So, their effect on accumulation of hydro-
phobic drugs should be attributed to an increase of the permeability
by enhancing drug solubility or dissolution and thus making the drug
available at the surface of plasmamembrane of cells, fromwhere it par-
titions into intracellular compartments (Loftsson and Brewster, 2013).
In such cases it is important to use proper cyclodextrins concentration
since excess may decrease the drug availability. Actually, at high β-
CDs concentrations, the rate of mTHPC accumulation in the cells is re-
duced due to the high probability of formation of inclusion complexes
in the extracellular environment.
Another mechanism affecting mTHPC absorption by cells may be
mediated by cyclodextrin-dependent perturbations in cellular mem-
brane. Cyclodextrins are able to bind several components of plasma
membrane of cell that causes changes in membrane composition and
structure, modifying its binding and barrier functions (López et al.,
2011; Zidovetzki and Levitan, 2007). In this connection, it is interesting
to consider the involvement of cellular cholesterol, the content ofwhich
significantly affects the relative affinity of porphyrins to cellular and
model biological membranes (Cohen and Margalit, 1985; Zorin et al.,
1997). Much of evidence reported suggests that β-CD derivatives very
effectively (up to 90%) eliminate cholesterol from plasma membrane
of various cells (Zidovetzki and Levitan, 2007). According to our results
on the fluorescence of cholesterol-specific stain filipin III the treatment
of HT29 cells with 10 μMofM-β-CD or 200 μMof Hp-β-CD led to deple-
tion of 15–20% cholesterol from the plasma membrane. Such a moder-
ate change in the level of cholesterol apparently cannot be the main
reason for multifold acceleration of sensitizer accumulation by treated
cells.
It is essential to take into account that exposing cells to β-CDs also
alter the relative distribution of cholesterol between different mem-
brane compartments with corresponding physiological effects
(Zidovetzki and Levitan, 2007). According to Decker et al. (2013)
mTHPC prefers cholesterol poor membrane compartments. In this con-
nection an appearance of bright spots at the fluorescent images of the
HT29 cells treated with β-CDs apparently could be attributed to an in-
creased level of mTHPC accumulation in cholesterol depleted areas of
plasma membrane.
Photosensitization studies have shown that the β-CDs enhance
mTHPC photocytotoxicity in respects of HT29 cells in culture (Fig. 5).
It is unlikely that this effect is connected with the direct influence of
β-CDs on photodynamic activity in inclusion complexes. According to
IR luminescence measurements of singlet oxygen described in
(Bautista-Sanchez et al., 2005)mTHPC associationwith β-CDs is accom-
panied with decreasing in the value of singlet oxygen quantum yield in
1.5 times. Beside that as it was mentioned above, the penetration of
mTHPC into the cell follows processes of its dissociation from the inclu-
sion complexes with β-CDs. It is well known that the photocytotoxicity
of PS depends on the level of its accumulation in cells (Castano et al.,
2005a). According to the data obtained in this work cyclodextrin-
depending acceleration of mTHPC uptake by HT29 cells provides in-
creasing in cells sensitivity to the phototreatment. There are strong cor-
relations between increasing of PS cellular uptake and decreasing of
LD50 value at different protocols of cells treatment (type of β-CD, incu-
bation time).
Changes of physico-chemical properties of sensitizer via inclusion
complexation with β-CDs are ought also to modify its biodistribution
in the whole body. Our results of in vivo fluorescence kinetics (Fig. 7)
and fluorescent imaging of mTHPC distribution in various tissues (Fig.
8) confirm this assumption. Indeed, intravenous administration of
mTHPC alone leads to formation of large non-fluorescent aggregates
distorting the pharmacokinetics and reducing drug bioavailability
(Sasnouski et al., 2005; Triesscheijn et al., 2007). The gradual destruc-
tion of these aggregates is accompanied by slow increase of monomeric
mTHPC concentration in bloodstreamand consequently itsfluorescence
intensity (Fig. 7, curve 1). Co-administration with β-CDs abolishes
mTHPC aggregation in blood, thus the highest levels of mTHPC fluores-
cence intensity are achieved in 15–30 min (Fig. 7, curve 2). Change of
mTHPC kinetic pattern should enhance of PS bioavailability immediate-
ly after injection.
In our work fluorescence imaging technique was used to evaluate
theβ-CDs effect onmTHPC accumulation by different tissue and organs.
It should be noted that the correlation between PS accumulation and its
fluorescent signal obtained by this non-invasive technique is a function
of tissue optical properties (scattering, reflection, endogenous chromo-
spheres etc.). For this reason, our fluorescent imaging data are suitable
only for qualitative comparison of PS accumulation in different tissues.
For the same tissuemeasured changes in the level of fluorescence signal
should clearly reflect variations in the accumulation of PS and fluores-
cent imaging technique allows quantifying β-CDs effect on mTHPC ac-
cumulation in different tissues.
Data obtained in this article suggest that co-administration of
mTHPC with M-β-CD and Hp-β-CD modifies mTHPC distribution in
tumor bearingmice. The tumor andmuscles uptake indicates that com-
plexation of mTHPC with β-CDs especially with M-β-CD results in
higher tumor-to-muscles ratio than mTHPC alone that may induce a
better selectivity of PDT treatment (Roby et al., 2007).Moreover, formu-
lation of mTHPC with M-β-CD and Hp-β-CD showed lower drug levels
in the skin compared to mTHPC alone (Fig. 8), thus indicating that the
side effects with both β-CDs may prove less severe. It should be noted,
that cyclodextrins are rapidly eliminated in the urine and can increase
renal clearance of lipophilic water-insoluble drugs (Stella et al., 1999).
This is in accordance with a significant increase in the fluorescence
level of mTHPC in the kidney as well as a reduction in the PS fluores-
cence level in the liver when applying a formulation withM-β-CD com-
pared to mTHPC alone. This indirectly confirms that even after
administration, a certain part of mTHPC remains associated with M-β-
CD.
5. Conclusion
Application of β-CD derivatives can open up new possibilities to
modify mTHPC biodistribution in the course of PDT. mTHPC formula-
tions with Hp-β-CD andM-β-CD showed sufficiently different behavior
in several studied biological systems: serum solutions, cellular cultures
and HT29 tumor bearing mice. Association of mTHPC with the β-CDs
completely abolishes its aggregation after introduction into blood that
should improve its pharmacokinetics and bioavailability. It was demon-
strated that the β-CDs have a concentration-dependent effect on the
process of mTHPC distribution in blood serum. At high concentrations
the β-CDs can form inclusion complexes with mTHPC in the blood
that can have a significant impact on PS distribution out of the vascular
system in solid tissues. Besides, the β-CDs increase diffusion movement
of mTHPC molecules that can significantly accelerate the delivery of PS
to the targets cells and tissues. In vivo study confirms the fact that the
use of β-CDs allows to modify mTHPC distribution processes in tumor
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bearing animals that is reflected in the decreased level of PS accumula-
tion in skin and muscles, as well as in the increased PS accumulation in
tumor. Further studies are underway to verify the optimal protocols of
mTHPC/β-CD formulation for PDT.
Abbreviations
PDT Photodynamic therapy
PS Photosensitizer
β-CD β-Cyclodextrin
M-β-CD Methyl-β-cyclodextrin
Hp-β-CD 2-Hydroxypropyl-β-cyclodextrin
mTHPC Meta-tetra(hydroxyphenyl)chlorin
PBS Phosphate buffered saline
FBS Fetal bovine serum
P The degree of fluorescence polarization
LD50 Lethal dose, inducing 50% cell death
LDL Low density lipoproteins
HDL High density lipoproteins
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2. Développement de méthodes de fluorescences pour le
monitoring du relargage de la mTHPC du complexe 
d’inclusion. 
La seconde partie des résultats est présentée dans l’article « Soret band shape indicates 
mTHPC distribution in biological systems » accepté dans le journal « Dyes and Pigments » et 
relate les méthodes de mesure de relargage et de distribution de la mTHPC.  
Les caractéristiques de fluorescence et d’absorbance de la mTHPC solubilisée dans 
différents solvants organiques et complexée avec différentes structures biologiques ont été 
analysées. Une nouvelle technique de mesure des spectres de fluorescence pour le contrôle 
non-invasif de la distribution de la mTHPC entre les nanotransporteurs β-CD et différentes 
structures biologiques a été décrite. Une analyse des données obtenues permet de conclure 
que les caractéristiques spectrales de la bande de Soret sont les plus sensible à la liaison de la 
mTHPC aux structures biologiques. La forme de la bande de Soret du spectre d’absorbance de 
la mTHPCs et la bande correspondante du spectre d’excitation de fluorescente sont fortement 
dépendantes du type de structures biologiques liées aux molécule pigmentaires.  
Le ratio de deux pics de bande de Soret est fortement dépendant du type de structures 
biologiques liée aux molécule pigmentaires. Une comparaison des résultats numériques 
obtenu à la suite de la déconvolution des spectres d’absorption et d’excitation démontre que le 
ratio Bx/By varie d’une valeur inférieure à 0,7 (mTHPC conjuguée aux vésicules lipidiques et 
aux protéines du sérum) à des valeurs de 1,03 – 1,42 pour le complexe mTHPC/β-CD.  En 
prenant en compte les mécanismes possibles d’incorporation des molécules de mTHPC dans 
les cavités des β-CDs ou dans les membranes lipidiques, on peut suggérer que la variabilité de 
la forme de la bande de Soret est associée aux changements de conformation des molécules de 
pigment. En se basant sur les variations de formes de la bande de Soret, la technique spectrale 
de monitoring en continu du relargage de la mTHPC des transporteurs β-CD dans un système 
biologique (e.g., distribution dans le sérum) a été développée. Cette approche peut être aussi 
utilisée dans l’étude de l’équilibre de distribution de la mTHPC dans un system complexe. 
Ces découvertes sont intéressantes pour le développement des techniques spectrales de 
monitoring non-invasif de la distribution de la mTHPC dans un system biologique.  
Cette partie du travail a été accepté dans le journal « Dyes and Pigments  » et présenté si 
après sous sa version publiée. 
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2. Development of fluorescence methods suitable for monitoring of
mTHPC release from inclusion complexes 
The second part of the results is presented in the article “Soret band shape indicates 
mTHPC distribution between β-cyclodextrins and serum proteins” accepted to Dyes and 
Pigments and is related to the methods of mTHPC release and distribution measurements.  
Fluorescence and absorbance characteristics of mTHPC in several organic solutions 
and in complexes with various biological structures have been analyzed. A new spectroscopic 
technique for noninvasive control of mTHPC distribution between β-CD nanocarriers and 
various biological structures was described. An analysis of received data allows concluding 
that Soret band is the most variable spectral characteristic sensitive to the binding of mTHPC 
to biological structures. The shapes of the Soret band of mTHPC absorbance spectrum and 
corresponding band of fluorescence excitation spectrum are strongly depended on the kind of 
biological structure bound with the pigment molecule.  
The ratio of two Soret band peaks are strongly depended on the kind of biological 
structure bound with the pigment molecule. A comparison of the numerical results for 
mTHPC absorption and excitation spectra deconvolution shows that the ratio Bx/By varies 
from less than 0.7 (mTHPC bound to lipid vesicles and serum proteins) to 1.03-1.42 for 
mTHPC/β-CD complexes. Taking in account the possible mechanism of incorporation of 
mTHPC molecule into the β-CD cavities or lipid membranes, one can suggest that the 
variability of Soret band shape is associated with the changes of pigment molecule 
conformation. On the basis of Soret band shape variations, the spectral technique for 
continuous monitoring of the release of mTHPC from β-CD carriers in biological systems 
(e.g., distribution in blood serum) was developed. This approach can be also applied in a 
study of equilibrium distribution of mTHPC in complex system. This finding is useful for the 
development of spectral technique for noninvasive continuous control of mTHPC distribution 
in biological systems. 
This part of the work was accepted in Dyes and Pigments and is presented thereafter 
in its published form.
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Fluorescence and absorbance characteristics of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin (mTHPC) in
several organic solutions and in complexes with various biological structures have been analyzed. A
comparison of data showed that the most variable mTHPC spectral characteristic is the Soret band shape.
The ratio of two Soret band peaks are strongly dependent on the kind of biological structure bound with
the pigment molecule. It has been suggested, that the observed variations of Soret band shape are
associated with conformational changes of mTHPC molecule, caused by the forced rotation of the aryl-
substitutes. On the basis of Soret band shape variations, the spectral technique for noninvasive moni-
toring of mTHPC release from inclusion complex with b-cyclodextrin carriers in blood serum was
developed.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
The expanding application of tetrapyrroles in photomedicine
techniques (photoimaging, photodynamic diagnosis and therapy
(PDT)) increases interest in the study of the porphyrin spectral
characteristics in biological systems [1e4]. The spectral properties
of porphyrins are often highly informative in analysis of the
porphyrin interaction with biological structures, for instance in
study of photosensitizer (PS) distribution in cellular and tissue
systems.
5,10,15,20-Tetra(m-hydroxyphenyl)chlorin (mTHPC) (Scheme
1), the potent second-generation PS, which is currently under
clinical trial for the palliative treatment of head and neck cancer,
appears as a promising PS exhibiting a high therapeutic ratio [5e7].
mTHPC possesses optimal photophysical characteristics for PDT [8],
selectively accumulates in the tumor tissue and sensitizes its
photodamage [7]. However, this drug is hydrophobic and is prone
to aggregation in biological media, resulting in a decreased
photodynamic efficacy, moderate selectivity and prolonged skin
photosensitivity [6,9]. To abolish these problems, special pharma-
cological forms such as liposomes [10,11], polymeric nanoparticles
[12] and bioconjugates [13] are proposed to use for mTHPC
administration.
b-Cyclodextrin (b-CD) derivatives can be successfully used for
nonpolar porphyrin administration [14e16]. Introduction of b-CDs
into aqueous solutions of porphyrins causes PS disaggregation by
forming the inclusion complexes [17]. It is also reported that por-
phyrins in combination with b-CDs efficiently accumulate in tumor
cells in vitro [18e20]. In our recent study we have proposed to use
b-CDs as a delivery system in mTHPC-PDT [20]. It was demon-
strated that the b-CDs have a concentration-dependent effect on
the process of mTHPC distribution in blood serum and significantly
alter the selectivity of mTHPC accumulation in the tumor tissue. It
was suggested, that b-CDs concentration dependent effect strongly
depends on mTHPC distribution between inclusion complexes and
Abbreviations: PDT, photodynamic therapy; PS, photosensitizer; mTHPC,
5,10,15,20-Tetra(m-hydroxyphenyl)chlorin; b-CD, b-cyclodextrin; DPPC, dipalmitoyl
phosphatidyl choline; DPPG, dipalmitoylphosphatidylglycerol; Me-b-CD, methyl-b-
cyclodextrin; TM-b-CD, trimethyl-b-cyclodextrin; DPBS, dulbecco's phosphate-
buffered saline; TGF, tetrahydrofuran; 4f, fluorescence quantum yields; P, fluor-
escence polarization degree; r2, adjusted coefficient of determination; N, the frac-
tion of mTHPC molecules bound to Me-b-CD.
* Corresponding author. Laboratory of Biophysics and Biotechnology, Physics
Faculty, Belarusian State University, 4 Nezavisimosti Ave, 220030, Minsk, Belarus.
E-mail address: vpzorin@mail.ru (V. Zorin).
1 These authors have contributed equally to this work.
Contents lists available at ScienceDirect
Dyes and Pigments
journal homepage: www.elsevier .com/locate/dyepig
http://dx.doi.org/10.1016/j.dyepig.2016.11.007
0143-7208/© 2016 Elsevier Ltd. All rights reserved.
Dyes and Pigments 137 (2017) 299e306
81
biological structures in the blood stream or interstitial media
(serum proteins and cellular membranes). From this point of view,
the rate and the extent of mTHPC transfer from the inclusion
complex is an important determinant of this PS pharmacokinetics.
In the present work we describe a new fluorescent spectral tech-
nique for noninvasive control of mTHPC distribution between b-CD
nanocarriers and various biological structures.
2. Materials and methods
2.1. Chemicals and reagent preparation
The photosensitizer mTHPC was kindly provided by Biolitec
Research GmbH (Jena, Germany) with the purity > 99%. Neutral
detergent Triton® X-100 was purchased from Sigma Aldrich
(France). Embryonal calf serum, dipalmitoylphosphatidyl choline
(DPPC) and dipalmitoylphosphatidylglycerol (DPPG) were pur-
chased from Sigma Chemical Co. (USA). The cyclodextrins methyl-
b-cyclodextrin (Me-b-CD) and trimethyl-b-cyclodextrin (TM-b-CD)
were purchased from AraChem (Tilburg, NL).
mTHPC stock solution (1 mM) was prepared in absolute ethanol
(99.6%) and was kept at 4 C in the dark. The concentration of
mTHPC in the solution was estimated by a spectrophotometric
method using molar extinction coefficient of 30 000 M-1 cm-1 at
650 nm in ethanol.
All aqueous solutions were prepared in Dulbecco's phosphate-
buffered saline (DPBS) (pH 7.4) at 25 C. To prepare mTHPC solu-
tion in organic solvents, mTHPC stock solution was dissolved 100
times. To prepare the solution with serum proteins, mTHPC was
incubated for 3 h with 2% serum at 37 C under light protection.
Me-b-CD and TM-b-CD complexes with mTHPC were formed
using the co-precipitation method [21]. Briefly, b-CDs were dis-
solved in DPBS at the required concentrations with subsequent
addition of the stock solution of mTHPC. The final content of
ethanol in the mTHPC/b-CD solutions did not exceed 0.5%. The
solution was thoroughly mixed for 15 min under magnetic stirring.
All other chemicals and solvents (ethanol, methanol, tetrahy-
drofuran (TGF), acetone) used in our experiments were commercial
products of the highest grade of purity and its manufacturers will
be specified below.
2.2. Preparation of liposomes
Unilamellar liposomes containing mTHPC were made by filter
extrusion technique as described in Ref. [22]. Briefly, 18 mg mL1 of
DPPC (Avanti, USA) and 2mgmL1 of DPPG (Avanti) were dissolved
in 1mL of 99.6% ethanol. A thin filmwas obtained by removal of the
solvent by rotary evaporation at 60 C. The film was hydrated in
1 mL of DPBS and underwent three freeze-thaw cycles. The sus-
pension was extruded 21 times through 100 nm polycarbonate
Nuclepore® membranes using Avanti Mini-Extruder (Avanti) at
50 C. After extrusion liposomes were stored at 4 C. mTHPC was
added to the lipid vesicles on the stage of receiving of the lipid film
to obtain dye: lipid ratio of 1: 100.
2.3. Spectroscopic measurements
The absorption spectra were measured on Solar PV1251 (Solar,
Belarus) spectrophotometer using 1 cm optical path quartz cu-
vettes. Fluorescent measurements were performed on Solar CM
2303 (Solar, Belarus) fluorescence spectrometer equipped with
thermostat cuvette compartment and magnetic stirring. The error
in the wavelength measurements was estimated as ± 1 nm.
The concentration of mTHPC in all samples was 0.5 mM. The
spectroscopicmeasurements were carried out at room temperature
22e24 C. Optical density at all measurements did not exceed 0.15
a.u. The concentrations of serum and Triton® X-100 were 5% (vol/
vol) and 0.2% (vol/vol) respectively. The concentration of b-CDs was
0.1 mM.
2.4. Quantum yield measurements
The fluorescence quantum yields (4f) were determined using
mTHPC in methanol (4f ¼ 0.089) [8] as the standard, and an exci-
tation wavelength of 416 nm. The absolute error in quantum yields
values was estimated as ± 0.01.
2.5. Fluorescence polarization measurements
Measurements of mTHPC fluorescence polarization degree (P)
were performed on Solar CM 2303 equipped with polarizers. In this
case, samples were excited at 430 nm and fluorescence was regis-
tered at 652 nm as published before [20]. The polarization degree
was calculated using a mean values of fluorescence intensities with
the polarizers in parallel and perpendicular positions. The absolute
error value for all measurements was less than 0.02.
2.6. Deconvolution of curve into component Gaussians
The experimental spectra were obtained and then were
deconvoluted using a MATLAB software (The Math Works, USA).
Using this program for an experimental curve, a multiple Gaussian
fit can be done. With the approximate input parameters as above
for each of the Gaussian curves an iterative nonlinear least square
fit method was used. For optimization of the fit conditions, itera-
tions ware carried out until the difference in the value of chi-square
for successive iterations was less than 5% of the previous value. The
adjusted coefficient of determination (r2) was more than 0.995 for
all calculations.
2.7. Statistical analysis
Each experiment was repeated at least three times. Data are
presented as mean ± SD. The datawere evaluated using Student's t-
test. The difference was considered significant at p < 0.05. Data
analysis was carried out with the STATISTICA 10 (StatSoft, Inc.,
USA).
Scheme 1. Representation of the molecular structure of the 5,10,15,20-tetra(m-
hydroxyphenyl)chlorin (mTHPC).
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3. Results and discussion
3.1. Absorption and fluorescence characteristics of mTHPC in
solvents and solutions with different biological structures
The results obtained from spectral studies of mTHPC in neat
solvents and different biological solutions are summarized in
Table 1. The spectral characteristics of mTHPC are generally defined
by PS belonging to chlorin-type compounds. Absorption spectra of
mTHPC reveal most prominent peaks in the region of 420 nm (B-
band or Soret band) and 651 nm (Q-band). In organic solvents
mTHPC intensively fluoresces at 652 nm with a quantum yield (4f)
around 0.09 [8] and the fluorescence lifetime of 10 ns [23]. In
different organic solvents we detected onlyminor spectral changes:
shifts of 1e2 nm in the peaks and the relative fluorescence quan-
tum yield varying within 10% compared to ethanol solution.
Like many hydrophobic tetrapyrroles, mTHPC molecules in
aqueous solutions tend to aggregate. The formation of large J-ag-
gregates leads to a significant change in the absorption and mTHPC
fluorescence properties [24,25]. The aggregated species are char-
acterized by the decreased extinction coefficients for all bands and
exhibit bathochromic shifts of the peaks (Table 1). According to the
data obtained, the fluorescence quantum yield of mTHPC in DPBS
decreases hundreds times.
The aggregation of mTHPC in aqueous media is completely
prevented via interaction and binding with different biological
structures i.e. liposomes, proteins, cyclodextrins [17,26e28].
Depending on the type of biological structure several features of
mTHPC spectral properties are observed (Table 1):
i) the positions of all spectral bands (except Soret band) remain
practically unchanged;
ii) an enhanced quantum yield of mTHPC fluorescence in solu-
tions with b-CDs and liposomes, while in Triton® X-100 and
serum solution this parameter is decreased;
iii) the presence of mTHPC polarized fluorescence (in liposomes,
neutral detergent micelles and serum proteins P up to 0.30,
in inclusion complexes with b-CDs P up to 0.05 only), while
in organic solutions fluorescence is totally depolarized (P less
than 0.02). The fluorescence decay time varies slightly in
studied samples [20], that allow us to use the detection of
polarized fluorescence to confirm mTHPC binding to studied
biological structures.
An analysis of the collected data allows the conclusion that the
Soret band is the most variable characteristic, when we compared
spectra of mTHPC bound to the studied biological structures (Fig.1).
This statement concerns both the position and the shape of the
band.
Soret band has a semi-resolved structure with two distinct
peaks. In organic solvents the maxima of these peaks are located at
410 nm and 417 nm respectively with the intensity ratio 0.85. The
binding of mTHPC to liposomes, neutral detergent micelles and
serum proteins leads to 3e4 nm bathochromic shift of Soret band
and the peaks intensity ratio decreasing by 15e20% compared to
ethanol solution. In b-CDs solutions similar spectral shift (2e3 nm)
is accompanied by the opposite changes of its shape (intensity of
shortwave shoulder almost reaches the value of main peak).
3.2. Formalization of mTHPC Soret band
To formalize the description of mTHPC Soret band shape vari-
ations in different solutions we used the deconvolution technique.
According to Palummo et al. [29], the absorption spectrum of free-
base porphyrins and their derivatives over the range 350e450 nm
may be approximated using five Gaussian components: Bx, By and
Nx, Ny, Lx (Fig. 2). The components of this system are labeled ac-
cording to the directions of polarization in the (x,y) planes of a
macrocyclic system. B-band also known as the Soret band is located
within the range 370e450 nm and is associated with the high-
Table 1
Spectral-fluorescent characteristics of mTHPC.
Surrounding Absorbance Fluorescence
lmax, nm (the Soret band) lmax, nm (Q(0,0)-band) lmax, nm 4f P, a.u
Ethanol 417 651 652 0.092 0.02 ± 0.01
Methanol 416 650 652 0.089 0.01 ± 0.01
Acetone 417 651 653 0.085 0.01 ± 0.01
TGF 418 653 654 0.083 0.01 ± 0.01
DPBS 430e438 654 654 <0.001 e
Triton X-100® 421 653 654 0.074 0.23 ± 0.02
Liposomes 420 651 652 0.132 0.30 ± 0.01
Serum proteins 421 653 654 0.063 0.26 ± 0.02
Me-b-CD 420 650 652 0.125 0.04 ± 0.01
TM-b-CD 419 650 652 0.142 0.05 ± 0.01
Fig. 1. Normalized fluorescence excitation spectra of mTHPC in various biological
media. The solid black line is the mTHPC Soret band spectrum in ethanol, the dots are
in liposomes, the dash dots are spectrum of mTHPC in complexes with TM-b-CD and
the dash line is Soret band spectral region of mTHPC in micelles of Trinton® X-100. The
concentration of mTHPC was 0.5 mM, the concentrations of serum and Triton® X-100
were 5% (vol/vol) and 0.2% (vol/vol) respectively. The concentration of TM-b-CD was
0.1 mM.
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energy p-p* transition to the 2nd degenerate excited state,
ðS0/S2Þ [29e31]. The B-band degenerates for the D4h high sym-
metry porphyrins and splits in the case of lower symmetry de-
rivatives such as mTHPC [31,32]. In the near UV region from 360 to
400 nm the higher-energy transitions known as the N-, L-bands are
also found. These bands are associated with the allowed p-p* (N-
band) and n-p* (L-band) electronic transitions to the high-energy
states ðS0/SnÞ [33,34].
The applied model may be used for the description and quan-
titative analysis of the observed spectral variations by Gaussian
function expansion of the electronic spectra using the wave-
numbers as coordinates [35,36]. The applicability of model pro-
posed was checked by adjusted coefficient of determination (r2) for
each sample.
To compare the contribution of each component to the changes
in the shape of the Soret band the relative weights of sub-bands
were calculated (Table 2). A comparison of the numerical results
for mTHPC absorption and excitation spectra deconvolution shows
that themain factor determining observedmTHPC spectral features
in the 360e450 nm region is a variation of ratio Bx/By. For mono-
meric unbound mTHPC molecules in organic solvents, the ratio By/
Bx is within the range 0.73e0.93, whereas for mTHPC/b-CD com-
plexes its values are 1.03e1.42. For mTHPC bound to lipid vesicles
and serum proteins, the value of By/Bx is less than 0.7.
3.3. The analysis of Soret band shape of mTHPC in solvents and
solutions with different biological structures
It is recognized, that the solvent impacts the spectral charac-
teristics of free base porphyrins and chlorins [3]. Quantum calcu-
lations suggest that the main mechanism of this effect deals with
the slight change of natural porphyrin ring conformation due to the
interactions of solvent molecules with the lateral substituents.
Based on mTHPC crystallographic data [37], we can suggest that in
solvents the planar chlorin ring of free mTHPC molecule is sur-
rounded by pairs of face-to-face positioned phenyl groups, with
two of them related to the macrocycle meanplane dihedral angles
(Fig. 3a). Organic solvents can have a minor impact on the rotation
of phenyl groups of mTHPC and only slightly change the mTHPC
Soret band shape. More significant changes of mTHPC conforma-
tion related to the phenyl groups are supposed to occur in orga-
nized biological structures as liposomes, serum proteins and
inclusion complexes.
An incorporation in lipid membrane suggests strong interaction
between mTHPC and lipid molecules [38]. Data concerning the
mTHPC fluorescence quenching by membrane impermeable
quenchers, mTHPC molecules penetrate into the lipid bilayer [39].
The inclusion of the mTHPC molecule into biological membranes in
intact conformation should lead to a significant disordering of lipid
bilayer and as the consequence to the modification of structural
characteristics and stability of lipid vesicles. In fact, mTHPC loading
into liposomes has practically no effect on the stability of the ves-
icles. Even at high dye: lipid ratio of 1: 12 the size of DPPC lipo-
somes changes by only a few nanometers while the liposomal
membrane retains the ability to change phase state when heated
[40].
Absorption and fluorescence wavelengths provide valuable in-
formation of the microenvironment experienced by mTHPC in lipid
membranes. It is proposed that the influence of the lipid bilayer on
mTHPC spectral characteristics can occur through the effect of
apolar environment or as a result of steric interactions in the bulk of
the lipid bilayer. In accordance with our results an alteration of
solvent polarity keeps the parameters of the Soret band unchanged
(Table 1). At the same time for mTHPC molecules incorporated into
lipid vesicles the membrane lateral pressure should change the
orientation of two or more phenyl meso-substituents and arrange
them in parallel relatively tetrapyrrolic cycle (Fig. 3b). This
conformation of mTHPC molecule provides a minimal effect on the
lipid bilayer structure. Discussed structural modification of mTHPC
molecule in lipid membrane is associated with a significant in-
crease of overlapping of the phenyl rings and chlorin core p-sys-
tems, and consequently with changes in the energy states and
electronic spectra.
In accordancewith our assumption, modifications of the mTHPC
molecule conformation should depend on the rigidity of lipid
bilayer. In this connection it is interesting to compare the
temperature-depended variations of the ratio Bx/By and polariza-
tion degree of fluorescence of mTHPC incorporated into DPPC lipid
vesicles (Fig. 4).
Highly polarized fluorescence (P ¼ 33%) of mTHPC in liposomes
in a quasi-crystal state (at the temperature less than 35 C) in-
dicates a significant restriction of fluorophore rotation in the lipid
matrix [42]. The heating above 40 C leads to the DPPC lipid bilayer
phase transition, accompanied with the changing of lipid packing
type [39]. The noted structural changes result in the increased
mobility of mTHPC molecules as evidenced by the lowering of the
fluorescence polarization degree by up to 24%. The decreased
packing density of lipid molecules and lateral pressure in a bilayer
[43], high conformational mobility of fatty-acid chains at temper-
atures above the phase-transition temperature should provide
Fig. 2. Gaussian deconvolution for mTHPC in ethanol for the Soret band region. The
open circles are the experimental data, the solid black lines are the theoretical curves
obtained from Gaussian deconvolution.
Table 2
Results for deconvolution of the mTHPC Soret band in various solvents and solutions
with different biological structures.
Medium Bx By Nx, Ny, Lx By/Bx r2
TM-b-CD 0.31 0.44 0.25 1.42 0.995
Me-b-CD 0.38 0.39 0.23 1.03 0.997
Ethanol 0.44 0.33 0.23 0.74 0.999
Methanol 0.45 0.33 0.22 0.73 0.998
Aceton 0.42 0.36 0.22 0.86 0.998
TGF 0.40 0.37 0.23 0.93 0.997
Triton X-100 0.45 0.35 0.20 0.78 0.998
Serum proteins 0.48 0.32 0.20 0.67 0.999
Liposomes 0.49 0.31 0.20 0.63 0.998
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enhanced freedom of mTHPC aryl substituents rotation. As a result,
for mTHPC in liposomes at high temperatures the By/Bx ratio is
growing.
It is recognized, that serum lipoproteins are the main binding
sites for mTHPC (95% of mTHPC in serum plasma are bound to high
and low density lipoproteins) [26]. This type of protein consists of a
core of hydrophobic lipids surrounded by a shell of proteins and
phosphatidyl glycerols and has quite similar structure as lipid mi-
celles. As in the liposomes, a high value of the fluorescence polar-
ization degree of mTHPC in serum indicates an extremely strong
fixation of PS molecules. Thus, based on studies of mTHPC spectral
characteristics in solutions of serum proteins, we can conclude that
the interaction of the PS molecule with lipoproteins leads to the
same conformational modifications as were observed in a lipid
bilayer.
mTHPC effectively forms inclusion complexes with b-CDs
[15,17]. b-CD/mTHPC complexes are reported to have a 1: 2 stoi-
chiometry [17] and are characterized by a high values of binding
constants (1.2 105 M1 for Me-b-CD) [15]. Molecular modeling and
NMR spectroscopy of b-CD/aryl-porphyrins complexes structure
indicate that two opposite porphyrin aryl-groups would be totally
located in the hydrophobic b-CD cavity from the secondary
hydroxyl-groups side (Fig. 3c) [17,44,45]. The proximity of b-CD's
face groups has to limit the rotation of two hydroxyphenyl-groups,
which are not involved into the formation of host-guest complex.
On the contrary to mTHPC in lipid bilayer, mTHPC binding to b-CD
induces steric restrictions leading to the increase of the average
value of dihedral angles between macrocycle and phenyl
Fig. 3. Possible steric structures of mTHPC molecules: а e in organic solvent (natural conformation: phenyl groups are related to the macrocycle meanplane with dihedral angles of
61 and 76), b e in lipid bilayer or serum lipoproteins (phenyl groups (grey coloured) tends to turn parallel to the macrocycle), c e in inclusion complex with b-CDs tends to turn
perpendicular to the macrocycle). The structures were modeled in UCSF Chimera [41].
Fig. 4. The dependence of polarization degree of mTHPC fluorescence (1) and I405/I418
value (2) from temperature for mTHPC in lipid bilayer. mTHPC concentration was
0.5 mM. The liposome ratio dye: lipid ¼ 1: 100. The results of three independent ex-
periments are expressed as the mean with the vertical bar showing S.D.
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substituents (Fig. 3c). A similar conclusion on conformational
changes of aryl-substituted porphyrins in complexes with b-CD has
been obtained by computational studies [17,44]. The conformation
changes of mTHPC molecule result in decreasing conjugation de-
gree between hydroxyphenyl-group and chlorin-ring systems.
Alteration of mTHPC electronic system is manifest as the decrease
of By and Bx relative weight disbalancing, which corresponds to
increasing of mTHPC By/Bx value in the complexes with b-CD.
It is obvious, that the role of discussed conformation-linked
mechanism of mTHPC spectral alterations depends on character-
istics of biological structures. Values of dihedral angles determine
the degree of orbital-overlapping p-conjugated electron systems of
aryl-groups and chlorin ring that affects the energy spectrum of
mTHPC in complexes with biological structures [44,45]. It has been
shown that increasing the degree of etherification of the hydroxyl
groups of the b-CD leads to the enhancement of affinity between b-
CD and mTHPC [17]. According to the obtained data, the ether-
ification of hydroxyl-groups results in increasing of binding con-
stants as well as increasing of the penetration depth of mTHPC's
aryl-groups in the b-CD's molecule.
3.4. Application of mTHPC spectral features for the control its
redistribution in serum
Our results show that Soret band shape is dependent on mTHPC
binding to the different biological structures (b-CDs and serum
proteins/lipid membranes). We suggest that this feature allow one
to control whethermTHPCmolecules are in inclusion complexwith
b-CDs or they are bound to the serum protein/membrane.
Fig. 5 shows the kinetics of Il1/Il2 value changes when mTHPC/
Me-b-CD complexes are mixed to the 5% serum solution (curve 1)
and whenMe-b-CD is added to the 5% serum solution preincubated
with mTHPC (curve 2). We analyzed mTHPC excitation spectrum at
652 nm using l1¼397 nm and l2¼ 422 nm excitationwavelengths,
providing the greatest difference in mTHPC emission intensities
ratio. The I397/I422 value of mTHPC complexed with Me-b-CD mol-
ecules is equal to 0.63, while the fluorescence spectrum of PS
associated with serum proteins is characterized by I397/I422 ¼ 0.41.
A competition between Me-b-CD and the serum proteins leads to
redistribution of mTHPC molecules from inclusion complexes to
serum proteins, which results in the drop of I397/I422 value. The
equilibrium value corresponding to used Me-b-CD and serum
concentrations is equal to 0.55. Return transfer of mTHPC mole-
cules from serum proteins to Me-b-CDs is controlled in a similar
way (Fig. 5, curve 2). The application of this technique allows the
estimation of the fraction of mTHPC molecules bound to serum
proteins/Me-b-CD at each time point and the kinetic characteristics
of mTHPC transfer.
Fig. 6a illustrates the kinetics of mTHPC redistribution from
serum proteins to Me-b-CD depending on b-CD concentration.
When Me-b-CD concentration is low (less that 20 mM) the Soret
band shape changes not significantly indicating that almost all
mTHPC molecules remained bound to serum proteins (Fig. 6a,
curves 1, 2, 3). In the samples containingmoderate concentration of
Me-b-CD, the I397/I422 ratio value reaches 0.52 in 10 min of incu-
bation meaning the transport of only limited amount of mTHPC
molecules from the serum proteins to Me-b-CD (Fig. 6a, curve 4).
Finally, after adding an excess amount of Me-b-CD (200 mM) to the
Fig. 5. Kinetics of I397/I422 value changes after mixing of serum with mTHPC/Me-b-CD
solution (curve 1) and after mixing of Me-b-CD solution with mTHPC/serum solution
(curve 2). The concentration of mTHPC was 0.5 mM, concentration of serum was 5%
(vol/vol). The concentration of Me-b-CD was 60 mM.
Fig. 6. A e The kinetics of I397/I422 value changes after mixing of Me-b-CD solutions with mTHPC/serum solution. The concentration of Me-b-CD in the samples was (1) 5 mM, (2)
10 mM, (3) 20 mM, (4) 50 mM or (5) 200 mM. B e Influence of Me-b-CD concentration on the equilibrium distribution of mTHPC in serum solution after 24 h of incubation at 37 C. N e
the fraction of mTHPC molecules bound to Me-b-CD. The concentration of mTHPC was 0.5 mM, the concentration of serumwas 5% (vol/vol). mTHPC was preincubated with serum at
37 C during 2 h until complete binding of photosensitizer.
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serum solution, containing mTHPC, the I397/I422 value grows from
0.41 to 0.62 in several minutes confirming complete PS redistri-
bution to Me-b-CD (Fig. 6a, curve 5).
Taking into account spectral shifts and variations of quantum
yield of mTHPC fluorescence, it is possible to convert the value of
Il1/Il2 ratio to the relative weights of fractions of mTHPC molecules
bound to serum proteins or b-CD. The dependence of the fraction of
mTHPC molecules bound to Me-b-CD (N) on the concentration of
Me-b-CD is shown on Fig. 6b. The data obtained allow to estimate
the interval of Me-b-CD concentrations in which mTHPC distribu-
tion pattern in serum has undergone changes.
Similar results of mTHPC distribution between b-CD and serum
proteins were obtained recently by means of fluorescence polari-
zation measurements [20]. In this connection it is worth noting,
that the spectral technique described in this paper is less sensitive
to the influence of various physical factors, such as light scattering,
fluorescence quenching. And for this reason the technique based on
spectral features of the Soret band shape is more reliable for the
non-invasive studies of mTHPC distribution in blood serum.
4. Conclusion
Spectral characteristics of Soret band is considered to be unin-
formative for the analysis of peculiarities of aryl-porphyrin micro-
environment. In the present study it was shown that the shapes of
the Soret band of mTHPC absorbance spectrum and corresponding
band of fluorescence excitation spectrum are strongly dependent
on the kind of biological structure bound with the pigment mole-
cule. The well-detected difference in ratio of two Soret band peaks
is observed for mTHPC molecules bound to b-CD on the one hand
and to serum proteins/lipid membranes on the other. Taking in
account the possible mechanism of incorporation of mTHPC
molecule into the b-CD cavities or lipid membranes, one can sug-
gest that the variability of Soret band shape is associated with the
changes of pigment molecule conformation. This finding is useful
for the development of spectral technique for noninvasive contin-
uous control of mTHPC distribution from b-CDs to biological
structures.
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GENERAL DISCUSSION 
The most effective clinically approved PSs have poor solubility in water resulting in 
unfavorable physico-chemical and biopharmaceutical properties. An important approach in 
this regard is the use of appropriate DDS. Since both CDs and tetrapyrrole PSs have been 
widely examined for applications in supramolecular chemistry (Kryjewski et al., 2015), it is 
not surprising that the CDs have been proposed as a DDS in PDT (Mazzaglia, 2011). 
Numerous studies have shown that CDs have a high affinity to porphyrinoid PSs especially 
aryl substituted (Lang et al., 2004; Wu et al., 2005).  Inclusion in CDs exerts a profound effect 
on physicochemical properties of guest molecules as they are temporarily locked or partially 
caged within the host cavity giving rise to beneficial modifications of guest molecule 
properties. These modifications may enhance the therapeutic potential of PSs by increasing 
their aqueous solubility and dissolution rate, diminishing their decomposition before drugs 
enter tissues and by altering how they enter tissues (Gidwani & Vyas, 2015). In this 
perspective, it is reasonable to assume that β-CDs can be used to improve the 
pharmacokinetic and biodistribution properties of mTHPC affecting its PDT efficiency. 
It is known that in water solutions mTHPC forms large J-aggregates leading to a 
significant change in the absorption and fluorescence properties (Ball et al., 1998; Sasnouski 
et al., 2005). Introduction of β-CD derivatives to the aqueous mTHPC solution results in 
monomerisation of mTHPC as shown by its spectral and fluorescence parameters: the value 
of relative quantum yield of mTHPC fluorescence in PBS shows more than 100 times 
increase in the presence of M-β-CD. Similar effects are observed when mTHPC aggregates 
interact with different structures, such as serum, lipid vesicles or detergent molecules, and the 
mechanism of this dissociation have been studied in details experimentally (Ball et al., 1998; 
Kachatkou et al., 2009; Rezzoug et al., 1998; Sasnouski et al., 2005). On the other hand, 
simultaneous administration of mTHPC with β-CD derivatives prevents its aggregation. 
Demore et al. (1999) showed that in water solution mTHPC forms readily inclusion 
complexes with β-CD derivatives confirmed by the presence of strong induced circular 
dichroism at the main band of mTHPC absorption spectrum  (Desroches et al., 2001). 
mTHPC similarly to other aryl-porphyrins is able to bind 1 or 2 molecules of β-CD 
derivatives and the side phenyl groups penetrate into CD cavity (Demore et al., 1999).  
An interesting peculiarity of mTHPC interaction with the microenvironment is a 
strong dependence of several photophysical characteristics on the type of biological 
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compound bound to mTHPC molecule. An analysis of received data allows concluding that 
both the degree of fluorescence polarization and the Soret band (the position and the shape) 
are the most informative and variable spectroscopic characteristics in respect to mTHPC 
microenvironment. It allows us to use the registration of these characteristics to confirm 
mTHPC binding to studied biological compounds. In case of mTHPC/CD inclusion 
complexes the value of fluorescence polarization degree is relatively low P=0.05 compared 
the PS bound to liposomes and serum proteins (P ≤ 0.30). Fluorescence of PS bound to 
proteins, liposomes, micelles and CDs is polarized due to mobility restrictions. Since the 
fluorescence decay time varies slightly in compared samples, the difference in the values of 
fluorescence polarization degree is determined by hydrodynamic volumes of each structure 
(proteins, liposomes, micelles, CDs) bound to mTHPC. It is worth noting that a measurement 
of fluorescence polarization degree is sensitive to the various factors, such as sample turbidity 
and PS concentration. Indeed, fluorescence polarization of mTHPC in lipid vesicles and 
serum proteins is strongly dependent on the local concentration of PS and increase of PS 
concentration leading to progressive depolarization of fluorescence (Kachatkou et al., 2009; 
Reshetov et al., 2011). On the other hand, excitation fluorescence-based measurements of 
mTHPC Soret band are more informative and less sensitive to the above mentioned factors.  
Unlike porphyrins with their symmetrical structure, the chlorin-type molecules are 
tetrapyrroles with the double bond in one pyrrole ring reduced, and, as a result, Soret band has 
a semi-resolved structure with two distinct peaks that can be represented by two Gaussian 
components (Bx, By) (Shkirman et al., 1999; Steiner & Fowler, 2006). Although in the near 
UV region from 360 to 400 nm the higher-energy transitions known as the N-, L-bands are 
also found (Palummo et al., 2009), according to our analysis they are not practically affected 
by different mTHPC surroundings and their contribution to the Soret band can be fixed. A 
comparison of the numerical results for mTHPC absorption and excitation spectra 
deconvolution shows that the ratio Bx/By varies from less than 0.7 (mTHPC bound to lipid 
vesicles and serum proteins) to 1.03-1.42 for mTHPC/β-CD complexes. Most probable that 
the main mechanism of this effect deals with the slightly change of tetrapyrrole ring 
conformation due to the interactions of the lateral substitutes with surrounding 
microenvironment (Noss et al., 1997; Rosa et al., 2006). So, an incorporation of mTHPC in 
lipid membrane or CD cavity should cause the rotation of phenyl groups around PS 
macrocycle; however, due to the different insertion mechanisms, rotation of phenyl 
substituents has a different direction in these cases. 
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After injection into the bloodstream the PS interacts primarily with plasma proteins. 
Drug release from vehicles and subsequent pattern of plasma protein binding are important 
factors governing the in vivo pharmacokinetics and biodistribution of PSs during PDT 
(Castano et al., 2005b). In the case of mTHPC about 95% of PS in plasma is associated with 
HDL and LDL (Reshetov et al. 2012, Triesscheijn et al. 2007) and mTHPC releases from 
lipoprotein carriers very slowly proceeding on a timescale of hours (Sasnouski et al. 2006, 
2005). According to Bautista-Sanchez et al. (2005) association constants for mTHPC with 
several β-CDs are very high (~105 M-1) and evidently the effective formation of mTHPC/β-
CD inclusion complex can be obtained in the whole plasma. Desroches et al. (2001) suggested 
using β-CDs for pharmacokinetic studies in order to improve the sensitivity of the detection of 
mTHPC in human plasma.  
We have proposed the use of techniques described above (fluorescence polarization, 
Soret band) for controlling the distribution of mTHPC between inclusion complexes with β-
CDs and serum proteins. Analysis of the data showed that these methods can be used for both 
kinetic and equilibrium distribution of mTHPC between β-CDs and serum. The data of 
mTHPC distribution between the serum proteins and β-CDs obtained by Soret band correlate 
well with those received by fluorescence polarization that is supported by the gel 
chromatography data. Complexation of mTHPC with β-CDs is a reversible process, i.e. each 
molecule can dissociate from the inclusion complex with the subsequent binding to other 
molecules like plasma proteins. Indeed, the introduction of mTHPC/β-CD complexes into the 
serum is followed by a competition between CD and the serum proteins leading to 
redistribution of mTHPC molecules from inclusion complexes to serum proteins. It is 
obviously that return transfer of mTHPC molecules from serum proteins to CDs is controlled 
in a similar way.  
The rate and the extent of mTHPC transfer from inclusion complex is an important 
determinant of PS pharmacokinetics. According to our studies, β-CDs cause a significant 
acceleration of mTHPC diffusion movement in plasma. The addition of M-β-CD causes a 
rapid dissociation of mTHPC molecules from complexes with proteins, resulting in an 
equilibrium distribution attained in 10-15 min. Further, introduction of a small content of β-
CDs in serum significantly accelerates the rate of mTHPC redistribution between serum 
proteins. Besides studying the release rate of mTHPC from CD carriers to serum proteins, it is 
equally important to determine the exact protein fractions that bind mTHPC, since this has a 
significant effect on the drug tumor binding. According to gel chromatography data, β-CDs 
do not affect the distribution profile of the drug between the major serum transport proteins 
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except an appearance of free inclusion complexes of mTHPC/β-CD. It should be noted that 
the β-CDs effect on the process of mTHPC distribution in blood serum is a concentration-
dependent. At low concentrations of CD (high concentration of serum) almost all mTHPC 
molecules are bound to the serum proteins. Increasing β-CDs concentration shifts equilibrium 
of PS distribution towards the formation of inclusion complexes. The final pattern of mTHPC 
equilibrium distribution in the blood serum is determined by relative content of CDs and 
affinity of CDs to the PS. From this we can conclude that mTHPC transport in the blood is 
defined by the constant of inclusion complex formation and may differ significantly in the 
case of various β-CD derivatives.  
Despite a considerable amount of papers relate to study the influence of CDs on PS 
interaction with cells in vitro, there are no clear criteria for determining obtained effect of 
CDs (an increase or inhibition of PS accumulation). Moreover, an increase in the 
accumulation due to the increase of water solubility of the PS is not always the case (Dentuto 
et al., 2007; Kitagishi et al., 2015). The obtained results showed that mTHPC accumulation 
by cells strongly depends on type of CDs and its concentration: the β-CDs can cause both 
acceleration and inhibition of mTHPC cellular uptake. The effect of CDs on accumulation of 
hydrophobic drugs should be attributed to an increase of the permeability by enhancing drug 
solubility and thus making the drug available at the surface of plasma membrane of cells, 
from where it partitions into intracellular compartments (Loftsson & Brewster, 2013). Since 
most of water soluble CDs are not able to penetrate into cells, it is important to use 
appropriate CD concentration because excess may decrease the drug availability (Másson et 
al., 1999).  Actually, at high β-CDs concentrations, the rate of mTHPC accumulation in the 
cells is reduced due to the high probability of formation of inclusion complexes in the 
extracellular environment. Furthermore, accumulation of mTHPC/CD inclusion complexes 
may be determined by specific mechanisms of CD interaction with cells. CDs are able to bind 
several components of cellular plasma membrane especially cholesterol that causes changes in 
membrane composition and structure, modifying its binding and barrier functions (López et 
al., 2011; Zidovetzki & Levitan, 2007). On the other hand, the level of membrane cholesterol 
significantly affects the relative affinity of porphyrins to cellular and model biological 
membranes (Cohen & Margalit, 1985; Zorin et al., 1997). According to our results on the 
fluorescence of cholesterol-specific stain filipin III the treatment of HT29 cells with 10 μM of 
M-β-CD or 200 μM of Hp-β-CD led to depletion of 15-20% cholesterol from the plasma 
membrane. Such a moderate change in the level of cholesterol apparently can not be the main 
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reason for multifold acceleration of mTHPC accumulation by treated cells, but it may be the 
cause of bright spots in the periphery of cells loaded with mTHPC.  
It is well known that the photocytotoxicity of PS depends on the level of its 
accumulation in cells (Castano et al., 2005a). According to the data obtained CD-depending 
acceleration of mTHPC uptake by cells provides better cells sensitivity to phototreatment.  It 
is unlikely that this effect is connected with the improved photophysical properties of mTHPC 
in the presence of β-CDs on mTHPC. According to Bautista-Sanchez et al. (2005), depending 
on used techniques of singlet oxygen measurements, the values ΦΔ(1O2) were either not 
affected or were even 1.5 lower by the mTHPC/CDs associations. Besides, the penetration of 
mTHPC into the cell follows the processes of its dissociation from the inclusion complexes 
with β-CDs.  
Finally, the processes of mTHPC biodistribution in HT29 tumor bearing mice after 
intravenous injection of PS alone or with the β-CDs were compared. Co-administration with 
β-CDs abolishes mTHPC aggregation in blood which was observed in the case of standard 
formulation, thus probably enhancing PS bioavailability immediately after injection. The 
formation of inclusion complexes in the plasma can have a significant impact on mTHPC 
distribution from the bloodstream and its localization in extravascular tissues including 
tumors. Indeed, the interstitial transport of molecules and particles is characteristically 
described by their effective interstitial diffusion coefficient, which decreases as their size is 
increased (Pluen et al. 2001). In addition, Chauhan et al. (2012) showed that smaller particles 
penetrate tumors better than larger particles. Thus, the smaller mTHPC/β-CDs inclusion 
complexes, with the size about 1.5-2.0 nm, must penetrate into extravascular tissues much 
faster as compare to mTHPC/HDL (8-12 nm) or mTHPC/LDL (20-25 nm) complexes. 
In vivo study confirms the fact that the use of β-CDs allows modifying mTHPC 
distribution processes in tumor bearing animals that is reflected in the decreased level of PS 
accumulation in skin and muscles, as well as in the increased PS accumulation in tumor. 
Enhancement tumor-to-muscles ratio may induce a better selectivity of PDT treatment (Roby 
et al., 2007). Moreover, formulation of mTHPC with M-β-CD and Hp-β-CD showed lower 
drug levels in skin compared to mTHPC alone, thus indicating that the side effects with both 
β-CDs may prove less severe. We can assume that even after administration, a certain part of 
mTHPC remains associated with M-β-CD. According to the literature the highest level of 
mTHPC was found in the liver (Senge & Brandt, 2011) and the PS is excreted unchanged via 
biliary excretion in the faeces (Cai et al., 1999a, 1999b). On the other hand, CDs are rapidly 
eliminated in the urine and can increase renal clearance of lipophilic water-insoluble drugs 
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(Stella et al., 1999). This is in accordance with a significant increase in the fluorescence level 
of mTHPC in the kidney as well as a reduction in the PS fluorescence level in the liver when 
applying a formulation with M-β-CD compared to mTHPC alone.  
Taken as a whole, complexation of mTHPC with β-CDs leads to increased water 
solubility, accelerated delivery of PS to the targets cells and tissues, improved the tumor-to-
muscles ratio and expected low skin photosensitivity. Thus, β-CDs are very attractive delivery 
systems of aryl-substituted PSs and these findings might have potential relevance in 
improvement of PDT treatment with mTHPC. 
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CONCLUSIONS AND OUTLOOK 
The present thesis covers the study of inclusion complexes of CDs and second 
generation photosensitizer mTHPC. The main research results are summarized as follows: 
1. According to the spectral data, mTHPC efficiently forms the inclusion complexes 
with β-CD molecules in solutions and in biological systems. The shape of mTHPC Soret band 
and fluorescence polarization degree are the most informative spectral features for the 
purposes of controlling mTHPC distribution between inclusion complex and biological 
compounds (e.g., serum proteins and biological membranes). 
2. β-CDs have a concentration-dependent effect on the process of mTHPC 
distribution in blood serum. At low concentrations (10-6-10-5 M) the CDs do not affect the 
equilibrium distribution of mTHPC in blood serum, but significantly increase its diffusion 
mobility accelerating sensitizer binding to serum proteins. At high concentrations (>10-4 M) 
β-CDs are strongly bound to mTHPC molecules.  
3. mTHPC accumulation by HT29 cells is strongly depended on β-CD 
concentrations. The β-CDs can cause both acceleration and inhibition of mTHPC cellular 
uptake. The main mechanism of mTHPC cellular uptake increase is the acceleration of 
mTHPC transfer from serum proteins to cellular membranes. On the other hand, most of 
water soluble CDs are not able to penetrate into cells. Thus, at high β-CDs concentrations, the 
rate of mTHPC accumulation in the cells is reduced due to the high probability of inclusion 
complexes formation in the extracellular environment. 
4. Variation of β-CD type leads to the shifts of optimal concentrations providing 
maximal increase of the PS accumulation due to the changes in binding constants with 
mTHPC. β-CDs increase mTHPC photocytotoxicity towards HT29 cells due to the increase of 
mTHPC accumulation level. 
5. Co-administration with β-CDs completely abolishes mTHPC aggregation in blood 
and enhances mTHPC bioavailability immediately after injection. Besides, use of β-CDs 
modifies mTHPC biodistribution pattern in tumor bearing mice in vivo. 
6. The tumor and muscles uptake indicates that complexation of mTHPC with β-CD, 
especially with M-β-CD, results in higher tumor-to-muscles ratio than mTHPC alone that may 
probably induce a better selectivity of PDT treatment and overcome some side effects. 
On the basis of data obtained, new pharmacological forms of the sensitizer based on 
CDs in the PDT may be designed. 
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Outlook 
Further continuation of research is related to the definition of optimal parameters of 
PDT treatment with mTHPC/CD inclusion complexes. Optimization of PDT regimens 
necessarily requires knowledge of mTHPC/CD complexes pharmacokinetics and 
biodistribution, including the intratumoral spatial distribution of the PS. 
Firstly, the in vivo study shall be conducted, comparing the pharmacokinetics 
(including drug release) and biodistribution  of mTHPC inclusion complexes with different 
CDs. Based on these findings the type of CD providing the most favorable biodistribution of 
mTHPC in tumor-bearing animals (i.e., higher tumor/muscles ration and low skin 
photosensitivity) will be defined. Further, the optimal concentrations of the CDs and PSs will 
be determined. 
Secondly, the localization of the mTHPC/CD complexes will be studied in the 
parenchyma and the vascular system of the tumor. The results obtained above suggest that 
CDs allow accelerating the rate of mTHPC uptake in target tissues, thus optimizing DLI of 
PDT. Based on the intratumoral mTHPC localization the optimal DLI for PDT treatment will 
be selected.  
Thirdly, another direction of future research would be development of spectral 
technique based on Sored band variation for continuous control of mTHPC distribution 
in vitro and in vivo. 
Fourthly, CDs can be used for controlled acceleration of mTHPC release from the 
various types of nanocarriers (liposomes, micelles, etc.). Indeed, CDs have high affinity to 
mTHPC molecules and, therefore, additional introduction of CDs should cause mTHPC 
release from nanocarriers in biological systems (in vitro and in vivo). 
Finally, the results of this work can be useful for the development of CD-based 
nanocarriers for PDT, including CD nanoassemblies, CD-nanoconjugates with different 
targeting molecule and different nanoparticles functionalized with CD molecules.  
The overall results of such work would be beneficial for understanding the behavior 
of CD-PDT drug. 
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INTRODUCTION  
Généralités 
La thérapie photodynamique (PDT) est un traitement peu invasif,  alternatif à la 
chirurgie, employé en oncologie et dans diverses pathologies. Cette technique est basée sur 
l’activation par la lumière d’une molécule, appelée photosensibilisateur (PS) qui génère sous 
l’effet d’une irradiation lumineuse et en présence d’oxygène des espèces réactives de 
l’oxygène (ROS) cytotoxiques responsables de dommages irréversibles dans le tissu cible. 
Les composés tetrapyrroliques tels que la méta-tétra(hydroxyphenyl)-chlorine (mTHPC) 
constituent la classe majeure des PS utilisée en PDT. Cependant, l’hydrophobicité élevée de 
ces composés, qui entraine leur faible solubilité en milieu biologique et leur agrégation dans 
le sang après injection intraveineuse, réduit leur application clinique. En effet, l’agrégation 
des PS génère une biodistribution et une sélectivité vis-à-vis du tissu cible médiocre se 
traduisant par une diminution de l’efficacité photodynamique combinée à une photosensibilité 
cutanée prolongée. 
Pour pallier ces problèmes, des formulations pharmaceutiques telles que liposomes, 
nanoparticules polymériques et bioconjugués ont été proposées pour une meilleure 
administration du PS. Parmi les composés biodégradables et non toxiques qui peuvent être 
utilisés pour l’administration de substances actives, les cyclodextrines (CD) sont attractives. 
Les CD constituent une famille d’oligosaccharides cycliques possédant une cavité interne 
hydrophobe et une surface externe hydrophile. Elles sont solubles en milieu aqueux, 
biocompatibles et peuvent former des complexes d’inclusion stables avec un large éventail de 
composés qu’ils soient liquides ou gazeux. L’inclusion dans la cavité interne de la CD d’une 
substance hydrophobe permet d’en améliorer la solubilité et d’en facilité la dissolution. Sa 
stabilité chimique et physique ainsi que sa durée de circulation dans le sang est également 
augmentée facilitant ainsi sa biodisponibilité. En outre, les CD sont utilisés dans l’élaboration 
de complexes dirigés vers le tissu cible, y compris de façon active (incorporation d’un ligand 
spécifique de certains récepteurs cellulaires), permettant la libération immédiate ou retardée 
des substances médicamenteuses. 
La mTHPC, actuellement évaluée en essai clinique pour le traitement palliatif des 
cancers de la tête et du cou est un PS de seconde génération très puissant et attractif en raison 
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de son ratio thérapeutique élevé. Des études précédentes ont montré que la mTHPC forme des 
complexes d’inclusion avec les dérivés de la ß-CD ce qui a pour conséquence d’améliorer sa 
solubilité et ses propriétés photophysiques en solution aqueuse. A ce jour, l’application de 
complexes mTHPC-CDs dans des modèles précliniques in vitro et/ou in vivo n’a pas été 
reportée. 
Nanovectorisation de substances actives 
Nombreuses sont les molécules médicamenteuses possédant des propriétés 
pharmacologiques non-optimales : faible solubilité, nature irritante, absence de stabilité, 
métabolisme rapide et distribution non sélective. La nanovectorisation, développée pour 
pallier ces inconvénients et améliorer l’administration médicamenteuse, est un domaine en 
plein développement de la nanomédecine en particulier pour la thérapie oncologique y 
compris la PDT (Calixto et al., 2016 ; Marchal et al., 2015). Ainsi, des nanoparticules (NP) 
jusqu’à 200 nm ont été développées (Khodabandehloo et al., 2016). La libération 
spatiotemporelle de la substance active à partir du nanovecteur pouvant être contrôlée, une 
augmentation de l’efficacité thérapeutique tout en réduisant les effets secondaires systémiques 
est attendue. L’observance thérapeutique par le patient est également améliorée car la dose et 
la fréquence d’administration sont diminuées (Lee & Yeo, 2015). 
Cyclodextrines 
Oligosaccharides cycliques, les CD possèdent une cavité interne hydrophobe et une 
surface externe hydrophile constituée par des unités D-glucopyranose à six -CD, sept ß-CD 
ou huit γ-CD. Les complexes issus de CD incluant une large variété de composés organiques 
ou non constituent la classe la plus simple des systèmes supramoléculaires étudiés dans les 
dernières années d’un point de vue théorique et pratique. C’est pourquoi, les CD ont été 
utilisés dans l’alimentation, les cosmétiques et l’industrie pharmaceutique où leur application 
est en constante évolution. Actuellement, il y a 40 formulations contenant des CD, et plus 
particulièrement des ß-CD et dérivés (Gidwani & Vyas, 2015). 
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Utilisation des cyclodextrines en thérapie photodynamique 
A ce jour, plus de 150 communications (articles et conférences) ont été publiées sur 
l’application des CD en PDT. La plupart de ces études concernent les PS tetrapyrroliques 
mais d’autres PS tels que l’hypericine (Sattler et al., 1997 ; Zhang et al., 2013), l’acide 
aminolévulinique (Aggelidiou et al., 2014), le fullerène (Ikeda et al., 2013 ; Iohara et al., 
2012 ; Zhao et al., 2009), le polyméthine squaraine (Arun et al., 2011), la curcumine (Hauvik 
et al., 2009 ; Wikene et al., 2014) et la phéno-safranine (Kundu et al., 2016). Par l’utilisation 
de CD, ces études ont abordé (i) l’augmentation de la solubilité du PS en milieu aqueux ; (ii) 
les changements des caractéristiques photophysiques ; (iii) l’amélioration de la distribution du 
PS dans les cellules ou tissus cibles. Les solutions à ces problématiques ont été apportées par 
différentes approches telles que la complexation par inclusion non-convalente, la conjugaison 
covalente ou la formation d’assemblage nanométriques entre le PS et les CD. 
 
 
Complexe d’inclusion avec une molécule tétrapyrrolique 
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OBJECTIF 
L’objectif de ce travail a été de déterminer l’effet de certains dérivés des ß-CD sur 
les propriétés in vitro et in vivo de la mTHPC et sa libération à partir de son vecteur CD. Dans 
ce but, les études suivantes ont été menées : 
 Déterminer la cinétique de distribution et l’état d’équilibre de la mTHPC  entre les
ß-CD et les protéines sériques ;
 Evaluer l’influence des dérivés de ß-CD sur le taux de mTHPC incorporée dans
les cellules ;
 Estimer l’influence des dérivés de ß-CD sur la l’accumulation intracellulaire de la
mTHPC et l’efficacité photodynamique in vitro ;
 Etudier la biodistribution des complexes mTHPC/CD chez la souris porteuse de
tumeur ;
 Déterminer les caractéristiques d’absorption et de fluorescence de la mTHPC en
solutions et en milieux biologiques. Les différences entre les caractéristiques
spectrales de fluorescence du PS lié aux CD et à d’autres structures biologiques
(protéines du sérum, membranes lipidiques par exemple) ont été identifiées ;
 Développer la méthode basée sur la variation de la bande de Soret de la mTHPC
pour estimer la redistribution du PS à partir des CD dans les milieux biologiques.
Les champs d’application potentielle de cette technique ont été examinés ;
 Comparer les méthodes basées sur les caractéristiques spectrales et de
fluorescence de la mTHPC pour estimer la relargage de la mTHPC des ß-CD en
milieu biologique.
RESULTATS ET DISCUSSION 
Il est connu que la mTHPC en solution aqueuse forme de larges agrégats de type J 
conduisant à un changement significatif des propriétés d’absorption et de fluorescence (Ball et 
al., 1998 ; Sasnouski et al., 2005). L’introduction de dérivés ß-CD à la solution aqueuse de 
mTHPC provoque une monomérisation de la mTHPC se traduisant par une modification des 
paramètres spectraux et la fluorescence. Des effets similaires sont observés quand les agrégats 
de mTHPC interagissent avec différentes structures telles que le sérum, les vésicules 
lipidiques ou les molécules de détergent et le mécanisme de cette dissociation a été étudié 
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expérimentalement en détail (Ball et al., 1998 ; Rezzoug et al., 1998 ; Sasnouski et al., 2005 ; 
Kachatkou et al., 2009). L’administration simultanée des dérivés ß-CD avec la mTHPC 
empêche l’agrégation de celle-ci. Demore et al. ont montré qu’en solution aqueuse la mTHPC 
forme rapidement des complexes d’inclusion avec les dérivés ß-CD (Demore et al., 1999). 
Les caractéristiques photophysiques de la mTHPC sont fortement dépendantes du 
composé biologique à laquelle elle est liée. L’analyse des données permet de conclure qu’à la 
fois le degré de polarisation de fluorescence et la bande de Soret (position et forme) sont les 
plus informatives sur le microenvironnement de la mTHPC. La modification de ces 
caractéristiques photochimiques permet de confirmer la liaison de la mTHPC au composé 
biologique étudié. 
Dans le cas des complexes d’inclusion mTHPC/CD la valeur du degré de 
polarisation de fluorescence est relativement bas (P = 0,05) comparé à celle du PS lié aux 
liposomes ou aux protéines du sérum (P = 0,3). La fluorescence du PS lié aux protéines, aux 
liposomes ou aux CD est polarisée du fait des restrictions de mobilité. Puisque la durée de la 
décroissance de la fluorescence ne varie que légèrement dans ces situations, la différence de la 
valeur du degré de polarisation est due au volume hydrodynamique de chaque structure 
(protéines, liposomes, CD…) liée à la mTHPC. 
Les molécules de type chlorine sont tetrapyrroliques avec une double liaison dans un 
des cycles pyrroles. Par conséquent, la bande de Soret est un spectre non résolu comportant 
deux pics représentés par deux paramètres gaussiens (Bx, By) (Shkirman et al., 1999 ; Steiner 
& Fowler, 2006). Une comparaison des résultats numériques issus de la déconvolution des 
spectres d’absorption et d’excitation montre que le ratio Bx/By varie d’environ 0,7 (mTHPC 
liée aux vésicules lipidiques ou aux protéines sériques) à 1,03-1,42 pour les complexes 
mTHPC/CD. L’explication la plus probable est qu’une légère modification de conformation 
des cycles tetrapyrroliques se produit lors des interactions des substituts latéraux avec le 
microenvironnement (Noss et al., 1997 ; Rosa et al., 2006). En se basant sur les variations de 
formes de la bande de Soret, la technique spectrale de monitoring en continu du relargage de 
la mTHPC des transporteurs β-CD dans un système biologique (e.g., distribution dans le 
sérum) a été développée. Cette approche peut être aussi utilisée dans l’étude de l’équilibre de 
distribution de la mTHPC dans un system complexe. Ces découvertes sont intéressantes pour 
le développement des techniques spectrales de monitoring non-invasif de la distribution de la 
mTHPC dans un system biologique.  
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Après injection dans la circulation sanguine, le PS interagit immédiatement avec les 
protéines du plasma. Nous avons appliqué les techniques décrites ci-dessus (polarisation de 
fluorescence, bande de Soret) pour contrôler la distribution de la mTHPC entre les ß-CD et les 
protéines sériques. L’analyse des data montre que ces méthodes donnent de bons résultats 
pour déterminer la cinétique de distribution et l’état d’équilibre de la mTHPC entre les ß-CD 
et les protéines du sérum. L’introduction des complexes mTHPC/ß-CD dans le sérum est 
suivie par une compétition entre les CD et les protéines sériques se traduisant par une 
redistribution des molécules de mTHPC des complexes d’inclusion vers les protéines du 
sérum. Le taux et la cinétique du transfert vers ces protéines sont déterminants pour la 
pharmacocinétique du PS. Selon nos études, les ß-CD causent une accélération de la diffusion 
de la mTHPC dans le plasma. L’ajout de M-ß-CD produit une rapide dissociation des 
molécules de mTHPC des complexes vers les protéines. De plus, l’effet des ß-CD sur le 
processus de redistribution de la mTHPC dans le sérum est concentration dépendant. A faible 
concentration de ß-CD presque toutes les molécules de mTHPC sont liées aux protéines 
sériques. L’augmentation de la concentration en ß-CD produit un shift de l’équilibre de la 
distribution vers la formation des complexes d’inclusion.  
Les résultats que nous avons obtenus sur l’accumulation de la mTHPC complexée 
aux CD montrent qu’elle dépend du type de CD et de leur concentration. Les ß-CD produisent 
à la fois une accélération et une inhibition de l’accumulation intracellulaire. L’effet des CD 
sur l’accumulation intracellulaire des molécules hydrophobes pourrait être attribué à une 
augmentation de la perméabilité membranaire due à la meilleure solubilisation et dissolution 
de la molécule en présence de CD (Loftsson & Brewster, 2013). Il semble cependant que le 
mécanisme principal soit une accélération du transfert de la mTHPC des protéines du serum 
aux membranes cellulaires. La plupart des ß-CD solubles dans l’eau n’étant pas capables de 
pénétrer dans les cellules, le taux d’accumulation de la mTHPC est réduit si les ß-CD sont 
hautement concentrées, ceci étant dû à la probable formation de complexes d’inclusion de 
mTHPC dans l’environnement extracellulaire. 
En ce qui concerne la photocytotoxicité des PS, il est évident qu’elle dépend 
essentiellement du niveau d’accumulation intracellulaire (Castano et al., 2005a). D’après nos 
résultats, l’accélération de l’accumulation intracellulaire en présence de ß-CD résulte en une 
phtocycotoxicité accrue. Il est peu probable que cet effet soit dû aux propriétés 
photophysiques améliorées de la mTHPC en présence de ß-CD. En effet, la pénétration de la 
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Images en épifluorescence des cellules HT29 incubées à 37°c pendant 1 heure avec 1.47 µM 
de mTHPC seule ou avec 10 µM de M-ß-CD 
 
mTHPC dans les cellules est consécutive à sa dissociation des complexes d’inclusion avec la 
ß-CD. La variation du type de ß-CD conduit au shift de la concentration optimale générant 
une accumulation intracellulaire de PS maximale, les constantes d’affinité étant alors 
modifiées. 
La dernière partie du travail concerne la biodistribution de la mTHPC vectorisée par 
les ß-CD, comparée à la mTHPC seule, chez la souris porteuse d’une tumeur 
d’adénocarcinome de colon humain (HT29). La co-administration de la mTHPC avec les ß-
CD abolit l’agrégation de la mTHPC dans le sang, observée dans le cas de l’injection de la 
formulation standard, ce qui probablement augmente sa biodisponibilité immédiatement après 
injection. La formation des complexes d’inclusion dans le plasma ont probablement un impact 
significatif sur la distribution de la mTHPC à partir du flux sanguin et la localisation de cette 
dernière au niveau des tissus extravasculaires y compris tumoraux. L’étude in vivo confirme 
que les ß-CD modifient les processus de biodistribution car l’accumulation de PS dans la peau 
et les muscles semble diminuée alors qu’elle est augmentée dans la tumeur. L’augmentation 
du ratio tumeur/muscle indique une meilleure sélectivité pour la PDT (Roby et al., 2007). De 
plus, la quantité de mTHPC dans la peau, après injection des formulations mTHPC 
complexée aux M-ß-CD ou Hp-ß-CD, est moindre par rapport à la mTHPC seule ce qui 
suggère que les effets secondaires peuvent être moins sévères. 
 
140 
 
Imagerie de fluorescence de differents organes et tissus prélevés d’une souris porteuse d’une 
tumeur HT29 24 h après l’injection de 0, 5 mg/kg de mTHPC seule ou avec 2,5 mg par kg de 
M-ß-CD ou 25 mg/kg de Hp-ß-CD 
 
CONCLUSIONS ET PERSPECTIVES 
 
Au cours de cette thèse, nous nous sommes intéressés aux complexes d’inclusion des 
CD avec le PS de deuxième génération mTHPC. Les principaux résultats peuvent être 
résumés ainsi : 
1. Selon les données spectrales, la mTHPC forme effectivement des complexes 
d’inclusion avec les molécules de ß-CD que ce soit en solution ou en milieu biologique. La 
forme de la bande de Soret de la mTHPC ainsi que le degré de polarisation de fluorescence 
sont les deux paramètres les plus informatifs permettant de contrôler la distribution de la 
mTHPC entre le complexe d’inclusion et les composants biologiques tels que les protéines 
sériques et les membranes biologiques. 
2. Les ß-CD ont un effet dépendant de leur concentration sur processus de 
distribution de la mTHPC dans le sérum. A faible concentrations (10-6-10-5M) les CD 
n’affectent pas l’état d’équilibre de la mTHPC mais augmente significativement sa diffusion 
en accélérant la liaison aux protéines. A concentrations élevées (>10-4 M) ß-CD et mTHPC 
sont solidement complexés.  
3. L’accumulation de la mTHPC dans les cellules HT29 est fortement dépendante 
des concentrations de ß-CD. Celles-ci causent à la fois l’accélération et l’inhibition de l’entrée 
de la mTHPC dans les cellules. L’accélération du transfert de la mTHPC des protéines du 
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serum aux membranes cellulaires en est le principal mécanisme. A forte concentration de ß-
CD, celles-ci solubles dans l’eau n’étant pas capables de pénétrer dans les cellules, le taux 
d’accumulation de la mTHPC est réduit de fait de la formation probable de complexes 
d’inclusion de mTHPC dans l’environnement extracellulaire. 
4. La variation du type de ß-CD modifiant les constantes d’affinité avec la
mTHPC, il en résulte un shift de la concentration optimale générant une accumulation 
intracellulaire de PS maximale. Les ß-CD augmentent la photocytotoxicité par l’augmentation 
de l’accumulation intracellulaire de la mTHPC. 
5. La co-administration de la mTHPC avec les ß-CD abolit l’agrégation du PS
dans le sang et augmente sa biodisponibilité. Des modifications de biodistribution in vivo de 
la mTHPC issue des complexes d’inclusion en résultent. 
6. Particulièrement avec la M-ß-CD, l’accumulation de la mTHPC dans la tumeur
et dans le muscle produit un ratio de mTHPC tumeur/muscle augmenté par rapport à celui de 
la mTHPC seule. Ceci indique une meilleure sélectivité tumorale avec des effets secondaires 
réduits. 
Sur la base des résultats obtenus, des formulations de mTHPC ou d’autres PS 
impliquant des complexes d’inclusion ß-CD peuvent être développées pour la PDT. 
Perspectives 
La continuation de ces travaux de recherche est liée à l’optimisation des paramètres 
de la PDT utilisant les complexes d’inclusion mTHPC/CD. Cela demande nécessairement une 
meilleure connaissance de la pharmacocinétique et de la biodistribution en particulier par une 
mise en évidence de la distribution spatiotemporelle du PS issu de ces complexes dans la 
tumeur.  
En premier lieu une étude in vivo comparant la pharmacocinétique et la 
biodistribution de la mTHPC complexée à différentes CD peut être envisagée. Ainsi, le type 
de CD donnant la biodistribution la plus favorable chez la souris porteuse de tumeur pourra 
être connue. La concentration optimale de CD et de PS devra être déterminée. 
Ensuite, la localisation des complexes mTHPC/CD pourrait être étudiée dans le 
parenchyme et le compartiment vasculaire de la tumeur. En fonction de la localisation 
intratumorale de la mTHPC, l’intervalle de temps optimal entre l’injection du PS et 
l’irradiation (IDL ; intervalle drogue-lumière) pourra être sélectionné.  
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Un autre aspect pour les recherches ultérieures pourrait être le développement de la 
méthode spectrale basée sur la variation de la bande de Soret pour un contrôle continu de la 
distribution de la mTHPC in vitro et in vivo. 
Pour finir, les CD peuvent être utilisées pour assurer une accélération contrôlée du 
relargage de la mTHPC à partir de différent types de nanovecteurs tels que les liposomes ou 
les micelles. De plus ces résultats sont encourageants pour développer d’autres nanovecteurs 
basés sur les CD pour une utilisation en PDT. Ce pourraient être des assemblages ou des 
nanométriques de CD, des conjugués à base de CD pour cibler les tumeurs et  différentes 
nanoparticules fonctionnalisées comportant des molécules de CD. 
 
Types de nanovectorisations impliquant CD et PS de type tetrapyrrolique 
 
De tels travaux ne pourraient qu’être bénéfiques pour comprendre le comportement 
des PSs associés aux CDs dans le cadre de la PDT.  
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ABSTRACT 
Photodynamic therapy (PDT) is a minimally invasive photochemical treatment with 
a promising clinical track record for oncological and some other diseases. Most PDT-drugs 
(photosensitizers) including a second-generation PS meta-tetra(hydroxyphenyl)chorin 
(mTHPC) are highly hydrophobic and require delivery systems. To improve mTHPC 
solubility and pharmacokinetic properties, β-cyclodextrins (β-CDs) derivatives were 
proposed.  
The present study investigates the effect of β-CDs on mTHPC behavior at various 
stages of its distribution in vitro and in vivo. Interaction of mTHPC with β-CDs leads to the 
formation of inclusion complexes that completely abolishes its aggregation after introduction 
into serum. It was demonstrated that the β-CDs have a concentration-dependent effect on the 
process of mTHPC distribution in blood serum and cellular cultures in vitro. In vivo study 
confirms the fact that the use of β-CDs allows modifying mTHPC distribution processes in 
tumor bearing animals that is reflected in the decreased level of PS accumulation in skin and 
muscles, as well as in the increased PS accumulation in tumor. In conclusion, application of 
β-CD derivatives can open up new possibilities to modify and control biodistribution and 
pharmacokinetics of mTHPC in the course of PDT.  
Key-Words : Photodynamic therapy, mTHPC, cyclodextrins, biodistribution, protein 
binding. 
RESUME 
La thérapie photodynamique (PDT) est un traitement minimalement invasif basé sur 
une approche photochimique. Ce traitement est prometteur en oncologie et pour d’autres 
pathologies. La plupart des drogues utilisées en PDT (photosensibilisateurs) y compris le PS 
de seconde génération, la méta-tétra (hydroxyphényl)chlorine (mTHPC), sont hautement 
hydrophobiques et nécessitent un système de transport. Pour améliorer la solubilité de la 
mTHPC et ses propriétés pharmacocinétiques, les dérivés des β-cyclodextrines (β-CDs) ont 
été proposés.  
L’étude présente a analysé l’effet des β-CDs sur le comportement de la mTHPC à 
différentes étapes de sa distribution in vitro et in vivo. L’interaction de la mTHPC avec les β-
CDs conduit à la formation de complexes d’inclusion qui abolissent complètement son 
agrégation après introduction dans le sérum. Il a été démontré que les β-CDs ont un effet lié à 
la concentration sur le processus de distribution de la mTHPC dans le sérum sanguin et les 
cultures cellulaires in vitro. L’étude in vivo confirme le fait que l’utilisation de β-CDs permet 
de modifier les processus de distribution de la mTHPC chez les animaux porteurs de tumeurs, 
ce qui se traduit par un taux moins élevé d’accumulation du PS dans la peau et les muscles, 
ainsi qu’une accumulation plus élevée du PS dans la tumeur. En conclusion, l’application des 
dérivés  β-CDs peut ouvrir de nouvelles possibilités pour modifier et contrôler la 
biodistribution et les pharmacocinétiques de la mTHPC au cours de la PDT. 
Mots-clés : Thérapie photodynamique, mTHPC, cyclodextrines, biodistribution, liaison aux 
protéines. 
